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A 30-year-old housewife visited the
psychiatric outpatient clinic with her
husband. They had a two-year-old son.
She complained of checking locks,
light switches and the door of the oven
excessively. These symptoms started
during her pregnancy. When her son
was born, she became very concerned
that he could hurt himself with needles
and other sharp objects. She therefore
started checking the ﬂoor for these
objects and vacuuming excessively.
Pharmacological and behavioral
treatment decreased her symptoms to 
a level at which she could function
normally. She was very happy with this
result.
Two years later they visited the
outpatient clinic again. Her symptoms
were still at an acceptable level, while
using medication. They would like to
have another child and wanted advice
about the use of medication during
pregnancy.
They decided to stop the medication
and continue behavioral therapy. Her
symptoms started to increase after six
weeks. She became pregnant two
months later. After their healthy
daughter was born, she was reinstated
on medication and her symptoms soon
subsided to previous levels.
Case II
A 43-year-old male visited the
psychiatric outpatient clinic. He was
ﬁfteen minutes late for his appoint-
ment and looked tense and timid at
arrival. He was dressed in worn-out
clothes and the skin of his hands was
coarse and red.
He complained of washing his hands
and clothes excessively because he was
afraid of getting contaminated with
carpet cleanser, medicinal ointment
and washing powder, which he had
used several years ago. At ﬁrst he tried
to clean out these contaminants from
his house, but they seemed to spread
throughout it. It made him very anxious
and took him hours to ﬁnish cleaning.
He often missed appointments because
he could not stop washing his hands
and cleaning. He thought that moving
to another apartment would resolve
this problem.
In the past ﬁve years he had moved
fourteen times. He lived surrounded by
movingboxes because he felt the house
was not clean enough to unpack.
The patient had successfully ﬁnished
high school but did not ﬁnish law
school because of these complaints and
was unemployed at the time. He lived
with his girlfriend. Their relationship
was under heavy strain.
Years of pharmacological and
behavioral treatment did not alleviate
his symptoms. He became severely
depressed. An admission in a specialized
clinic was arranged, but he refused to
admit because he wanted to move ﬁrst.
10
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with major impact on their personal, social and occupational lives. Pharmacological
and behavioral treatment can diminish obsessive-compulsive symptoms, however a
substantial group of patients do not respond to the available treatment.
These two patients serve as an example of the people for whom it is essential that
research is done on the cause of their disease and for other possibilities for treatment.
The Psychiatric Disorder: Obsessive-compulsive Disorder
Phenomenology
Obsessive-compulsive disorder (OCD) is characterized by recurrent obsessions and/or
compulsions which cause marked distress (see Table 1 for DSM-IV criteria)
1. Obsessions
are ideas, thoughts, impulses or images which are experienced by patients as intrusive
and inappropriate (e.g. fear of contamination, hurting someone with a kitchen knife,
having left a door unlocked). Compulsions are repetitive behaviors (washing hands,
checking or ordering) or mental acts (praying, counting or repeating words silently)
which are performed excessively and according to certain rules or in a stereotyped
fashion. Compulsions are performed to reduce stress, but some patients also perform
compulsions without being able to indicate why. At some point during this disorder
patients recognize that the obsessions or compulsions are excessive and unreasonable,
however there are patients with poor insight in this.
Obsessions and compulsions cause marked distress, are time consuming or
signiﬁcantly interfere with the patient’s personal, occupational or social life. This can
lead to ineffective functioning, avoidance behavior and may substantially affect the
quality of life of patients
2, 3.
Prevalence
OCD has a lifetime prevalence of 2.5% and a 1-year prevalence of 1.5-2.1%, which
makes it one among the most common psychiatric disorders, together with major
depressive disorder (life-time prevalence 2-25%), substance related disorder (16%),
other anxiety disorders (3-13%), and schizophrenia (1-1.5%)
4.
11 Chapter 1
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The onset of OCD is generally in adolescence or early adulthood, but it may also
begin during childhood. OCD is equally common in males and females, but there is
an age-dependant gender difference; OCD occurs in males at a younger age. There is
also a small group of females in which the onset of OCD occurs during pregnancy
5, 6.
The onset of OCD is gradual and in general not linked to major life events. OCD
has a chronic course with a waxing and waning of symptoms. During the course of
OCD the symptoms can vary, for instance if fears of contamination and washing
compulsions subside, they may later be followed by checking compulsions.
Table 1. DSM-IV Diagnostic criteria for Obsessive-compulsive disorder.
A.  Either obsessions or compulsions:
Obsessions as deﬁned by (1), (2), (3), and (4):
(1) recurrent and persistent thoughts, impulses, or images, that are experienced, at
some time during the disturbance, as intrusive and inappropriate and that cause
marked anxiety or distress
(2) the thoughts, impulses, or images are not simply excessive worries about real-life
problems
(3) the person attempts to ignore or suppress such thoughts, impulses, or images, or
to neutralize them with some other thought or action
(4) the person recognizes that the obsessional thoughts, impulses, or images are a
product of his or her own mind (not imposed from without as in thought
insertion).
Compulsions are deﬁned by (1) and (2):
(1) repetitive behaviors (e.g. handwashing, ordering, checking) or mental acts (e.g.
praying, counting, repeating words silently) that the person feels driven to
perform in response to an obsession, or according to rules that must be applied
rigidly
(2) the behaviors or mental acts are aimed at preventing or reducing distress or
preventing some dreaded event or situation; however, these behaviors or
mental acts either are not connected in a realistic way with what they are
designed to neutralize or prevent, or are clearly excessive.
B.  At some point during the course of the disorder, the person has recognized that the
obsessions or compulsions are excessive or unreasonable. Note: this does not apply
to children.
12
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more than an hour a day); or signiﬁcantly interfere with the person’s normal routine,
occupational (or academic) functioning, or usual social activities or relationships.
D.  If another axis I disorder is present, the content of the obsessions or compulsions is
not restricted to it (eg, preoccupation with food in the presence of an eating disorder;
hair pulling in the presence of a trichotillomanie; concern with appearance in the
presence of body dysmorphic disorder; preoccupation with drugs in the presence of
a substance use disorder; preoccupation with having a serious illness in the presence
of hypochondriasis; preoccupation with sexual urges or fantasies in the presence of
a paraphilia; or guilty ruminations in the presence of major depressive disorder).
E.  The disturbance is not due to the direct effects of a substance (e.g. a drug of abuse, a
medication) or a general medical condition.
Specify if:
With poor insight: if, for most of the time during the current episode, the person does not
recognize that the obsessions and compulsions are excessive or unreasonable.
Psychiatric comorbidity
OCD is associated with major depressive disorder, other anxiety disorders and eating
disorders. Comorbid personality disorders in OCD are in general cluster C personality
disorder (avoidant, dependant, passive-aggressive and obsessive-compulsive)
7, but the
rate of diagnoses drops significantly after adequate treatment
8. There is a distinct
occurrence of OCD in Tourette’s disorder (35-50%) and 20-30% of patients with OCD
report current or past tics
1.
Several neurological disorders are associated with OCD, e.g. Sydenham’s chorea in
acute rheumatic fever, viral encephalitic lethargica (epidemic in 1915-1926) with
parkinsonian features, Huntington’s disease, Parkinson’s disease, and basal ganglia
pathology
9. Besides these gross neurological disorders there is a high incidence of soft
neurological signs in OCD, e.g. fine motor coordination, involuntary and mirror
movements and visual spatial dysfunction
10.
Recently a cohort of psychiatric disorders are postulated as obsessive-compulsive
spectrum disorders, e.g. somatoform disorders (body dysmorphic disorder and
hypochondriasis), dissociative disorders (depersonalization), eating disorders (anorexia
nervosa and binge eating), impulse control disorders (trichotillomania, pathological
gambling, compulsive buying, sexual compulsions) and neurologic disorders (autism,
Tourette’s syndrome, Sydenham’s chorea, parkinsonism, epilepsy). These spectrum
13 Chapter 1
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response, aetiology and associated features like demographics, family history and
comorbidity
11.
Treatment options
Pharmacological treatment with serotonin reuptake inhibitors (SRIs, antidepressants)
is found effective in diminishing obsessive-compulsive symptoms
12. Although a
substantial number of OCD patients beneﬁt from this treatment, a sizable minority is
refractory and in those who do respond residual symptoms usually persist, despite a
meaningful clinical response. Generally, improvement is attained in about 40-60% of
the patients on monotherapy with SRIs
13. Pharmacological treatment is generally
continued for years, as symptoms reappear when treatment is discontinued.
The tricyclic antidepressant clomipramine is also effective in diminishing obsessive-
compulsive symptoms
14. Clomipramine is a 5-HT reuptake inhibitor, but its major
metabolite desmethylclomipramine has noradrenergic function
15.
Further investigation on treatment options in OCD patients has been performed on
antipsychotic medication. Recently, two placebo-controlled antipsychotic augmentation
studies to SRIs in treatment resistant OCD patients showed that addition of
risperidone
16 and quetiapine
17 (5-HT2C and D2 antagonist) to SRIs induced additional
treatment response in patients. This should be considered carefully as there are also
reports which mentioned exacerbation of obsessive-compulsive symptoms following
antipsychotic treatment (see paragraph pharmacological challenges).
Non-pharmacological treatment options like cognitive behavioral therapy (CBT) is
found effective in treatment of OCD patients. For the patients who do not respond to
pharmacological treatment and CBT, psychosurgery is an options, under strict
inclusion criteria
4.
The Serotonin System
The serotonin (5-HT = 5-hydroxytryptamine) system is extensivelly distributed along
the brain and there is a wide subdivision of its receptors known
18. 5-HT plays a
physiological role in sleep, agression, thermoregulation, cardiovascular system, sexual
activity, neuroendocrine system, appetite, motor drive, learning and memory. 5-HT is
implicated in psychiatric syndromes as major depression, anorexia nervosa, bulimia,
anxiety disorders, schizophrenia and obsessive-compulsive disorder
19. The involvement
14
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with selective serotonin reuptake inhibitors (SSRIs). Also pharmacological challenge
studies point to a major role for 5-HT in the pathophysiological mechanism in OCD.
The localisation of 5-HT cell bodies and receptors
5-HT is mainly located in the gastrointestinal tract. Only 2% is located in the brain.
5-HT has a widespread localisation in the brain, and it is therefore expected to have an
extensive function in the brain.
The cell bodies of the serotonergic neurons are located in the brain stem and can be
divided in an superior and inferior group of nuclei
18. The superior group consists of 
4 nuclei: the caudal linear nucleus, median raphe nuclei, the lateral cells in the nucleus
pontis centralis oralis and dorsal raphe nucleus. The inferior group consists of 5 nuclei:
the nucleus raphe obscurus, nucleus raphe pallidus, nucleus raphe magnus,
ventrolateral medulla and the area postrema.
The 5-HT neurons have extensive rostral and caudal projections from the cell-
bodies
18-20. The dorsal raphe nucleus innervates the basal ganglia and substantia nigra.
The neocortex, hippocampus and septum are innervated by the median raphe nucleus.
Serotonin synthesis
5-HT is formed through a cascade of enzymatic reactions. The primary compound
from which it is formed is the essential amino acid tryptophan, which is present in a
normal diet. In the neuron, tryptophan is hydroxylated into 5-hydroxytryptophan 
(5-HTP) and decarboxylated into 5-hydroxytryptamine (5-HT). 5-HT is inactivated by
mono-amine-oxidase (MAO) and aldehyde-dehydrogenase into 5-hydroxy-indole-acid
(5-HIAA), which is is excreted in the urine.
The serotonin receptor system
The serotonin receptor system is a complex system with an impressively vast
subdivision. Until now the 5-HT receptors are divided in 7 subfamilies; 5-HT1 up to 
5-HT7 receptors. Each has specific distribution in the brain, and signal transducing
function
21. All 5-HT receptors are G-protein coupled receptors, with the exception of
the 5-HT3 receptor which is a ligand-gated ion-channel. 5-HT1A receptors are located
both presynaptically on the cell body and postsynaptically, and mediate neuronal
inhibition. 5-HT1D has both autoreceptor function on cortical neurons and postsynaptic
function
22.
15 Chapter 1
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Depolarization of the cell membrane causes the opening of ion channels which are
located in the cell membrane
23. This opening allows transport of ions (Na
+, K
+ and Cl
–)
through these channels and an action potential is generated. This action potential
travels through the axon and causes another electrical or a chemical transmission (by
means of a neurotransmitter). The neurotransmitter is stored in synaptic vesicles, is
transported to the active zone in the presynaptic terminal and released in the synaptic
cleft. This chemical transmission can be either excitatory or inhibitory.
The neurotransmitter binds with postsynaptic receptors. These postsynaptic receptors
are divided into two groups; (I) ionotropic receptors, which directly gate ion channels,
and (II) G-protein coupled receptors which trigger a second messenger system. This
second messenger system is for instance cAMP, phosphoinositol system or arachidon
acid system. In the second messenger system, the neurotransmitter changes the
conformation of the postsynaptic receptor and a second messenger is produced. The
effect of 5-HT is terminated by reuptake in the presynaptic terminal by means of the
5-HT transporter.
Pharmacological Challenges in Obsessive-compulsive
Disorder
The pathophysiological mechanisms of various psychiatric disorders are currently
under extensive investigation. One way to investigate the neurobiological functions
of a neurotransmitter system is with a challenge paradigm. This paradigm is based on
the notion that modiﬁcation of the neurotransmitter system may result in changes in
specific biological functions, which are under influence of that particular neuro-
transmitter. A commonly used method is a pharmacological challenge paradigm,
during which changes can occur in for instance endocrine-, physiological or behavioral
functions. An example is a neuroendocrine challenge through stimulation of the
serotonin (5-HT) system, whereby the release of pituitary hormones is measured.
A pharmacological challenge can be performed with various probes, for instance
precursors of the neurotransmitter system thought to be involved or more speciﬁcally
by receptor agonists or antagonists. In OCD patients the 5-HT system is closely
investigated with this method.
During treatment with atypical antipsychotica there are reports of an exacerbation
of, or occurence of de novo, obsessive-compulsive symptoms
24. This occured in various
16
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OCD patients with comorbid diagnoses. Antipsychotics used were risperidone,
olanzapine, quetiapine and clozapine treatment. Also, emergence of obsessive-
compulsive symptoms in schizophrenia was reported during clozapine withdrawal,
which disappeared after reinstatement of the treatment regime
25. These reports point
to a role for DA in OCD and investigations into this relationship are ongoing.
Pharmacological probes used in challenge studies in obsessive-compulsive
disorder
The most commonly used serotonergic probe is meta-chlorophenylpiperazine
(mCPP), a 5-HT releaser and non-selective partial 5-HT agonist with high afﬁnity for
the 5-HT2C receptor, but also with affinity for 5-HT1A, 5-HT1D, 5-HT2A, α1-, α2- and 
β-adrenergic and dopamine receptors
26. 
Other 5-HT agents used for challenge purposes are the the 5-HT2A and 5-HT2C agonist
MK-212, 5-HT precursor L-5-hydroxy-tryptophan and tryptophan, 5-HT enhancer
fenfluramine, 5-HT1A receptor agonists buspirone and ipsapirone, 5-HT1D receptor
agonist sumatriptan, the non-speciﬁc 5-HT receptor antagonist metergoline and the 
5-HT3 antagonist ondansetron.
A limited number of pharmacological challenges in OCD patients assessed nor-
adrenergic function; the noradrenergic receptor antagonist yohimbine and noradrenaline
reuptake inhibitor desipramine were used. Single studies with methylphenidate
(amphetamine), naloxon (morfineantagonist) and pentagastrin (cholecystokinine
CCK4 analogon) are reported.
meta-Chlorophenylpiperazine (mCPP)
Oral administration of mCPP 0.5 mg/kg caused a signiﬁcant increase in obsessive-
compulsive symptoms in several studies, by two groups of investigators
27-33 (see Table
2). In some of these investigations, OCD patients also became more anxious and more
depressed during mCPP
27-29. From these ﬁndings a postsynaptic 5-HT hypersensitivity
in OCD has been hypothesized. Pre-treatment with the non-specific 5-HT receptor
antagonist metergoline was able to block these behavioral effects
29, which is suggestive
for a serotonergic origin of the behavioral effects and in particular for the 5-HT2C
receptor.
In other reports however, orally administered mCPP did not induce obsessive-
compulsive symptoms
34-37, and only one of these studies found increased anxiety and
depressive ratings
35. Pigott
34 compared his positive and negative ﬁndings during mCPP
17 Chapter 1
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several other confounding factors involved in challenge studies which are discussed
in the corresponding paragraph.
mCPP was also investigated during intravenous administration. A 90 second mCPP
bolus (0.08 and 0.1 mg/kg) was able to exacerbate obsessive-compulsive symptoms
34, 38.
This effect was blocked by pre-treatment with metergoline
34, but not by the 5-HT3
antagonist ondansetron
38, which does not support 5-HT3-receptor involvement in the
behavioral effects of mCPP. A 20 minutes infusion of mCPP 0.1 mg/kg on the other
hand, was not able to induce obsessive-compulsive symptoms
35,  39. Both i.v.
administration methods however, induced significant increases in anxiety and
depression. This might indicate that the anxiety-depressive and obsessive-compulsive-
symptom responses are segregated behavioral effects in response to mCPP.
During effective treatment by chronic administration of clomipramine or ﬂuoxetine,
oral mCPP was not able to induce symptoms in OCD patients
28, 30, 37. SRI treatment
induces a receptor downregulation which causes a subsensitivity of the postsynaptic
receptors. mCPP may then no longer be able to exacerbate symptoms. It was also noted
that mCPP plasma levels were higher during SRI treatment. With the hypothesis of 
5-HT hypersensitivity in OCD, high mCPP plasma levels may cause an extensive
increase in anxiety symptoms that may impair the assessment of obsessive-compulsive
symptoms.
The differences in symptom inducing properties of mCPP are not easily understood
and may reﬂect methodological differences between studies, which are discussed in the
following paragraph. The heterogenous findings may also indicate varying
neurobiology of OCD between patient subgroups.
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The discrepancies between the findings of the challenge tests can not easily be
understood. There are a number of confounding factors which should be considered
when interpreting the ﬁndings
41.
Behavioral ratings vary between investigations. Various rating scales are available
and both patient-rated and clinician-rated scales have been used during challenge
tests. The timing of the ratings is essential; consensus for the interval between ratings
of obsessive-compulsive symptoms is 60 minutes. More frequent ratings are not more
accurately in assessing obsessive-compulsive symptoms
42, 43. As some studies use a
battery of rating scales, it is important that patients have enough time between
assessments, to allow them to experience possible symptoms. The completion of rating
scales can be a distracting task and usually blood sampling and physiological measures
are taken simultaneoulsy. Raters should also be well trained and inter-rater variability
should be considered. If patients suffer from situational evoked obsessive-compulsive
symptoms, it should be noted explicitely whether patients are asked to imagine these
situation or whether simultaneously in vivo exposure was conducted.
Patient characteristics can influence outcome. Patients may experience their
symptoms in an exclusive environment only. Different papers have excluded this
subgroup of patients to homogenize their group of OCD patients, but this might also
limit the generalizability of the results. Other factors to be considered are severity of
obsessive-compulsive symptoms (which might cause a ceiling effect on symptoms
during behavioral challenges), the duration of symptoms, gender, previous behavioral
or cognitive therapy, response to pharmacological treatment, family history and
comorbid diagnoses.
Also, the environmental situation during the challenge procedure can substantially
affect results. Experience of obsessive-compulsive symptoms might be triggered by
objects in the testroom and the presence of the investigator might either be symptom
provoking (drawing of blood) or, on the contrary, have a reassuring effect.
Taken together, many factors can inﬂuence challenge tests. Some of them are difﬁcult
to standardize, and careful description of the challenge procedure may help to clarify
these confounding factors.
Serotonergic challenge probes (not mCPP)
Several other serotonergic probes were investigated in OCD (see Table 3). Obsessive-
compulsive symptoms were not exacerbated during these challenges, but an increase
in anxiety- and depressive symptoms during tryptophan
39, fenﬂuramine
31 and MK-212
21 Chapter 1
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44 were reported. Tryptophan and fenfluramine have an overall effect on 
5-HT receptors and stimulate both pre- and postsynaptic receptors. The presynaptic
effects of these compound may account for the different effects at obsessive-compulsive
symptoms as compared to mCPP.
MK-212 also increased anxiety and depressive symptoms, but had no effect on
obsessive-compulsive symptoms
44. The major difference between MK-212 and mCPP is
the afﬁnity for the 5-HT1D receptor of the latter compound. mCPP is, in a number of
challenges, able to exacerbate obsessive-compulsive symptoms, whereas MK-212 is not.
To evaluate the involvement of the 5-HT1D receptor in OCD, a prelimenary report of a
challenge test with the 5-HT1D receptor agonist sumatriptan found an increase in
obsessive-compulsive symptoms. No extensive data on the methods were presented
however
45.
Noradrenergic challenges
The noradrenergic challenge (see Table 4) agents, yohimbine
46 and desimipramine
47
were not able to induce obsessive-compulsive symptoms. Also no changes in anxiety
or mood symptoms were seen. Based on these limited and mostly single challenges test,
noradrenalin does not seem to play a major role in OCD.
22
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Until the introduction of modern neuroimaging, research on brain anatomy relied
solely on postmortem dissection. Neuroimaging technology has created opportunities
to visualize the nervous system in vivo, that is in living human beings, and enables us
to further our understanding of the anatomy of the brain and its functions.
Neuroimaging can be broadly divided into two categories; structural imaging,
primarily aimed at anatomical localisation of pathological processeses, and functional
imaging, focussed on physiological processes of the brain. The rapidly developing
technology in neuroimaging has created possibilities to more accurately visualize and
measure brain anatomy and metabolic, biochemical and electrophysiological
processes. With these available techniques at hand, we are challenged to relate
processes of various brain regions to human behavior, e.g. thought, perception or
motivation, and from there onward to psychiatric syndromes.
Structural neuroimaging
Structural imaging techniques as Computed Tomography (CT) and Magnetic
Resonance Imaging (MRI) are developed for anatomical localisation. Also information
on pathological processes can be obtained and volume measurements of different
brain regions of interests can be performed.
CT technology is based on the principle that the absorption rate of X-ray photons
varies with tissue density. The X-ray photons that pass through the tissue are detected
and quantified and then converted into a computer image
48. Because of the low
resolution for soft tissues, CT is of limited use in psychiatric brain research.
MRI technology is based on Nuclear Magnetic Resonance (NMR). NMR technology
is characterized by atomic nuclei that possess intrinsic spin (protons most abundantly)
and generating a small magnetic ﬁeld. When tissue is placed in a three-dimensional
homogeneous magnetic gradient ﬁeld, these protons will spin about the axis of this
external magnetic ﬁeld. The protons lign up parallel (lower energy level) and anti-
parallel (higher energy level) to this magnetic ﬁeld. A small majority of the protons are
in the lower energy state. A radiofrequent pulse causes the protons in the lower energy
level to be knocked out of alignment and to be excited to a higher energy level. When
the protons relax back to their former energy state, the absorbed energy is released
(spin-lattice or longitudinal relaxation, T1). This energy is recorded and converted into
a computer image of the brain. T2 (spin-spin or transverse relaxation) is a time constant
with which the protons relax in a direction perpendicular to the external magnetic
25 Chapter 1
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constant for T1 and T2, which determines the contrast in MRI
49. The advantage of MRI
is that it produces high contrasts between different types of soft tissue without exposing
subjects to ionizing radiation. It is therefore frequently used in brain research.
Functional neuroimaging
Functional imaging visualizes the brain ‘while in function’. There are a number of
techniques, each with its speciﬁc characteristics; EEG (Electro-Encephalography) and
MEG (Magneto-Encephalography) record electrical activity, MRS (Magnetic Resonance
Spectroscopy) can detect chemical compositions e.g. carbon, phosphorus or hydrogen,
PET (Positron Emission Tomography) and SPECT (Single Photon Emission Computed
Tomography) can measure metabolic processes like glucose utilisation, oxygen
consumption, cerebral blood ﬂow and receptor binding. fMRI (functional MRI) uses
deoxyhemoglobin to evaluate oxygen utilisation.
The most commonly used functional imaging techniques in OCD research are PET
and SPECT. One of the advantages of PET over SPECT is the higher resolution, allowing
more accurate localization of brain regions. Also, with PET it is possible to quantify the
amount of tracer administered. SPECT, on the other hand, does not necessitate a
cylotron for production of radiopharmaceuticles at its vicinity and it is less costly.
Radioactive isotopes
PET and SPECT techniques require radioactive isotopes, which are labeled to
biological or pharmacological compounds and can thus measure various processes;
18F-FDG (ﬂuorodeoxyglucose) and 
11C-DG (deoxyglucose) measure glucose utilisation,
H2
15O assesses oxygen consumption, 
99mTc-HMPAO (hexamethylpropylene-amine-
oxime) and 
133Xe register cerebral blood flow, 
123I-beta-CIT has binding capacity for
serotonin and dopamine transporters and 
123I-BZM (iodobenzamide) is a D2-receptor
ligand. These processes are visualized by radiation detectors which fluoresce when
exposed to ionizing radiation. The ﬂuorescence is converted into electrical signals,
which are reconstructed into a computer image
50.
SPECT and PET have distinct nuclear features (see Figure 1). SPECT uses isotopes
that are photon (γ-rays) emitters. These photons are emitted randomly and in a 360º
geometry. The photons emitted are singular and have, in general, an energy varying
from 70-390 keV. SPECT uses collimators to detect only those photons which are
emitted in one direction, to ensure more accurate localization of the photons emitted.
PET, on the other hand, uses isotopes that emit positrons (β-rays) during their decay.
26
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annihilation process two photons (each 511 keV) are formed that are emitted 180º
opposite to each other. The presence of a positron is detected by simultaneous
registration of the two annihilation photons by two opposing detectors. The distance
a positron travels through the tissue is related to its energy level (β-energy). The
radioisotopes used in PET have low β-energy and travel only small distances in the
tissue
50, 51. The small travel distance and simultaneous registration by two detectors
ensure accurate localization of the positron.
Figure 1. PET en SPECT nuclear features.
The half-life of radioisotopes used in PET and SPECT (see Table 5) has important
implications for psychiatric brain research
50. When isotopes with a short half-life are
used, the time between administration of the radiopharmaceutical and image
acquisition is limited. The isotope should then be administered while the patient is
positioned in the scanner. This poses limitations to for instance psychometric tasks to
be performed by the patient because of limited space. The scanner can also be a
distracting or even anxiety provoking surrounding. It is also necessary to produce these
radioisotopes on site, for which a cyclotron at the vicinity of the scanner is required.
Radiopharmaceuticals with an isotope with a longer half-life can be administered at
a location away from the scanner. The surrounding conditions necesarry for a
psychiatric challenge test for instance, can be more accurately standardized in a
surrounding other than the scanner. Also speciﬁc or even more complex tasks can be
performed by the patients if they are at a different location (e.g. behavioral or
pharmacological symptom provocation).
27 Chapter 1
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PET SPECT
Radioisotope
13N
15O
11C
18F
99mTc
123I
133Xe
Half-life 10 min 2 min 20 min 110 min 6 h 13 h 127 h
min = minutes, h = hours, PET = Positron Emission Tomography, 
SPECT = Single Photon Emission Computed Tomography
In order to transport a radioisotope through the human body, it has to be coupled to
a carrier molecule. In this thesis, cerebral blood ﬂow is measured with SPECT by means
of technetium (Tc), coupled to the carrier molecule HMPAO (hexamethyl-propylene-
amine-oxime). The 
99mTc-d,l-HMPAO complex is lipophilic, it can cross the blood-brain
barrier and has good penetration abilities into the brain (4.1% of the total amount
administered)
52.
99mTc-d,l-HMPAO is converted into a meso-isomere within several minutes after
administration. This meso-isomere is hydrophilic and cannot cross the blood-brain-
barrier. It is retained in the brain for up to 8 hours
53, 54. These characteristics cause
99mTc-d,l-HMPAO to ‘freeze’ the cerebral activity at the time of administration. Image
acquisition can be performed up to several hours after HMPAO administration.
Regions of interest
The methods used for deﬁning regions of interest (ROIs) differ considerably between
studies. ROIs are drawn on the PET or SPECT image and guided by the activity
displayed, stereotactic brain atlasses of reference are used or artificial borders are
deﬁned (for instance wheel-shaped template placed on the PET or SPECT image). Also
one MRI or CT scan of the brain is used to define one common set of anatomical
borders, or the subject’s own MRI or CT scan is used to deﬁne individual borders for
the different ROIs. In some studies, ROIs are deﬁned on one slice only, whereas others
use all slices in which the ROIs are seen. The ongoing technological developments
will also provide new means to deﬁne brain regions of interest; with the possibility of
multi-modality imaging (combined analysis of structural and functional imaging),
accurate positioning of the ROIs is attainable.
Reference regions
Because of its nuclear features, measurements of 
99mTc-d,l-HMPAO cannot be
quantiﬁed
53, 55. Interindividual differences occur in tracer uptake and this effects is also
28
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effects, tracer uptake is measured as relative uptake to a reference region (‘normalized’
values). Different normalization methods can be used, which all have different effects
on the data. The most optimal choice for normalization is measuring the region of
interest to a standard measure ( = normalization area)
56, 57.
In OCD research, a wide variety of brain areas are used for normalization, e.g. whole
brain, cerebellum, ipsilateral hemisphere, global grey activity, cortical mean, activity
of the slice of region of interest deﬁnition, occcipital and calcarine cortex. The choice
of reference region can also have a significant impact on the cerebral acitivity
measured; it can either underestimate or overestimate the activity measured
58, 59. The
debate over the best normalization method and reference areas is still ongoing.
Structural imaging studies in OCD
Structural imaging studies in OCD (see Table 6) have used both CT and MRI
techniques for volume measurements and various regions of interest were under
investigation. All studies were performed with a healthy control group.
Two CT studies found increased ventricular-brain ratio in OCD patients, and in par-
ticular in patients with high compared to low neurological soft sign scores
60, 61. Five MRI
studies however, did not ﬁnd changes in cerebrospinal ﬂuid (CSF) measurements
62-66.
Volumetric ﬁndings on the caudate nucleus are divergent; increased caudate volume
were found in pediatric OCD patients
67 and decreased caudate volume was reported
with CT and MRI findings
63, 68. The majority of the studies however, did not find
volumetric changes in caudate nucleus volume
61, 65, 66, 69-72.
Frontal white matter volume was found increased in OCD patients
71. Findings on
the orbitofrontal cortex reported both increased
73 and decreased
74 volumes, whereas
other studies did not ﬁnd volumetric changes
63, 70, 75. White matter volume decrease
was found for retrocallosal white matter
64, 65 and cerebral white matter
65.
Some interesting findings were seen in the thalamus. Thalamic volumes were
increased in OCD patients
73, 76, but after 12 week treatment with paroxetine, volumetric
differences were no longer present
76. This phenomenon is important as results in
imaging studies can be influenced by treatment interventions and this should be
controlled in future investigations.
A brain region not generally thought to be involved in OCD and therefore not
frequently investigated is the cerebellum. Jenike
65 reported a decrease in cerebellar
white matter volume and also decreased left cerebellar volume was mentioned
73. These
volumetric findings, together with some reports on the cerebellum in functional
imaging studies call for further investigation of the cerebellum.
29 Chapter 1
1Hfdst1 XP  18-01-2005  14:00  Pagina 2930
T
a
b
l
e
 
6
.
 
S
t
r
u
c
t
u
r
a
l
 
i
m
a
g
i
n
g
 
i
n
 
o
b
s
e
s
s
i
v
e
-
c
o
m
p
u
l
s
i
v
e
 
d
i
s
o
r
d
e
r
 
(
O
C
D
)
.
A
u
t
h
o
r
s
M
e
t
h
o
d
S
u
b
j
e
c
t
s
R
O
I
F
i
n
d
i
n
g
s
R
e
m
a
r
k
s
I
n
s
e
l
 
e
t
 
a
l
.
 
C
T
6
M
,
 
4
F
 
O
C
D
 
v
e
n
t
r
i
c
u
l
a
r
 
,
 
b
r
a
i
n
 
r
a
t
i
o
 
O
C
D
 
=
 
c
o
n
t
r
o
l
s
c
o
n
t
r
o
l
s
 
d
i
a
g
n
o
s
e
d
 
w
i
t
h
 
s
o
m
a
t
i
c
 
d
i
s
o
r
d
e
r
s
 
1
9
8
3
 
1
2
5
6
M
,
 
4
F
 
c
o
n
t
r
o
l
s
h
e
m
i
s
p
h
e
r
i
c
 
s
y
m
m
e
t
r
y
a
l
l
 
s
u
b
j
e
c
t
s
 
d
r
u
g
-
f
r
e
e
c
o
r
t
i
c
a
l
 
a
t
r
o
p
h
y
 
B
e
h
a
r
 
e
t
 
a
l
.
 
C
T
1
4
F
,
 
3
M
 
O
C
D
*
 
v
e
n
t
r
i
c
u
l
a
r
 
,
 
b
r
a
i
n
 
r
a
t
i
o
O
C
D
 
>
 
c
o
n
t
r
o
l
s
O
C
D
 
m
e
a
n
 
a
g
e
 
±
S
D
 
1
3
.
7
 
±
1
.
6
 
1
9
8
4
 
6
0
1
3
F
,
 
3
M
 
c
o
n
t
r
o
l
s
*
*
a
l
l
 
p
e
d
i
a
t
r
i
c
 
s
u
b
j
e
c
t
s
L
u
x
e
n
b
e
r
g
 
e
t
 
a
l
.
 
C
T
1
0
M
 
O
C
D
 
v
e
n
t
r
i
c
l
e
s
 
c a u d a t e   n c l :
a
b
s
o
l
u
t
e
 
v
o
l
u
m
e
 
a
s
 
%
 
o
f
 
i
n
t
r
a
c
r
a
n
i
a
l
 
s
e
g
m
e
n
t
 
1
9
8
8
 
6
8
1
0
M
 
c
o
n
t
r
o
l
s
c
a
u
d
a
t
e
 
n
c
l
.
 
O
C
D
 
<
 
c
o
n
t
r
o
l
s
a
l
l
 
d
r
u
g
-
f
r
e
e
 
l
e
n
t
i
c
u
l
a
r
 
n
c
l
.
O
C
D
 
c
h
i
l
d
h
o
o
d
-
o
n
s
e
t
G
a
r
b
e
r
 
e
t
 
a
l
.
 
M
R
I
 
2
0
M
,
 
1
2
F
 
O
C
D
 
c
a
u
d
a
t
e
 
n
c
l
.
 
f r o n t a l   w h i t e   R :
1
9
 
O
C
D
 
u
s
i
n
g
 
S
R
I
’
s
1
9
8
9
 
7
1
9
M
,
 
5
F
 
c
o
n
t
r
o
l
s
f
r
o
n
t
a
l
 
c
.
 
O
C
D
 
>
 
c
o
n
t
r
o
l
s
a
n
t
e
r
i
o
r
 
c
i
n
g
u
l
a
t
e
 
c
t
r
.
 
b
d
l
.
 
f
r
o
n
t
a
l
 
w
h
i
t
e
 
o
r
b
i
t
o
f
r
o
n
t
a
l
 
c
.
 
l
e
n
t
i
c
u
l
a
r
 
n
c
l
.
 
m
e
d
.
 
t
e
m
p
o
r
a
l
K
e
l
l
n
e
r
 
e
t
 
a
l
.
 
M
R
I
7
M
,
 
5
F
 
O
C
D
 
c
a
u
d
a
t
e
 
n
c
l
.
 
O
C
D
 
=
 
c
o
n
t
r
o
l
s
1
9
9
1
 
6
9
7
M
,
 
5
F
 
c
o
n
t
r
o
l
s
c
i
n
g
u
l
a
t
e
 
g
y
r
u
s
 
c
o
r
p
u
s
 
c
a
l
l
o
s
u
m
 
i
n
t
r
a
c
a
u
d
a
t
e
 
,
 
f
r
o
n
t
a
l
 
h
o
r
n
 
r
a
t
i
o
H
a
r
r
i
s
 
e
t
 
a
l
.
 
M
R
I
1
0
M
 
O
C
D
 
t
o
t
a
l
 
b
r
a
i
n
 
O
C
D
 
=
 
c
o
n
t
r
o
l
s
1
9
9
1
 
6
2
1
0
M
 
c
o
n
t
r
o
l
s
C
S
F
A
y
l
w
a
r
d
 
e
t
 
a
l
.
 
M
R
I
1
3
M
,
 
6
F
 
O
C
D
 
b
i
c
a
u
d
a
t
e
 
r
a
t
i
o
 
O
C
D
 
=
 
c
o
n
t
r
o
l
s
1
9
9
1
 
7
0
1
9
M
,
 
6
F
 
c
o
n
t
r
o
l
s
b
i
f
r
o
n
t
a
l
 
r
a
t
i
o
S
c
a
r
o
n
e
 
e
t
 
a
l
.
 
M
R
I
8
M
,
 
1
2
F
 
O
C
D
 
c
a
u
d
a
t
e
 
n
c
l
.
 
R
O
C
D
 
>
 
c
o
n
t
r
o
l
s
a
l
l
 
O
C
D
 
u
s
i
n
g
 
S
R
I
’
s
 
1
9
9
2
 
6
7
1
0
M
,
 
6
F
 
c
o
n
t
r
o
l
s
s
a
m
e
 
s
u
b
j
e
c
t
 
g
r
o
u
p
 
a
s
 
i
n
 
C
a
l
a
b
r
e
s
e
 
e
t
 
a
l
.
 
1
2
6
C
a
l
a
b
r
e
s
e
 
e
t
 
a
l
.
 
M
R
I
 
8
M
,
 
1
2
 
O
C
D
 
c
a
u
d
a
t
e
 
n
c
l
.
 
L
 
&
 
R
a
s
y
m
m
e
t
r
i
c
 
S
I
 
a
l
l
 
O
C
D
 
u
s
i
n
g
 
S
R
I
’
s
 
1
9
9
3
 
1
2
6
8
M
,
 
6
F
 
c
o
n
t
r
o
l
s
i
n
 
O
C
D
s
a
m
e
 
s
u
b
j
e
c
t
 
g
r
o
u
p
 
a
s
 
i
n
 
S
c
a
r
o
n
e
 
e
t
 
a
l
.
 
6
7
1Hfdst1 XP  18-01-2005  14:00  Pagina 3031 Chapter 1
S
t
e
i
n
 
e
t
 
a
l
.
 
C
T
5
M
,
 
3
F
 
O
C
D
 
v
e
n
t
r
i
c
l
e
s
 
v e n t r i c l e s :
a
b
s
o
l
u
t
e
 
v
o
l
u
m
e
s
 
a
s
 
%
 
o
f
 
t
o
t
a
l
 
1
9
9
3
 
6
1
h
i
g
h
 
n
e
u
r
o
l
.
 
c
a
u
d
a
t
e
 
n
c
l
.
 
h
i
g
h
 
O
C
D
 
>
 
c
o
n
t
r
o
l
s
i
n
t
r
a
c
r
a
n
i
a
l
 
v
o
l
u
m
e
 
s
o
f
t
 
s
i
g
n
s
 
l
e
n
t
i
c
u
l
a
r
 
n
c
l
.
h
i
g
h
 
O
C
D
 
>
 
l
o
w
 
O
C
D
a
l
l
 
s
u
b
j
e
c
t
s
 
d
r
u
g
-
f
r
e
e
5
M
,
 
3
F
 
O
C
D
 
l
o
w
 
n
e
u
r
o
l
.
 
s
o
f
t
 
s
i
g
n
s
 
3
M
,
 
5
F
 
c
o
n
t
r
o
l
s
B
r
e
i
t
e
r
 
e
t
 
a
l
.
 
M
R
I
6
F
 
O
C
D
 
r
e
t
r
o
c
a
l
l
o
s
a
l
 
w
h
i
t
e
 
r e t r o c a l l o s a l   w h i t e :
5
 
O
C
D
 
u
s
i
n
g
 
m
e
d
i
c
a
t
i
o
n
 
1
9
9
4
 
6
4
8
F
 
c
o
n
t
r
o
l
s
&
 
g
r
e
y
 
m
a
t
t
e
r
 
O
C
D
 
<
 
c
o
n
t
r
o
l
s
 
5
 
O
C
D
 
c
o
m
o
r
b
i
d
 
d
i
a
g
n
o
s
e
s
 
l
a
t
e
r
a
l
 
v
e
n
t
r
i
c
l
e
 
(
M
D
,
 
S
P
,
 
e
a
t
i
n
g
 
d
i
s
o
r
d
e
r
)
c
o
r
p
u
s
 
c
a
l
l
o
s
u
m
R
o
b
i
n
s
o
n
 
e
t
 
a
l
.
 
M
R
I
1
4
M
,
 
1
2
F
 
O
C
D
 
t
o
t
a
l
 
b
r
a
i
n
 
c a u d a t e   n c l .
:
 
6
 
O
C
D
 
c
o
m
o
r
b
i
d
 
d
i
a
g
n
o
s
e
s
 
1
9
9
5
 
6
3
1
6
M
,
 
1
0
F
 
c
o
n
t
r
o
l
s
p
r
e
f
r
o
n
t
a
l
 
c
.
 
O
C
D
<
 
c
o
n
t
r
o
l
s
(
M
D
,
 
d
y
s
t
h
y
m
i
a
,
 
s
i
m
p
l
e
 
p
h
o
b
i
a
,
 
c
a
u
d
a
t
e
 
n
c
l
.
 
t
r
i
c
h
o
t
i
l
l
o
m
a
n
i
a
)
l
a
t
e
r
a
l
 
v
e
n
t
r
i
c
l
e
s
 
t
h
i
r
d
 
v
e
n
t
r
i
c
l
e
J
e
n
i
k
e
 
e
t
 
a
l
.
 
M
R
I
1
0
F
 
O
C
D
 
c
e
r
e
b
r
a
l
 
c
.
 
&
 
w
h
i
t
e
O C D   <   c o n t r o l s :
v
o
l
u
m
e
 
a
s
 
%
 
o
f
 
t
o
t
a
l
 
v
o
l
u
m
e
1
9
9
6
 
6
5
1
0
F
 
c
o
n
t
r
o
l
s
m
a
t
t
e
r
 
,
 
c
e
r
e
b
e
l
l
a
r
 
c
e
r
e
b
r
a
l
 
w
h
i
t
e
 
c
.
 
&
 
w
h
i
t
e
 
m
a
t
t
e
r
 
c
e
r
e
b
e
l
l
a
r
 
w
h
i
t
e
 
c
a
u
d
a
t
e
 
n
c
l
.
 
,
 
p
u
t
a
m
e
n
r
e
t
r
o
c
a
l
l
o
s
a
l
 
w
h
i
t
e
 
g
l
o
b
u
s
 
p
a
l
l
i
d
u
s
 
 
O C D   >   c o n t r o l s :
t
h
a
l
a
m
u
s
c
e
r
e
b
r
a
l
 
c
o
r
t
e
x
o
p
e
r
c
u
l
u
m
o
p
e
r
c
u
l
u
m
d
i
e
n
c
e
p
h
a
l
o
n
 
h
i
p
p
o
c
a
m
p
u
s
 
a
m
y
g
d
a
l
a
 
,
 
i
n
s
u
l
a
 
3
&
4
 
v
e
n
t
r
i
c
l
e
 
c
o
r
p
u
s
 
c
a
l
l
o
s
u
m
 
c
e
r
e
b
e
l
l
u
m
 
b
r
a
i
n
 
s
t
e
m
1Hfdst1 XP  18-01-2005  14:00  Pagina 3132
A
y
l
w
a
r
d
 
e
t
 
a
l
.
 
M
R
I
1
7
M
,
 
7
F
 
O
C
D
 
C
S
F
 
O
C
D
 
=
 
c
o
n
t
r
o
l
s
d
r
u
g
-
f
r
e
e
 
m
i
n
 
4
 
w
e
e
k
s
,
 
7
 
O
C
D
 
d
r
u
g
-
n
a
i
v
e
 
 
1
9
9
6
 
6
6
1
4
M
,
 
7
F
 
c
o
n
t
r
o
l
s
t
o
t
a
l
 
b
r
a
i
n
 
2
0
 
O
C
D
 
c
o
m
o
r
b
i
d
 
d
i
a
g
n
o
s
e
s
 
c
a
u
d
a
t
e
 
n
c
l
.
 
(
G
A
D
,
 
P
D
,
 
S
P
,
 
s
i
m
p
l
e
 
p
h
o
b
i
a
)
p
u
t
a
m
e
n
 
1
9
/
2
4
 
s
u
b
j
e
c
t
s
 
f
r
o
m
 
A
y
l
w
a
r
d
 
e
t
 
a
l
.
 
7
0
b
i
c
a
u
d
a
t
e
 
r
a
t
i
o
G
r
a
c
h
e
v
 
e
t
 
a
l
.
 
M
R
I
1
0
F
 
O
C
D
 
o
r
b
i
t
o
f
r
o
n
t
a
l
 
c
.
 
O
C
D
 
=
 
c
o
n
t
r
o
l
s
r
e
-
a
n
a
l
y
s
i
s
 
o
f
 
J
e
n
i
k
e
 
e
t
 
a
l
.
 
6
5
1
9
9
8
 
7
5
1
0
F
 
c
o
n
t
r
o
l
s
a
n
t
.
 
c
i
n
g
u
l
a
t
e
 
o
p
e
r
c
u
l
u
m
B
a
r
t
h
a
 
e
t
 
a
l
.
 
M
R
S
 
/
 
M
R
I
7
M
,
 
6
F
 
O
C
D
 
c
a
u
d
a
t
e
 
n
c
l
.
O
C
D
 
=
 
c
o
n
t
r
o
l
s
9
 
O
C
D
 
S
S
R
I
-
n
a
ï
v
e
,
 
1
 
O
C
D
 
M
D
 
1
9
9
8
 
7
2
7
M
,
 
6
F
 
c
o
n
t
r
o
l
s
N
-
a
c
e
t
y
l
-
a
s
p
a
r
t
a
t
e
 
d
a
t
a
 
s
e
e
 
T
a
b
l
e
 
7
S
z
e
s
z
k
o
 
e
t
 
a
l
.
 
M
R
I
1
4
M
,
 
1
2
F
 
O
C
D
 
m
e
s
i
o
t
e
m
p
o
r
a
l
 
l
o
b
e
 
O C D   <   c o n t r o l s :
1
9
9
9
 
7
4
1
6
M
,
 
1
0
F
 
c
o
n
t
r
o
l
s
h
i
p
p
o
c
a
m
p
u
s
 
o
r
b
i
t
o
f
r
o
n
t
a
l
 
c
o
r
t
e
x
 
a
m
y
g
d
a
l
a
 
a
m
y
g
d
a
l
a
 
R
f
r
o
n
t
a
l
 
l
o
b
e
 
a
n
t
.
 
c
i
n
g
u
l
a
t
e
G
i
l
b
e
r
t
 
e
t
 
a
l
.
 
M
R
I
 
7
M
,
 
1
4
F
 
O
C
D
*
 
t
h
a
l
a
m
u
s
 
p r e t r e a t m e n t  
1
0
 
O
C
D
 
p
a
r
o
x
e
t
i
n
e
 
1
2
w
,
 
7
 
r
e
s
p
o
n
d
e
r
s
 
2
0
0
0
 
7
6
p
a
r
o
x
e
t
i
n
e
7
M
,
 
1
4
F
 
c
o
n
t
r
o
l
s
*
i
n
t
r
a
c
r
a
n
i
a
l
 
v
o
l
u
m
e
t h a l a m u s :
c
o
m
o
r
b
i
d
 
a
n
x
i
e
t
y
 
d
i
s
o
r
d
e
r
,
 
d
y
s
t
h
y
m
i
a
,
 
O
C
D
  >
c
o
n
t
r
o
l
s
 
t
r
i
c
h
o
t
i
l
l
o
m
a
n
i
a
,
 
o
p
p
o
s
i
t
i
o
n
a
l
 
d
e
ﬁ
a
n
t
 
f o l l o w - u p :
d
i
s
o
r
d
e
r
 
O
C
D
 
=
 
c
o
n
t
r
o
l
s
*
a
l
l
 
p
e
d
i
a
t
r
i
c
 
s
u
b
j
e
c
t
s
R
o
s
e
n
b
e
r
g
 
e
t
 
a
l
.
 
M
R
I
 
5
M
,
 
6
F
 
O
C
D
*
 
t
h
a
l
a
m
u
s
 
t h a l a m u s
O
C
D
 
c
o
m
o
r
b
i
d
 
d
i
a
g
n
o
s
i
s
 
(
3
 
o
t
h
e
r
 
a
n
x
i
e
t
y
 
2
0
0
0
 
1
3
0
C
B
T
i
n
t
r
a
c
r
a
n
i
a
l
 
v
o
l
u
m
e
p
r
e
 
=
 
p
o
s
t
-
t
r
e
a
t
m
e
n
t
d
i
s
o
r
d
e
r
s
,
 
2
 
d
y
s
t
h
y
m
i
a
,
 
1
 
A
D
H
D
,
 
1
 
t
r
i
c
h
o
t
i
l
l
o
m
a
n
i
a
 
*
a
l
l
 
p
e
d
i
a
t
r
i
c
 
p
a
t
i
e
n
t
s
T
a
b
l
e
 
6
(
c
o
n
t
i
n
u
e
d
)
.
 
S
t
r
u
c
t
u
r
a
l
 
i
m
a
g
i
n
g
 
i
n
 
o
b
s
e
s
s
i
v
e
-
c
o
m
p
u
l
s
i
v
e
 
d
i
s
o
r
d
e
r
 
(
O
C
D
)
.
A
u
t
h
o
r
s
M
e
t
h
o
d
S
u
b
j
e
c
t
s
R
O
I
F
i
n
d
i
n
g
s
R
e
m
a
r
k
s
1Hfdst1 XP  18-01-2005  14:00  Pagina 3233 Chapter 1
K
i
m
 
e
t
 
a
l
.
 
M
R
I
1
7
M
,
 
8
F
 
O
C
D
 
S
P
M
O C D   >   c o n t r o l s :
O
C
D
 
c
o
m
o
r
b
i
d
 
d
i
a
g
n
o
s
i
s
 
(
3
 
M
D
,
 
1
 
M
D
 
a
n
d
 
2
0
0
1
 
7
3
1
7
M
,
 
8
F
 
c
o
n
t
r
o
l
s
s
u
p
.
 
t
e
m
p
o
r
a
l
 
g
y
r
u
s
 
b
u
l
i
m
i
a
 
n
e
r
v
o
s
a
)
 
o
r
b
i
t
o
f
r
o
n
t
a
l
 
c
o
r
t
e
x
 
L
 
8
 
O
C
D
 
d
r
u
g
-
n
a
ï
v
e
i
n
f
.
 
p
a
r
i
e
t
a
l
 
l
o
b
e
 
t
h
a
l
a
m
u
s
 
,
 
i
n
s
u
l
a
 
R
 
m
i
d
d
l
e
 
t
e
m
p
o
r
a
l
 
g
y
r
u
s
 
i
n
f
.
 
o
c
c
i
p
i
t
a
l
 
c
o
r
t
e
x
 
h
y
p
o
t
h
a
l
a
m
u
s
 
O C D   <   c o n t r o l s :
c
e
r
e
b
e
l
l
u
m
 
L
 
c
u
n
e
u
s
 
L
C
S
F
 
=
 
c
e
r
e
b
r
o
s
p
i
n
a
l
 
ﬂ
u
i
d
,
 
S
R
I
 
=
 
s
e
r
o
t
o
n
i
n
 
r
e
u
p
t
a
k
e
 
i
n
h
i
b
i
t
o
r
s
,
 
R
O
I
 
=
 
r
e
g
i
o
n
 
o
f
 
i
n
t
e
r
e
s
t
,
 
c
.
 
=
 
c
o
r
t
e
x
,
 
c
t
r
.
 
b
d
l
.
 
=
 
c
e
n
t
r
a
l
 
b
u
n
d
l
e
,
 
M
D
 
=
 
m
a
j
o
r
 
d
e
p
r
e
s
s
i
o
n
,
S
P
 
=
 
s
o
c
i
a
l
 
p
h
o
b
i
a
,
 
G
A
D
 
=
 
g
e
n
e
r
a
l
i
z
e
d
 
a
n
x
i
e
t
y
 
d
i
s
o
r
d
e
r
,
 
P
D
 
=
 
p
a
n
i
c
 
d
i
s
o
r
d
e
r
,
 
L
 
=
 
l
e
f
t
,
 
R
 
=
 
r
i
g
h
t
,
 
S
P
M
 
=
 
s
t
a
t
i
s
t
i
c
a
l
 
p
a
r
a
m
e
t
r
i
c
 
m
a
p
p
i
n
g
,
 
C
B
T
 
=
 
c
o
g
n
i
t
i
v
e
b
e
h
a
v
i
o
r
a
l
 
t
h
e
r
a
p
y
1Hfdst1 XP  18-01-2005  14:00  Pagina 33In conclusion, structural imaging ﬁndings in OCD are divergent on all brain areas
under investigation. Volumetric changes of the caudate nucleus, frontal cortex,
thalamus and white matter in OCD patients were seen. Several methodological
differences like different scan techniques and ROI segmentation play an important
role in these divergent ﬁndings. It seems also important to standardize patient groups
for use of medication and comorbid diagnoses.
Functional imaging studies in OCD
Functional imaging studies in OCD have been performed with PET, SPECT, MRS
and fMRI under different condition; at baseline (without intervention), during
pharmacological and behavioral symptom provocation and during treatment.
Functional imaging under baseline conditions
Different areas of the frontal cortex were under investigation; the orbitofrontal cortex
(OFC), prefrontal cortex (PFC), medio-, postero-, inferior- and superior frontal cortex
(see Table 7). When ﬁndings on the various frontal cortex areas are taken together,
increased activity was found in OCD patients in most studies
77-86. One PET and 1 SPECT
investigation reported decreased frontal activity
87, 88. In these 2 studies a substantial
number of patients were using drugs, in contrast to the studies which mentioned
increased frontal activity. No change in activity was measured with a SPECT
89 and MRS
investigation
90, in which there were also patients using medication. Pharmacological
treatment can inﬂuence imaging results; in a structural imaging study thalamic volume
was decreased during pharmacological treatment
76 (see Table 6). These ﬁndings stresses
the importance of controlling study designs for drug histories.
In the caudate nucleus decreased activity was reported in OCD patients at baseline
82,
86, 88, 89, 91 and one report found increased activity
85. In several other studies in which
the caudate nucleus was under investigation no changes were measured in caudate
nucleus activity
77-80, 83, 84, 87, 90.
Putamen activity activity was found increased
85, 93 and decreased
89 at baseline, but 3
other studies did not report changes in activity
77, 79, 82.
Thalamic ﬁndings are also divergent; increased activity
83, 84, 93, 94 and decreased activity
was mentioned at baseline measurements
88, 95. Also a substantial number of reports did
not ﬁnd changes in thalamic activity
77, 80, 82, 87, 89, 90.
Anterior cingulate activity was found increased in 2 studies
80, 93, whereas other studies
did not measure changes in activity
77, 79, 83, 84, 89, except for one study in which increased
activity was seen
80.
34
1Hfdst1 XP  18-01-2005  14:00  Pagina 34In conclusion, ﬁndings in baseline functional imaging in OCD showed divergent
results regarding activity found in the frontal cortex, caudate nucleus, putamen and
thalamus; increased activity in the frontal cortex and decreased activity in caudate
nucleus seem to be the most consistent ﬁndings. The thalamus is found to be involved
in OCD, but it is not clear whether activity is increased or decreased at baseline. There
are several investigations however, in which in aforementioned ROIs no signiﬁcant
changes in activity were found.
Functional imaging during symptom provocation
Imaging findings during challenge procedures on the other hand were more
consistent than during baseline imaging. All ROIs under investigation in all imaging
challenge studies showed increased activity during symptom exacerbation, that is in
the frontal and temporal cortex, anterior cingulate, caudate nucleus, putamen and
thalamus (see Table 8). One 
133Xe-SPECT study found decreased cortical activity during
severe anxiety, but subcortical brain areas can not be measured with this technique
97.
A PET study found a negative correlation with symptom intensity for the prefrontal
cortex and temporo-parietal cortex
98.
Functional imaging during treatment
The activity of the frontal cortex was generally decreased during pharmacological
treatment
85, 86, 99-102, but in some studies no changes in activity was found
87, 93, 103, 104 (see
Table 9).
Also in the caudate nucleus activity was decreased during pharmacological
treatment
85, 86, 101-104, although some studies did not ﬁnd differences in activity
87, 93, 100.
Interestingly, behavioral therapy also induced decrease of caudate nucleus activity
103,
104, suggesting a common pathophysiological mechanism between the two treatment
regimes.
Except for one study in which increased activity in the putamen was seen during
treatment
85, all other investigation showed no changes in activity as compared to pre-
treatment measurements
86, 93, 102-104.
In the thalamus, activity was decreased during treatment
101-103, although a substantial
number of studies did not ﬁnd involvement of the thalamus during treatment
86, 87, 93, 104.
The anterior cingulate activity decreased during treatment
93, 101, 103, but this was not
conﬁrmed in other investigations
100, 104.
In general, activity of the various ROIs were decreased during treatment, although
this decrease was not seen in all studies.
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i
z
a
t
i
o
n
 
w
h
o
l
e
 
c
o
r
t
i
c
a
l
 
m
e
a
n
R
u
b
i
n
 
e
t
 
a
l
.
 
1
3
3
X
e
 
 
1
0
M
 
O
C
D
 
T c
-
H
M
P
A
O
:
 
X e :
O
C
D
 
d
r
u
g
-
f
r
e
e
 
m
i
n
.
 
4
 
w
e
e
k
s
,
 
1
9
9
2
 
8
2
9
9
m
T
c
-
1
0
M
 
c
o
n
t
r
o
l
s
c
o
r
t
e
x
 
O
C
D
 
=
 
c
o
n
t
r
o
l
s
 
3
 
O
C
D
 
d
r
u
g
-
n
a
i
v
e
 
H
M
P
A
O
c
a
u
d
a
t
e
 
n
c
l
.
 
T c
-
H
M
P
A
O
:
 
c
o
r
t
i
c
a
l
 
R
O
I
 
a
l
g
o
r
i
t
h
m
,
 
b
a
s
a
l
 
g
g
l
.
 
h
a
n
d
d
r
a
w
n
 
p
u
t
a
m
e
n
 
,
 
t
h
a
l
a
m
u
s
O C D   >   c o n t r o l s
:
p
a
t
t
e
r
n
 
o
f
 
s
i
g
n
i
ﬁ
c
a
n
c
e
 
d
e
t
e
r
m
i
n
e
d
 
d
o
r
s
o
-
p
a
r
i
e
t
a
l
 
n
o
r
m
a
l
i
z
a
t
i
o
n
 
c
e
r
e
b
e
l
l
u
m
 
a
n
d
 
c
e
r
e
b
r
a
l
 
c
o
r
t
e
x
p
o
s
t
e
r
o
-
f
r
o
n
t
a
l
 
L
 
o
r
b
i
t
o
-
f
r
o
n
t
a
l
 
O C D   <   c o n t r o l s
:
c
a
u
d
a
t
e
 
n
c
l
.
E
d
m
o
n
s
t
o
n
e
 
e
t
a
l
.
9
9
m
T
c
-
e
x
a
-
7
M
,
 
5
 
O
C
D
 
f
r
o
n
t
a
l
 
c
.
 
,
 
t
e
m
p
o
r
a
l
 
c
.
 
c a u d a t e   n c l .   R :
1
2
 
O
C
D
,
 
1
0
 
M
D
 
u
s
i
n
g
 
m
e
d
i
c
a
t
i
o
n
 
1
9
9
4
 
8
9
m
e
t
a
z
i
n
e
7
M
,
 
5
F
 
M
D
 
c
i
n
g
u
l
a
t
e
 
O
C
D
 
<
 
c
o
n
t
r
o
l
s
 
n
o
r
m
a
l
i
z
a
t
i
o
n
 
o
c
c
i
p
i
t
o
-
c
a
l
c
a
r
i
n
e
 
a
r
e
a
7
M
,
 
5
F
 
c
o
n
t
r
o
l
s
 
c
a
u
d
a
t
e
 
n
c
l
.
 
p u t a m e n :
p
u
t
a
m
e
n
 
,
 
t
h
a
l
a
m
u
s
O
C
D
 
<
 
c
o
n
t
r
o
l
s
 
t e m p o r a l   s u p .
c o r t e x   R :
O
C
D
 
=
 
c
o
n
t
r
o
l
s
 
>
 
M
D
P
e
r
a
n
i
 
e
t
 
a
l
.
 
1
8
F
-
F
D
G
3
M
,
 
8
F
 
O
C
D
 
f
r
o
n
t
a
l
 
c
.
 
,
 
p
a
r
i
e
t
a
l
 
c
.
 
O C D   >   c o n t r o l s :
d
r
u
g
-
f
r
e
e
 
m
i
n
.
 
2
 
w
e
e
k
s
 
1
9
9
5
 
9
3
1
1
M
,
 
4
F
 
c
o
n
t
r
o
l
s
t
e
m
p
o
r
a
l
 
c
.
 
c
i
n
g
u
l
a
t
e
 
c
.
 
s
i
g
n
i
ﬁ
c
a
n
c
e
 
l
e
v
e
l
 
p
 
<
 
0
.
0
2
 
o
c
c
i
p
i
t
a
l
 
c
.
 
p
a
l
l
i
d
u
m
 
,
 
p
u
t
a
m
e
n
 
n
o
r
m
a
l
i
z
a
t
i
o
n
 
g
l
o
b
a
l
 
h
e
m
i
s
p
h
e
r
e
 
c
i
n
g
u
l
a
t
e
 
c
.
 
t
h
a
l
a
m
u
s
 
t
r
e
a
t
m
e
n
t
 
d
a
t
a
 
s
e
e
 
T
a
b
l
e
 
9
c
a
u
d
a
t
e
 
n
c
l
.
 
p
u
t
a
m
e
n
 
,
 
t
h
a
l
a
m
u
s
 
c
e
r
e
b
e
l
l
u
m
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L
u
c
e
y
 
e
t
 
a
l
.
 
9
9
m
T
c
-
1
7
M
,
 
1
3
F
 
O
C
D
 
f
r
o
n
t
a
l
 
c
.
 
,
 
t
e
m
p
o
r
a
l
 
c
.
 
O C D   <   c o n t r o l s :
8
 
O
C
D
 
u
s
i
n
g
 
S
R
I
’
s
 
1
9
9
5
 
8
8
H
M
P
A
O
1
7
M
,
 
1
3
F
 
c
o
n
t
r
o
l
s
p
a
r
i
e
t
a
l
 
c
.
 
,
 
o
c
c
i
p
i
t
a
l
 
c
.
 
c
a
u
d
a
t
e
 
n
c
l
.
 
R
 
s
i
m
i
l
a
r
 
ﬁ
n
d
i
n
g
s
 
w
h
e
n
 
S
R
I
 
p
a
t
i
e
n
t
s
 
w
e
r
e
 
c
a
u
d
a
t
e
 
n
c
l
.
 
,
 
t
h
a
l
a
m
u
s
 
t
h
a
l
a
m
u
s
 
R
 
e
x
c
l
u
d
e
d
 
f
r
o
m
 
s
t
a
t
i
s
t
i
c
a
l
 
a
n
a
l
y
s
e
s
 
c
e
r
e
b
e
l
l
u
m
 
,
 
b
r
a
i
n
 
s
t
e
m
i
n
f
.
 
f
r
o
n
t
a
l
 
R
 
n
o
r
m
a
l
i
z
a
t
i
o
n
 
c
e
r
e
b
e
l
l
u
m
s
u
p
.
 
f
r
o
n
t
a
l
 
l
a
t
.
 
t
e
m
p
o
r
a
l
 
L
 
p
a
r
i
e
t
a
l
 
L
R
u
b
i
n
 
e
t
 
a
l
.
 
1
3
3
X
e
 
8
M
 
O
C
D
 
f
r
o
n
t
a
l
 
c
.
 
,
 
t
e
m
p
o
r
a
l
 
c
.
 
X e :
d
r
u
g
-
f
r
e
e
 
m
i
n
.
 
4
 
w
e
e
k
s
 
1
9
9
5
 
8
6
9
9
m
T
c
-
8
M
 
c
o
n
t
r
o
l
s
p
a
r
i
e
t
a
l
 
c
.
 
,
 
o
c
c
i
p
i
t
a
l
 
c
.
 
O
C
D
 
=
 
c
o
n
t
r
o
l
s
 
n
o
r
m
a
l
i
z
a
t
i
o
n
 
c
e
r
e
b
e
l
l
u
m
 
a
n
d
 
H
M
P
A
O
c
a
u
d
a
t
e
 
n
c
l
.
 
,
 
p
u
t
a
m
e
n
 
T c - H M P A O :
c
e
r
e
b
r
a
l
 
c
o
r
t
e
x
 
t
h
a
l
a
m
u
s
 
,
 
c
e
r
e
b
e
l
l
u
m
p
a
r
i
e
t
a
l
:
 
O
C
D
 
>
 
c
o
n
t
r
o
l
s
 
t
r
e
a
t
m
e
n
t
 
d
a
t
a
 
s
e
e
 
T
a
b
l
e
 
9
f
r
o
n
t
a
l
:
 
O
C
D
 
>
 
c
o
n
t
r
o
l
s
 
c
a
u
d
a
t
e
:
 
O
C
D
 
<
 
c
o
n
t
r
o
l
s
B
a
r
t
h
a
 
e
t
 
a
l
.
 
M
R
S
/
M
R
I
7
M
,
 
6
F
 
O
C
D
 
l
e
f
t
 
c
o
r
p
u
s
 
s
t
r
i
a
t
u
m
O C D   <   c o n t r o l s :
9
 
O
C
D
 
S
S
R
I
-
n
a
ï
v
e
,
 
4
 
O
C
D
 
6
 
w
 
d
r
u
g
-
f
r
e
e
,
 
1
9
9
8
 
9
1
7
M
,
 
6
F
 
c
o
n
t
r
o
l
s
N
A
A
 
c
o
r
p
u
s
 
s
t
r
i
a
t
u
m
 
L
1
 
O
C
D
 
c
o
m
o
r
b
i
d
 
M
D
 
M
R
I
 
d
a
t
a
 
s
e
e
 
T
a
b
l
e
 
6
O
h
a
r
a
 
e
t
 
a
l
.
 
M
R
S
1
0
M
,
 
2
F
 
O
C
D
 
l
e
n
t
i
c
u
l
a
r
 
n
c
l
.
 
O
C
D
 
=
 
c
o
n
t
r
o
l
s
2
 
O
C
D
 
d
r
u
g
-
n
a
i
v
e
,
 
1
0
 
u
s
i
n
g
 
1
9
9
9
 
9
0
1
0
M
,
 
2
F
 
c
o
n
t
r
o
l
s
i
n
s
u
l
a
 
c
.
 
,
 
f
r
o
n
t
a
l
 
c
.
 
c
l
o
m
i
p
r
a
m
i
n
e
 
o
r
 
h
a
l
o
p
e
r
i
d
o
l
 
c
a
u
d
a
t
e
 
n
c
l
.
 
,
 
t
h
a
l
a
m
u
s
M
R
S
 
m
e
a
s
u
r
e
m
e
n
t
s
 
c
h
o
l
i
n
e
,
 
c
r
e
a
t
i
n
e
 
a
n
d
N
A
A
F
i
t
z
g
e
r
a
l
d
 
e
t
 
a
l
.
 
M
R
S
4
M
,
 
7
F
 
O
C
D
*
 
t
h
a
l
a
m
u
s
O C D   <   c o n t r o l s :
5
 
O
C
D
 
c
o
m
o
r
b
i
d
 
a
n
x
i
e
t
y
 
d
i
s
o
r
d
e
r
s
 
2
0
0
0
 
9
5
4
M
,
 
7
F
 
c
o
n
t
r
o
l
s
*
m
e
d
i
a
l
 
t
h
a
l
a
m
u
s
M
R
S
 
m
e
a
s
u
r
e
m
e
n
t
s
 
c
h
o
l
i
n
e
,
 
c
r
e
a
t
i
n
e
 
a
n
d
N
A
A
 
*
a
l
l
 
p
e
d
i
a
t
r
i
c
 
s
u
b
j
e
c
t
s
R
o
s
e
n
b
e
r
g
 
e
t
 
a
l
.
 
M
R
S
4
M
,
 
7
F
 
O
C
D
*
 
t
h
a
l
a
m
u
s
O C D   >   c o n t r o l s :
i
d
e
n
t
i
c
a
l
 
p
a
t
i
e
n
t
g
r
o
u
p
 
a
s
 
F
i
t
z
g
e
r
a
l
d
 
e
t
 
a
l
.
 
9
5
2
0
0
1
 
1
3
3
4
M
,
 
7
F
 
c
o
n
t
r
o
l
s
*
c
h
o
l
i
n
e
 
m
e
d
i
a
l
 
t
h
a
l
a
m
u
s
*
a
l
l
 
p
e
d
i
a
t
r
i
c
 
s
u
b
j
e
c
t
s
T
a
b
l
e
 
7
(
c
o
n
t
i
n
u
e
d
)
.
 
B
a
s
e
l
i
n
e
 
f
u
n
c
t
i
o
n
a
l
 
i
m
a
g
i
n
g
 
i
n
 
o
b
s
e
s
s
i
v
e
-
c
o
m
p
u
l
s
i
v
e
 
d
i
s
o
r
d
e
r
 
(
O
C
D
)
.
A
u
t
h
o
r
s
M
e
t
h
o
d
S
u
b
j
e
c
t
s
R
O
I
F
i
n
d
i
n
g
s
R
e
m
a
r
k
s
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A
l
p
t
e
k
i
n
 
e
t
 
a
l
.
 
9
9
m
T
c
-
3
M
,
 
6
F
 
O
C
D
 
c
e
r
e
b
e
l
l
u
m
 
,
 
f
r
o
n
t
a
l
 
c
.
 
O C D   >   c o n t r o l s :
5
 
O
C
D
 
d
r
u
g
-
n
a
i
v
e
,
 
4
 
O
C
D
 
d
r
u
g
-
f
r
e
e
 
2
0
0
1
 
8
3
H
M
P
A
O
2
M
,
 
4
F
 
c
o
n
t
r
o
l
s
p
a
r
i
e
t
a
l
 
c
.
 
,
 
t
e
m
p
o
r
a
l
 
c
.
 
t
h
a
l
a
m
u
s
 
R
 
6
 
m
o
n
t
h
s
,
 
T
u
r
k
i
s
h
 
p
o
p
u
l
a
t
i
o
n
 
o
c
c
i
p
i
t
a
l
 
c
.
 
,
 
c
a
u
d
a
t
e
 
n
c
l
 
f
r
o
n
t
o
-
t
e
m
p
o
r
a
l
 
L
 
n
o
r
m
a
l
i
z
a
t
i
o
n
 
c
e
r
e
b
e
l
l
u
m
t
h
a
l
a
m
u
s
 
,
 
c
i
n
g
u
l
a
t
e
 
c
.
o
r
b
i
t
o
f
r
o
n
t
a
l
 
c
o
r
t
e
x
S
a
x
e
n
a
 
e
t
 
a
l
.
 
1
8
F
-
F
D
G
1
2
M
,
 
1
5
F
 
O
C
D
 
t
h
a
l
a
m
u
s
O C D   >   c o n t r o l s :
d
a
t
a
 
o
n
 
M
D
 
p
a
t
i
e
n
t
s
 
a
n
d
 
O
C
D
 
w
i
t
h
 
M
D
 
2
0
0
1
 
9
4
c
o
n
t
r
o
l
s
t
h
a
l
a
m
u
s
n
o
t
 
g
i
v
e
n
 
n
o
r
m
a
l
i
z
a
t
i
o
n
 
i
p
s
i
l
a
t
.
 
h
e
m
i
s
p
h
e
r
e
L
a
c
e
r
d
a
 
e
t
 
a
l
.
 
9
9
m
T
c
-
8
M
,
 
8
F
 
O
C
D
 
f
r
o
n
t
a
l
 
c
.
 
,
 
p
a
r
i
e
t
a
l
 
c
.
 
O C D   >   c o n t r o l s :
1
0
 
O
C
D
 
d
r
u
g
-
n
a
i
v
e
 
2
0
0
3
 
8
4
H
M
P
A
O
1
0
M
,
 
7
F
 
c
o
n
t
r
o
l
s
t
e
m
p
o
r
a
l
 
c
.
 
f
r
o
n
t
a
l
 
c
o
r
t
e
x
 
R
 
n
o
r
m
a
l
i
z
a
t
i
o
n
 
c
e
r
e
b
e
l
l
u
m
 
b
a
s
a
l
 
g
a
n
g
l
i
a
 
t
h
a
l
a
m
u
s
a
f
t
e
r
 
B
o
n
f
e
r
r
o
n
i
 
c
o
r
r
e
c
t
i
o
n
:
 
s
i
g
n
i
ﬁ
c
a
n
t
 
t
h
a
l
a
m
u
s
 
ﬁ
n
d
i
n
g
s
 
f
o
r
 
t
h
a
l
a
m
u
s
 
o
n
l
y
a
n
t
.
 
c
i
n
g
u
l
a
t
e
 
g
y
r
u
s
 
v
i
s
u
a
l
 
c
.
 
,
 
v
e
r
m
i
s
M
D
 
=
 
m
a
j
o
r
 
d
e
p
r
e
s
s
i
o
n
,
 
S
P
 
=
 
s
o
c
i
a
l
 
p
h
o
b
i
a
,
 
G
A
D
 
=
 
g
e
n
e
r
a
l
 
a
n
x
i
e
t
y
 
d
i
s
o
r
d
e
r
,
 
P
D
 
=
 
p
a
n
i
c
 
d
i
s
o
r
d
e
r
,
 
r
C
B
F
 
=
 
r
e
g
i
o
n
a
l
 
c
e
r
e
b
r
a
l
 
b
l
o
o
d
 
ﬂ
o
w
,
 
R
O
I
=
 
r
e
g
i
o
n
 
o
f
i
n
t
e
r
e
s
t
,
 
M
D
=
m
a
j
o
r
 
d
e
p
r
e
s
s
i
o
n
,
 
L
=
l
e
f
t
,
 
R
=
r
i
g
h
t
,
 
w
h
e
n
 
n
o
t
 
m
e
n
t
i
o
n
e
d
 
o
t
h
e
r
w
i
s
e
 
ﬁ
n
d
i
n
g
s
 
a
r
e
 
b
i
l
a
t
e
r
a
l
l
y
,
 
N
A
A
 
=
 
N
-
a
c
e
t
y
l
-
a
s
p
a
r
t
a
t
e
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T
a
b
l
e
 
8
.
 
F
u
n
c
t
i
o
n
a
l
 
i
m
a
g
i
n
g
 
d
u
r
i
n
g
 
s
y
m
p
t
o
m
 
p
r
o
v
o
c
a
t
i
o
n
 
i
n
 
o
b
s
e
s
s
i
v
e
-
c
o
m
p
u
l
s
i
v
e
 
d
i
s
o
r
d
e
r
 
(
O
C
D
)
.
A
u
t
h
o
r
s
M
e
t
h
o
d
S
u
b
j
e
c
t
s
R
O
I
F
i
n
d
i
n
g
s
R
e
m
a
r
k
s
Z
o
h
a
r
 
e
t
 
a
l
.
 
1
3
3
X
e
4
M
,
 
6
F
 
O
C
D
 
p
r
e
f
r
o
n
t
a
l
 
c
.
 
ﬂ o o d i n g   >   r e l a x a t i o n :
O
C
D
 
d
r
u
g
-
f
r
e
e
 
m
i
n
.
 
3
 
w
e
e
k
s
1
9
8
9
 
9
7
r
e
l
a
x
a
t
i
o
n
,
 
p
r
e
c
e
n
t
r
a
l
 
c
.
 
t
e
m
p
o
r
a
l
 
c
.
 
i
m
a
g
i
n
a
l
 
ﬂ
o
o
d
i
n
g
,
 
p
a
r
i
e
t
a
l
 
c
.
 
i n   v i v o   e x p o s u r e   <  
i
n
 
v
i
v
o
 
e
x
p
o
s
u
r
e
 
t
e
m
p
o
r
a
l
 
c
.
 
r e l a x a t i o n :
(
t
o
 
R
 
h
a
n
d
)
p
a
r
i
e
t
o
-
o
c
c
.
 
c
.
t
e
m
p
o
r
a
l
 
c
.
 
p
a
r
i
e
t
a
l
 
c
.
 
a
n
d
 
p
o
s
t
e
r
i
o
r
 
c
.
R
a
u
c
h
 
e
t
 
a
l
.
 
C
1
5
O
2
5
M
,
 
3
F
 
O
C
D
 
o
r
b
i
t
o
-
f
r
o
n
t
a
l
 
c
.
 
p r o v o c a t i v e   >   i n n o c u o u s
O
C
D
 
d
r
u
g
-
f
r
e
e
 
m
i
n
.
 
2
 
w
e
e
k
s
1
9
9
4
 
1
3
4
i
n
n
o
c
u
o
u
s
 
a
n
d
 
c
a
u
d
a
t
e
 
n
c
l
.
 
c
a
u
d
a
t
e
 
n
c
l
.
 
R
 
p
r
o
v
o
c
a
t
i
v
e
 
a
n
t
.
 
c
i
n
g
u
l
a
t
e
 
a
n
t
.
 
c
i
n
g
u
l
a
t
e
 
L
 
s
t
i
m
u
l
i
 
(
t
o
 
L
 
a
r
m
)
t
h
a
l
a
m
u
s
o
r
b
i
t
o
-
f
r
o
n
t
a
l
 
c
.
M
c
G
u
i
r
e
 
e
t
 
a
l
.
 
H
2
1
5
O
4
M
 
O
C
D
 
p o s i t i v e   c o r r e l a t i o n :
s
t
i
m
u
l
i
 
i
n
 
r
a
n
d
o
m
 
o
r
d
e
r
 
1
9
9
4
 
9
8
1
2
 
s
t
i
m
u
l
i
 
w
i
t
h
 
i
n
f
.
 
f
r
o
n
t
a
l
 
R
 
1
 
O
C
D
 
d
r
u
g
-
n
a
ï
v
e
,
 
3
 
O
C
D
 
d
r
u
g
-
f
r
e
e
 
i
n
c
r
e
a
s
i
n
g
 
s
y
m
p
t
o
m
 
c
a
u
d
a
t
e
 
n
c
l
.
 
c
o
r
r
e
l
a
t
i
o
n
 
b
e
t
w
e
e
n
 
r
C
B
F
 
a
n
d
 
p
r
o
v
o
c
a
t
i
o
n
 
a
b
i
l
i
t
i
e
s
p
u
t
a
m
e
n
 
R
 
s
y
m
p
t
o
m
 
i
n
t
e
n
s
i
t
y
g
l
.
 
p
a
l
l
i
d
u
s
 
R
 
t
h
a
l
a
m
u
s
 
R
 
h
i
p
p
o
c
a
m
p
u
s
 
L
 
p
o
s
t
.
 
c
i
n
g
u
l
a
t
e
 
L
 
c
u
n
e
u
s
 
L
 
n e g a t i v e   c o r r e l a t i o n :
s
u
p
.
 
p
r
e
f
r
o
n
t
a
l
 
R
 
t
e
m
p
o
r
o
-
p
a
r
i
e
t
a
l
 
R
H
o
l
l
a
n
d
e
r
 
e
t
 
a
l
.
 
1
3
3
X
e
1
2
M
,
 
2
F
 
O
C
D
 
c
o
r
t
i
c
a
l
 
b
l
o
o
d
 
ﬂ
o
w
r e s p o n d e r s :
7
/
1
4
 
O
C
D
 
r
e
s
p
o
n
d
e
r
s
 
1
9
9
5
 
3
3
m
C
P
P
 
0
.
5
 
m
g
/
k
g
 
p
.
o
.
 
r
C
B
F
 
↑
d
r
u
g
-
f
r
e
e
 
m
i
n
.
 
2
 
w
e
e
k
s
 
S
P
E
C
T
 
a
t
 
t
 
=
 
0
,
 
1
2
0
 
n o n - r e s p o n d e r s :
o
p
e
n
-
l
a
b
e
l
 
d
e
s
i
g
n
a
n
d
 
2
4
0
 
m
i
n
r
C
B
F
 
=
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A
d
l
e
r
 
e
t
 
a
l
.
 
f
M
R
I
3
M
,
 
4
F
 
O
C
D
 
o
r
b
i
t
o
f
r
o
n
t
a
l
 
c
.
 
p r o v o k e d   >   n e u t r a l   s t a t e
4
 
O
C
D
 
d
r
u
g
-
n
a
i
v
e
,
 
3
 
d
r
u
g
-
f
r
e
e
 
2
 
y
e
a
r
s
2
0
0
0
 
1
3
5
i
n
n
o
c
u
o
u
s
 
a
n
d
 
a
n
t
.
 
c
i
n
g
u
l
a
t
e
 
f
r
o
n
t
a
l
 
c
o
r
t
e
x
 
p
r
o
v
o
c
a
t
i
v
e
 
s
t
i
m
u
l
i
t
e
m
p
o
r
a
l
 
c
.
 
t
e
m
p
o
r
a
l
 
c
o
r
t
e
x
 
b
a
s
a
l
 
g
a
n
g
l
i
a
a
n
t
.
 
c
i
n
g
u
l
a
t
e
R
a
u
c
h
 
e
t
 
a
l
.
 
C
1
5
O
2
4
M
,
 
5
F
 
O
C
D
 
S
P
M
p r o v o k e d   >   n e u t r a l   s t a t e
s
t
r
i
c
t
l
y
 
c
o
n
t
a
m
i
n
a
t
i
o
n
 
O
C
D
 
2
0
0
2
 
1
3
6
i
n
n
o
c
u
o
u
s
 
a
n
d
 
o
r
b
i
t
o
f
r
o
n
t
a
l
 
c
o
r
t
e
x
 
R
1
 
O
C
D
 
c
o
m
o
r
b
i
d
 
d
y
s
t
h
y
m
i
a
,
 
2
 
a
n
x
i
e
t
y
 
p
r
o
v
o
c
a
t
i
v
e
 
s
t
i
m
u
l
i
 
d
i
s
o
r
d
e
r
 
L
 
a
r
m
n
o
r
m
a
l
i
z
a
t
i
o
n
 
w
h
o
l
e
 
b
r
a
i
n
 
t
r
e
a
t
m
e
n
t
 
d
a
t
a
 
T
a
b
l
e
 
9
R
=
r
i
g
h
t
,
 
L
=
l
e
f
t
,
 
f
M
R
I
=
f
u
n
c
t
i
o
n
a
l
 
M
R
I
,
 
c
.
=
c
o
r
t
e
x
,
 
S
P
M
 
=
 
s
t
a
t
i
s
t
i
c
a
l
 
p
a
r
a
m
e
t
r
i
c
 
m
a
p
p
i
n
g
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T
a
b
l
e
 
9
.
 
F
u
n
c
t
i
o
n
a
l
 
i
m
a
g
i
n
g
 
d
u
r
i
n
g
 
p
h
a
r
m
a
c
o
l
o
g
i
c
a
l
 
a
n
d
 
b
e
h
a
v
i
o
r
a
l
 
t
r
e
a
t
m
e
n
t
 
i
n
 
o
b
s
e
s
s
i
v
e
-
c
o
m
p
u
l
s
i
v
e
 
d
i
s
o
r
d
e
r
 
(
O
C
D
)
.
A
u
t
h
o
r
s
M
e
t
h
o
d
S
u
b
j
e
c
t
s
R
O
I
F
i
n
d
i
n
g
s
R
e
m
a
r
k
s
B
e
n
k
e
l
f
a
t
 
e
t
 
a
l
.
 
1
8
F
-
F
D
G
4
M
,
 
4
F
 
O
C
D
 
o
r
b
i
t
o
-
f
r
o
n
t
a
l
 
c
.
 
p o s t   <   p r e t r e a t m e n t :
c
l
o
m
i
p
r
a
m
i
n
e
 
1
2
5
-
3
0
0
 
m
g
/
d
,
 
1
6
 
w
e
e
k
s
 
1
9
9
0
 
8
5
3
0
 
c
o
n
t
r
o
l
s
p
u
t
a
m
e
n
 
c
a
u
d
a
t
e
 
n
c
l
.
 
L
 
4
 
g
o
o
d
-
,
 
3
 
p
a
r
t
i
a
l
-
,
 
1
 
p
o
o
r
 
r
e
s
p
o
n
d
e
r
 
c
a
u
d
a
t
e
 
n
c
l
.
o
r
b
i
t
o
-
f
r
o
n
t
a
l
 
c
o
r
t
e
x
 
5
 
O
C
D
 
c
o
m
o
r
b
i
d
 
d
i
a
g
n
o
s
i
s
 
(
G
A
D
,
 
P
D
,
 
p
u
t
a
m
e
n
 
R
 
d
y
s
t
h
y
m
i
a
,
 
d
e
p
r
e
s
s
i
o
n
,
 
a
d
j
u
s
t
m
e
n
t
 
r e s p o n d e r s   <   n o n - r e s p .
d
i
s
o
r
d
e
r
)
 
c
a
u
d
a
t
e
 
n
c
l
.
b
a
s
e
l
i
n
e
 
d
a
t
a
 
s
e
e
 
T
a
b
l
e
 
7
 
n
o
r
m
a
l
i
z
a
t
i
o
n
 
g
l
o
b
a
l
 
g
r
e
y
M
a
r
t
i
n
o
t
 
e
t
 
a
l
.
 
1
8
F
-
F
D
G
4
 
O
C
D
f
r
o
n
t
a
l
 
c
.
 
p o s t   >   p r e t r e a t m e n t
4
 
O
C
D
 
t
r
e
a
t
m
e
n
t
 
(
b
e
n
z
o
 
&
 
S
S
R
I
,
 
C
B
T
,
 
1
9
9
0
 
8
7
s
e
n
s
o
r
y
-
m
o
t
o
r
 
c
.
 
w
h
o
l
e
 
c
o
r
t
e
x
 
n
o
t
 
c
o
n
t
r
o
l
l
e
d
)
,
 
f
o
l
l
o
w
-
u
p
 
8
-
1
7
 
m
o
n
t
h
s
t
e
m
p
o
r
a
l
 
c
.
 
r e l a p s e   ( n = 1 )
b
a
s
e
l
i
n
e
 
d
a
t
a
 
s
e
e
 
T
a
b
l
e
 
7
 
a
u
d
i
t
o
r
y
 
c
.
 
w
h
o
l
e
 
c
o
r
t
e
x
 
↓
n
o
r
m
a
l
i
z
a
t
i
o
n
 
g
l
o
b
a
l
 
c
o
r
t
i
c
a
l
 
r
a
t
e
p
o
s
t
e
r
i
o
r
 
c
.
 
s
t
r
i
a
t
u
m
 
,
 
t
h
a
l
a
m
u
s
H
o
e
h
n
 
S
a
r
i
c
 
e
t
 
a
l
.
9
9
m
T
c
-
3
M
,
 
3
F
 
O
C
D
m
e
d
i
o
-
f
r
o
n
t
a
l
 
c
.
 
p o s t   <   p r e t r e a t m e n t
8
0
-
1
0
0
 
m
g
/
d
 
ﬂ
u
o
x
e
t
i
n
e
,
 
f
o
l
l
o
w
-
u
p
 
3
-
4
 
1
9
9
1
 
9
9
H
M
P
A
O
 
o
r
b
i
t
o
-
f
r
o
n
t
a
l
 
c
.
m
e
d
i
o
-
f
r
o
n
t
a
l
 
c
o
r
t
e
x
m
o
n
t
h
s
 
4
 
O
C
D
 
c
o
m
o
r
b
i
d
 
G
A
D
,
 
1
 
t
r
a
n
s
i
t
o
r
y
 
t
i
c
s
n
o
r
m
a
l
i
z
a
t
i
o
n
 
w
h
o
l
e
 
c
o
r
t
i
c
a
l
 
m
e
a
n
S
w
e
d
o
 
e
t
 
a
l
.
 
1
8
F
-
F
D
G
6
M
,
 
7
F
 
O
C
D
p
r
e
f
r
o
n
t
a
l
 
c
.
 
p o s t   <   p r e t r e a t m e n t
1
0
 
O
C
D
 
u
s
i
n
g
 
S
R
I
 
(
7
 
r
e
s
p
o
n
d
e
r
s
,
 
1
9
9
2
 
1
0
0
o
r
b
i
t
o
f
r
o
n
t
a
l
 
c
.
 
o
r
b
i
t
o
-
f
r
o
n
t
a
l
 
c
o
r
t
e
x
 
3
 
n
o
n
-
r
e
s
p
o
n
d
e
r
s
)
,
 
3
 
d
r
u
g
-
f
r
e
e
,
 
f
o
l
l
o
w
-
a
n
t
.
c
i
n
g
u
l
a
t
e
 
u
p
 
1
9
.
9
 
±
5
.
6
 
m
o
n
t
h
s
 
c
a
u
d
a
t
e
 
n
c
l
.
r
e
s
p
o
n
d
e
r
s
 
g
r
e
a
t
e
r
 
d
e
c
r
e
a
s
e
 
t
h
a
n
 
n
o
n
-
r
e
s
p
o
n
d
e
r
s
 
n
o
r
m
a
l
i
z
a
t
i
o
n
 
m
e
a
n
 
c
o
r
t
i
c
a
l
 
g
r
e
y
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B
a
x
t
e
r
 
e
t
 
a
l
.
1
8
F
-
F
D
G
 
3
M
,
 
6
F
 
O
C
D
c
a
u
d
a
t
e
 
n
c
l
.
ﬂ u o x e t i n e :
ﬂ
u
o
x
e
t
i
n
e
 
a
n
d
 
C
B
T
 
1
0
 
w
e
e
k
s
1
9
9
2
1
0
3
ﬂ
u
o
x
e
t
i
n
e
2
M
,
 
2
F
 
c
o
n
t
r
o
l
s
p
u
t
a
m
e
n
 
p o s t   <   p r e t r e a t m e n t :
7
/
9
 
d
r
u
g
-
r
e
s
p
o
n
d
e
r
s
,
 
C
B
T
a
n
t
.
 
c
i
n
g
u
l
a
t
e
 
a
n
t
.
 
c
i
n
g
u
l
a
t
e
 
,
 
t
h
a
l
a
m
u
s
6
/
9
 
C
B
T
-
r
e
s
p
o
n
d
e
r
s
o
r
b
i
t
a
l
 
c
.
c
a
u
d
a
t
e
 
n
c
l
.
t
h
a
l
a
m
u
s
C B T :
p o s t   <   p r e t r e a t m e n t :
c
a
u
d
a
t
e
 
n
c
l
P
e
r
a
n
i
 
e
t
 
a
l
.
 
1
8
F
-
F
D
G
3
M
,
 
8
F
 
O
C
D
 
f
r
o
n
t
a
l
 
c
.
 
,
 
p
a
r
i
e
t
a
l
 
c
.
 
p o s t   <   p r e t r e a t m e n t
9
 
O
C
D
 
S
R
I
 
t
r
e
a
t
m
e
n
t
,
 
1
2
 
w
e
e
k
s
 
1
9
9
5
 
9
3
1
1
M
,
 
4
F
 
c
o
n
t
r
o
l
s
t
e
m
p
o
r
a
l
 
c
.
 
c
i
n
g
u
l
a
t
e
 
c
o
r
t
e
x
s
i
g
n
i
ﬁ
c
a
n
c
e
 
l
e
v
e
l
 
p
 
<
 
0
.
0
2
 
o
c
c
i
p
i
t
a
l
 
c
.
 
b
a
s
e
l
i
n
e
 
d
a
t
a
 
s
e
e
 
T
a
b
l
e
 
7
 
c
i
n
g
u
l
a
t
e
 
c
.
 
n
o
r
m
a
l
i
z
a
t
i
o
n
 
g
l
o
b
a
l
 
h
e
m
i
s
p
h
e
r
e
c
a
u
d
a
t
e
 
n
c
l
.
 
p
u
t
a
m
e
n
 
t
h
a
l
a
m
u
s
 
c
e
r
e
b
e
l
l
u
m
R
u
b
i
n
 
e
t
 
a
l
 
1
3
3
X
e
 
8
M
 
O
C
D
 
f
r
o
n
t
a
l
 
c
.
 
X e :
c
l
o
m
i
p
r
a
m
i
n
e
,
 
f
o
l
l
o
w
-
u
p
 
2
.
1
-
9
.
8
 
1
9
9
5
 
8
6
9
9
m
T
c
-
8
M
 
c
o
n
t
r
o
l
s
t
e
m
p
o
r
a
l
 
c
.
 
O
C
D
 
=
 
c
o
n
t
r
o
l
s
 
m
o
n
t
h
s
 
w
h
e
n
 
r
e
s
p
o
n
s
e
 
o
c
c
u
r
e
d
 
H
M
P
A
O
p
a
r
i
e
t
a
l
 
c
.
 
T c - H M P A O :  
b
a
s
e
l
i
n
e
 
d
a
t
a
 
s
e
e
 
T
a
b
l
e
 
7
 
o
c
c
i
p
i
t
a
l
 
c
.
p o s t   <   p r e t r e a t m e n t :
n
o
r
m
a
l
i
z
a
t
i
o
n
 
c
e
r
e
b
e
l
l
u
m
 
a
n
d
 
c
a
u
d
a
t
e
 
n
c
l
.
 
p
a
r
i
e
t
a
l
 
c
o
r
t
e
x
 
c
e
r
e
b
r
a
l
 
c
o
r
t
e
x
p
u
t
a
m
e
n
 
,
 
t
h
a
l
a
m
u
s
 
f
r
o
n
t
a
l
 
c
o
r
t
e
x
c
e
r
e
b
e
l
l
u
m
S
c
h
w
a
r
t
z
 
e
t
 
a
l
.
 
1
8
F
-
F
D
G
2
M
,
 
7
F
 
O
C
D
f
r
o
n
t
a
l
 
c
.
 
c a u d a t e   n c l .   d e c r e a s e :
d
r
u
g
-
f
r
e
e
 
2
 
w
e
e
k
s
,
 
C
B
T
 
8
-
1
2
 
w
e
e
k
s
,
 
1
9
9
6
 
1
0
4
t
e
m
p
o
r
a
l
 
c
.
 
r
e
s
p
o
n
d
e
r
s
 
>
 
n
o
n
-
r
e
s
p
.
6
 
r
e
s
p
o
n
d
e
r
s
 
a
n
t
.
 
c
i
n
g
u
l
a
t
e
 
n
o
r
m
a
l
i
z
a
t
i
o
n
 
i
p
s
i
l
a
t
.
 
h
e
m
i
s
p
h
e
r
e
c
a
u
d
a
t
e
 
n
c
l
.
 
p
u
t
a
m
e
n
 
,
 
t
h
a
l
a
m
u
s
B
r
o
d
y
 
e
t
 
a
l
.
 
1
8
F
-
F
D
G
 
 
6
M
,
 
1
2
F
 
O
C
D
 
C
B
T
 
o
r
b
i
t
o
f
r
o
n
t
a
l
 
c
.
 
p r e d i c t o r s   t o   B T :
B
T
:
 
1
 
c
o
m
o
r
b
i
d
 
a
f
f
e
c
t
i
v
e
 
d
i
s
o
r
d
e
r
,
 
1
9
9
8
 
1
3
7
3
M
,
 
6
F
 
O
C
D
 
a
n
t
.
 
c
i
n
g
u
l
a
t
e
 
h
i
g
h
 
o
r
b
i
t
o
f
r
o
n
t
a
l
 
L
 
2
 
a
n
x
i
e
t
y
 
d
i
s
o
r
d
e
r
s
 
ﬂ
u
o
x
e
t
i
n
e
c
a
u
d
a
t
e
 
n
c
l
.
 
p r e d i c t o r s   t o   ﬂ u o x e t i n e :
ﬂ
u
o
x
e
t
i
n
e
:
 
1
 
c
o
m
o
r
b
i
d
 
a
f
f
e
c
t
i
v
e
 
l
o
w
 
o
r
b
i
t
o
f
r
o
n
t
a
l
 
L
d
i
s
o
r
d
e
r
,
 
2
 
a
n
x
i
e
t
y
 
d
i
s
o
r
d
e
r
,
 
1
 
T
o
u
r
e
t
t
e
’
s
 
d
i
s
o
r
d
e
r
n
o
r
m
a
l
i
z
a
t
i
o
n
 
i
p
s
i
l
a
t
.
 
h
e
m
i
s
p
h
e
r
e
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S
a
x
e
n
a
 
e
t
 
a
l
.
 
1
8
F
-
F
D
G
1
3
M
,
 
7
F
 
O
C
D
a
n
t
e
r
o
l
a
t
.
 
f
r
o
n
t
a
l
 
c
.
 
p o s t   <   p r e t r e a t m e n t :
p
a
r
o
x
e
t
i
n
e
,
 
8
-
1
2
 
w
e
e
k
s
,
 
1
9
9
9
 
1
0
1
(
A
L
O
F
C
)
 
r e s p o n d e r s :  
1
1
 
r
e
s
p
o
n
d
e
r
s
 
p
o
s
t
e
r
o
m
e
d
.
 
f
r
o
n
t
a
l
 
A
L
O
F
C
 
2
 
c
o
m
o
r
b
i
d
 
m
o
t
o
r
 
t
i
c
s
 
c
.
 
,
 
c
a
u
d
a
t
e
 
n
c
l
.
 
c
a
u
d
a
t
e
 
R
 
n
o
r
m
a
l
i
z
a
t
i
o
n
 
i
p
s
i
l
a
t
.
 
h
e
m
i
s
p
h
e
r
e
t
h
a
l
a
m
u
s
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Imaging ﬁndings have showed the involvement of the frontal cortex, striatum and
thalamus in OCD and they suggest that the fronto-striatal-thalamic-frontal circuit is
involved in the pathogenesis of OCD. Symptoms such as difficulty in planning,
learning of new information, perseveration, or shifting of behavioral sets are associated
with dysfunction in this brain circuit
105, 106.
The fronto-striatal-thalamic-frontal circuit is a functional pathway in which input
from multiple cortical areas are funnelled through subcortical nuclei to the thalamus
and subsequently projected back to specific cortical areas. Five known fronto-
subcortical circuits (motor, oculomotor, dorsolateral prefrontal, lateral orbitofrontal,
and anterior cingulate circuit) have been deﬁned, each with its speciﬁc functions, e.g.
motor functions, executive functions, social behavior and motivational states. Each
circuit has both a direct and an indirect pathway with opposing effects on the thalamus.
The direct loop connects the striatum, via the globus pallidus interna - substantia nigra
complex directly with the thalamus. The indirect loop runs from the striatum via the
globus pallidus externa and the subthalamic nucleus to the globus pallidus interna -
substantia nigra complex and then to the thalamus. Functionally, the direct pathway
has a net excitatory effect on the thalamus, whereas the indirect pathway has a net
inhibitory inﬂuence on the thalamus
105, 107.
It is not possible to narrow down the exact role of all the separate components of this
neuronal circuit is, as the interplay between the components is of higher importance
108.
Yet, it is attempted to consider its functions (for review see
12). The OFC has a major role
in cognitive appraisal of stimuli and desicion-making, taking previous experience into
consideration. The striatum and thalamus are anatomically positioned to conduct a
modulatory function for information traveling to and from the cortex. The striatum
is found to have a role in shifting attention from one type of sensory or cognitive
input to another. With this “gating” function, relevant and irrelevant stimuli are
separated. Also, it has a role in learning processes
109, 110. The thalamus is associated with
attention, working memory, emotional and cognitive functions.
Hypothesis of Pathophysiological Mechanism in OCD
General behavior and in particular psychiatric symptoms cannot be related to a speciﬁc
brain region or one single neurotransmitter or receptor subtype. That would be overly
45 Chapter 1
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The data gathered in the OCD studies described above though, give rise to the start
of unraveling the pathophysiological mechanism in this psychiatric disorder. However,
even when replicable data are found, these ﬁndings may still represent only a limited
part of the whole. With this limitation in mind, a hypothesis of the pathophysiological
mechanism in OCD is proposed.
Imaging results underline the fronto-striatal-thalamic-frontal circuit as major point
of focus in the pathophysiological mechanism in OCD. One hypothesis is that when
the sensory gating function of the subcortical nuclei become dysfunctional, an
uninterupted ﬂow of information “comes to mind”; patients with OCD experience
continuous irrelevant information about their surroundings, so called obsessions.
They are highly bothered by this and seem unable to stop this ﬂood of information,
although in general they can understand the irrelevance of its contents. As a results they
respond with an exaggerated or inappropriate behavior, that is, they respond with
performing compulsions.
Functional imaging results show a general hyperactivity of brain regions during
symptom exacerbation. This can be in accordance with a dysfunctional sensory gating
function, leading to increased activity in the fronto-striatal-thalamic-frontal circuit.
Interestingly, activity within this neuronal circuits seems state-dependant as, during
effective treatment with SSRI’s, a normalization in cerebral activity is measured.
Three OCD models have been proposed, all describing a dysfunction in the fronto-
striatal-thalamic-frontal circuit, but each with a distinguished primary site of action
12.
Modell suggests that the striatum is the primary pathogenetic mechanism, in which
it’s normal modulating action is decreased. As a consequence an abberant positive-
feedback loop between the OFC and thalamus develops. Baxter puts a desequilibrium
between the direct and indirect thalamic pathway as the primary problem, with a
resultant hyperactivity in the OFC, cingulate and dorsolateral prefrontal circuit. Finally,
according to Schwartz, disturbance in the “gating” function of the caudate nucleus
will considerably modify cortical activity.
The heterogenous findings of both the pharmacological as well as the imaging
studies are striking and underline the many confounding factors battled against in
research. They need to be elucidated for future investigations. Hypotheses considering
the cause of OCD, for instance a neurodevelopmental abnormality, neurodegenerative
nature or autoimmune process, are being investigated
73, 111.
46
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Obsessive-compulsive disorder is a severe and chronic disorder and state-of-the-art
treatment is able to alleviate symptoms only partially and usually only temporary. It
is generally accepted that the serotonin system plays an important role in this disorder.
The serotonin system and especially its many subreceptors, are under investigation
through pharmacological challenge tests, but the ﬁndings up to now are divergent
and need further investigation. Neuroimaging studies have given insight in the role
of the fronto-striatal-thalamic-frontal circuit in OCD and are an important tool in
further research.
Effective treatment with SRIs suggests an important role of 5-HT in OCD. The 5-HT
system however is a complex system in which many subreceptors have been identiﬁed.
Information on the involvement of various subreceptors in OCD is necessary for a
better understanding of this disorder. This thesis therefore aims:
A. to investigate the role of serotonin subreceptors on behavioral effects in OCD,
by means of symptom provocation tests with the serotonin receptor agonists meta-
chlorophenylpiperazine (mCPP) and sumatriptan.
(Chapter 2, 3 and 4)
Brain imaging techniques have made it possible to investigate the human brain not
only in structure, but also functionally. In vivo processes like glucose metabolism and
cerebral blood flow can be measured. With these techniques, there is a distinct
opportunity to combine pharmacological intervention and functional brain imaging
and thus creating the possibility:
B.  to identify the brain regions involved in OCD during symptom provocation
with the serotonin receptor agonist meta-chlorophenylpiperazine (mCPP) by
measuring regional cerebral blood ﬂow with SPECT and MRI.
(Chapter 2 and 3)
The merely partial effect of drug treatment in OCD patients emphasizes further
understanding of the mechanisms underlying SRI treatment. We therefore investigated
cerebral blood ﬂow in the fronto-striatal-thalamic-frontal:
C.  to explore possible differential effects on brain regions of OCD responders and
non-responders to ﬂuvoxamine treatment by measuring regional cerebral blood
ﬂow with SPECT and MRI.
(Chapter 5)
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A number of studies have shown that the serotonin receptor agonist meta-
chlorophenylpiperazine (mCPP) can exacerbate symptoms in patients with obsessive-
compulsive disorder (OCD). The aim of the present investigation was to study the
effect of this compound on regional cerebral blood ﬂow (rCBF) in patients and controls.
Seven OCD patients and 8 healthy controls were randomly allocated to a double-blind
challenge study with mCPP (0.5 mg/kg orally). rCBF was measured by 
99mTc-HMPAO
single photon emission computed tomography. mCPP did not induce OCD symptoms
in patients, but caused a significant decrease in rCBF in OCD patients, but not in
controls. The decrease was seen in the reference regions cerebellum and whole brain,
and in the frontal cortex, caudate nucleus, putamen, and thalamus. The effect of mCPP
on the reference regions in patients posed methodological problems in the
normalization methods. A possible role of the cerebellum in OCD is discussed.
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In obsessive-compulsive disorder (OCD) serotonin (5-HT) reuptake inhibitors are
effective therapeutic agents
1, 2. Further investigation of the role of 5-HT in OCD showed
that the 5-HT receptor agonist meta-chlorophenylpiperazine (mCPP) can affect OCD
by causing an exacerbation of symptoms
3-6. These ﬁndings gave rise to the serotonin
hypothesis in OCD.
Functional imaging studies found increased cerebral activity in the frontal cortex
and basal ganglia of OCD patients
7-11. Effective pharmacologic treatment induced a
decrease of activity in previously mentioned brain regions
11-15, whereas during in vivo
exposure increased activity in the frontal cortex and basal ganglia was seen
16, 17.
Hollander et al.
18 combined an open-label challenge with mCPP and 
133Xe-single photon
emission computed tomography (SPECT) in OCD patients and found increased cortical
blood ﬂow during exacerbation of symptoms. To further investigate this, we performed
a placebo-controlled mCPP challenge in OCD patients and controls, combined with
99mTc-hexamethyl-propyleneamineoxime (HMPAO) SPECT.
Subjects and Methods
Subjects
Patients suffering from OCD according to the Diagnostic and Statistical Manual of
Mental Disorders (DSM-IV)
19 were recruited from the psychiatric outpatient clinic of
the University Medical Center Utrecht. Patients with concomitant other anxiety
disorders, major depressive disorder, a score higher than 15 on the Hamilton Depression
Rating Scale (HDRS)
20 and alcohol or drug abuse were excluded. All patients were drug-
free for at least two weeks before the challenge procedure. Those taking ﬂuoxetine
had to be drug-free for 8 weeks.
Volunteers with no psychiatric history, present psychiatric illness or medical disorder
as determined by interview, were included in the study. All subjects were in good
physical health as determined by physical examination, routine laboratory tests and
an electrocardiogram. All subjects were aged between 18 - 60 years. Female subjects
who were pregnant, lactating women and women not using reliable methods for
contraception were excluded.
Seven patients (2women, 5men) and 8healthy controls (3women, 5men) participated
in the study (see Table 1). Patients experienced contamination compulsions, repeating
and checking compulsions and one patient suffered from obsessions only. The mean 
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±SD duration of symptoms was 11.8±6.8years, with a minimal of 4years. Three patients
were drug-naive, 4had previously received SRI treatment. Two males in both patient- and
controls group were left-handed. The study was approved by the Ethics Committee of the
University Hospital Utrecht, and written informed consent was obtain from all subjects.
Procedure
Patients were tested using a double-blind, placebo-controlled, cross-over design with
mCPP (0.5 mg/kg p.o.). Patients were randomly allocated to the order of the tests,
which were performed one week apart. mCPP was obtained from Aldrich Chemical
Company, Milwaukee, WI. Patients were asked to refrain from alcohol or coffee 12
hours before the challenge procedure. They remained in a semi-recumbent position
for the duration of the challenge procedure and were not allowed to eat or sleep.
Patients arrived in the morning for the challenge procedure. An indwelling
intravenous catheter was inserted in an antecubital vein and kept patent with 1 ml
heparine 100 units, following each blood-sample drawing. Blood pressure, pulse rate
and oral temperature were measured at t = -60 minutes and repeated every half hour
Table 1. Subjects Characteristics (mean ± SD).
Obsessive-compulsive   Healthy controls p-value
*
disorder
Age (years) 31.9 ± 8.7 23.6 ± 7.7 0.073
Education (years) 10.4 ± 1.1 8.8 ± 0.7 0.004
Duration of symptoms 
(years) 11.4 ± 6.8 – –
YBOCS 25 ± 7.3 – –
HAS 11.4 ± 4.6 0.88 ± 0.99 < 0.001
HDRS 7.1 ± 3.9 0.38 ± 0.52 < 0.001
Placebo mCPP Placebo mCPP Placebo mCPP
mCPP (ng/mL) 0 28 ± 19.2 0 28 ± 19.1 – –
Anxiety (baseline) 6.0 ± 3.7 5.9 ± 4.3 0.6 ± 0.9 1.4 ± 2.8 0.002 0.029
Depression (baseline) 4.9 ± 3.0 2.9 ± 1.3 0.9 ± 1.1 0.8 ± 1.4 0.004 0.011
YBOCS = Yale-Brown Obsessive-compulsive Scale, HAS = Hamilton Anxiety Rating Scale, HDRS =
Hamilton Depression Rating Scale, mCPP = meta-chlorophenylpiperazine,* = independent t-test
between OCD and controls
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Behavioral effects were measured with the Yale-Brown Obsessive-Compulsive
Challenge Scale (YBOCCS) (derived from the YBOCS
21, a 10-item scale validated for 
60 minute interval ratings and the Dutch translation of the Profile of Mood Scale
(POMS)
22, a 21-item self-rating scale for mood and anxiety changes. From the POMS,
six subscales (anxiety, depression, vigor, somatic symptoms, hostility and fatigue) were
derived. The YBOCCS and the POMS were obtained every hour, starting at t = -60
minutes. Baseline measurements were taken at t = 0. Blood samples were drawn at 
t = -30 minutes, and this was repeated every 30 minutes with the last measurement at
t = 210 minutes. Blood samples for mCPP plasma level determination were analyzed
using a high performance liquid chromatographic method
23. At 10.30 AM patients
received capsules with mCPP or placebo (t = 0 minutes). 
99mTc-HMPAO was
administered intravenously 180 minutes after administration of mCPP/placebo. From
15 minutes before up to 10 minutes after administration of 
99mTc-HMPAO patients were
instructed to remain silent. SPECT acquisition started 60 minutes after administration
of HMPAO, at the department of Nuclear Medicine.
SPECT analysis
Regions of interest (ROIs) were manually drawn on the SPECT scans in contiguous
transoblique slices along the acanthomeatal line with the use of MedView (MedImage
Inc., USA) on computer display (Apple computer Inc., USA). A priori selected ROIs were
the frontal cortex, caudate nucleus, putamen, and thalamus. Mean HMPAO uptake
(total counts/pixel) and normalized values (ratio to the reference regions cerebellum
and whole brain) were calculated for each ROI.
Statistical analysis
The psychometric and HMPAO uptake data were analyzed using multivariate analysis
of variance (MANOVA) for repeated measures. Bonferroni correction was used for
multiple comparisons. Baseline differences were analyzed using MANOVA. Age was used
as a covariate for the HMPAO data. All scores were reported as signiﬁcant when p< 0.05.
Results
The challenge procedure was well tolerated by all subjects. Symptoms reported during
mCPP challenge were lightheadedness, perspiration, nausea, headache, hot and cold
chills, fatigue, depressed mood and nervousness.
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Peak mCPP plasma levels were 43 ng/ml (range 11-124) in OCD and 42 ng/ml (range
12-81) in controls. During the challenge, mCPP levels were at a plateau level. At the
time of HMPAO administration the mean mCPP plasma level was 28 ng/ml for both
groups.
Psychometric results
Patients experienced no signiﬁcant exacerbation of obsessive-compulsive symptoms,
measured with the YBOCCS, during mCPP as compared to placebo. No significant
differences were found on the POMS subscales anxiety, depression, hostility, vigor,
physical symptoms, and fatigue for both subject groups when comparing mCPP to
placebo. At baseline, OCD patients were signiﬁcantly more anxious and more depressed
than controls (see Table 1).
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Table 2. Mean (total counts/pixel) HMPAO uptake in Obsessive-compulsive Disorder
(OCD) patients and healthy controls during placebo and mCPP challenge.
Obsessive-compulsive Healthy  Controls p-value
Disorder
ROI Placebo mCPP Placebo mCPP OCD Controls
Whole brain 11393 9487 9418 9704 0.023 0.432
Cerebellum 14615 11395 11781 12178 0.002 0.443
Frontal L 13598 11330 10948 11258 0.040 0.558
Frontal R 12376 10831 10278 10434 0.112 0.686
Caudate ncl L 12316 9989 10000 10493 0.007 0.371
Caudate ncl R 13531 10926 10520 10957 0.021 0.459
Putamen L 14610 11084 12651 13615 0.019 0.201
Putamen R 14616 11909 13094 13555 0.011 0.486
Thalamus L 14667 13243 12184 12186 0.359 0.997
Thalamus R 15119 12509 11528 11820 0.027 0.572
HMPAO = hexamethyl-propyleneamineoxime, ROI = region of interest, mCPP = meta-
chlorophenylpiperazine, L = left, R = right
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mCPP induced a signiﬁcant decrease in mean HMPAO uptake when compared with
placebo in OCD patients, but not in controls. This decrease was seen in the reference
regions whole brain and cerebellum, and the frontal cortex, caudate nucleus, putamen,
and thalamus (see Table 2).
Physiological Effects
No significant differences were found for pulse rate, temperature, systolic and
diastolic blood pressure for both groups when comparing mCPP and placebo.
Discussion
The 5-HT receptor agonist mCPP had an effect on cerebral HMPAO uptake of OCD
patients, without inducing behavioral effects. mCPP caused a decrease of mean HMPAO
uptake in the reference regions cerebellum and whole brain and most regions of
interest in OCD patients, but not in controls.
The effect of mCPP on the reference regions posed a serious methodological problem
in the normalization methods. As the reference regions were affected by mCPP in
patients only, these regions might play a role in OCD. The reference regions chosen
are generally used in OCD research
11, 24 and are considered not to be implicated in the
pathogenesis of OCD. The present ﬁndings do not meet this presumption and call for
validation of the normalization methods in OCD .
Until now, the cerebellum has been thought not to be involved in OCD. Swedo et
al.
10 however, found an increased absolute glucose metabolic rate in the cerebellum of
OCD patients, and a magnetic resonance imaging study showed decreased cerebellar
white matter volume in OCD patients
25. The cerebellum also seems to be affected in
psychiatric disorders such as schizophrenia, autism, and dementia
26, and cognitive
functions such as memory , planning, and visuospatial and linguistic functions have
been attributed to the cerebellum
27-30. Together with the present ﬁndings, it is of interest
to further investigate the role of the cerebellum in OCD.
In the study presented mCPP was not capable of exacerbating OCD symptoms in
patients. The ﬁndings on the symptom-provocative abilities of mCPP are inconclusive
with, besides studies showing exacerbation of OCD symptoms, reports that could not
replicate this
5, 31, 32. It is possible that mCPP might exacerbate OCD symptoms in a
subgroup of patients only.
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2Hfdst2-6 XP  18-01-2005  14:02  Pagina 63The decreased cerebral activity seen in our patients during mCPP can be compared
to the decrease in cortical blood flow of patients without exacerbation of OCD
symptoms as reported by Hollander et al.
18. It gives, however, no explanation as to
why HMPAO uptake of controls was not affected by mCPP. It is possible that OCD
patients may have a different sensitivity for mCPP, on which dose-response studies
may shed more light.
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Treatment studies have provided circumstantial evidence with regard to the role of
serotonin (5-HT) in the pathogenesis of obsessive-compulsive disorder (OCD). meta-
Chlorophenyl-piperazine (mCPP), a 5-HT releasing agent with 5-HT2C receptor agonistic
properties, has also been used to probe the functioning of the 5-HT system in OCD, but
results are equivocal. Imaging studies have provided evidence for the role of the fronto-
striatal-thalamic-frontal circuit in the pathogenesis of OCD. The aim of this study was
to evaluate the effects of mCPP on the behavioral symptoms and regional cerebral
blood ﬂow (rCBF) in OCD patients. Seven OCD patients were subjected to a placebo-
controlled, double-blind, cross-over challenge test with mCPP (0.5 mg/kg p.o.). rCBF
was measured using 
99mTc-HMPAO SPECT imaging with MRI co-registration. mCPP
signiﬁcantly induced anxiety, but not obsessive-compulsive symptoms. mCPP did not
affect rCBF in any of the regions of interest, but YBOCCS ratings were positively
correlated to the rCBF in the putamen. Patients who responded to the test, irrespective
of challenge conditions, with an increase in obsessive-compulsive symptoms had a
significantly higher rCBF in the left orbitofrontal cortex as compared to non-
responders. The present study supports the previous ﬁndings of increased rCBF during
experience of obsessive-compulsive symptoms, but obsessive-compulsive symptom
provoking properties of mCPP remain controversial and are probably due to differences
in study design.
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Obsessive-compulsive disorder (OCD) is a chronic and disabling, but still under-
recognized psychiatric condition, affecting approximately 2-3% of the general
population. Although little is known about the pathology of the disorder, treatment
studies have provided circumstantial evidence as to the role of serotonin (5-HT)
1, 2.
Meta-chlorophenylpiperazine (mCPP) is a 5-HT releasing agent with predominantly
5-HT2C receptor agonistic properties. mCPP is often used to probe the function of the
serotonergic system using neuroendocrine or behavioral endpoints, but in OCD the
results are not unequivocal. Some studies have found mCPP to exacerbate obsessive-
compulsive symptoms
3-7, while others did not ﬁnd such effects
7-10. Aspects like patients
characteristics, symptom assessment and, probably most importantly, environmental
factors during the test procedure, might explain these discrepancies.
Several investigators demonstrated that brain imaging can be used to study the
relationship between symptomatology and regional brain activity. Obsessive-
compulsive symptoms have been associated with a speciﬁc brain circuitry including
the orbitofrontal cortex, the striatum and the thalamus
11. There is evidence to suggest
that the activation of this so-called fronto-striatal-thalamic-frontal circuitry is state
dependant in OCD patients. Successful therapeutic interventions decrease the activity
in this circuitry
12-19, whereas symptom provocation has been shown to increase
metabolic activity in these brain regions
20-23.
Imaging studies using mCPP as a pharmacological challenge are scanty. Hollander
24
measured cortical blood ﬂow with 
133Xe-single photon emission computed tomography
(SPECT) during an open-label challenge with mCPP and found a global increase in
cortical blood ﬂow during exacerbation of obsessive-compulsive symptoms. In a previous
study we reported on effects of mCPP on rCBF in OCD patients using 
99mTc-HMPAO
SPECT imaging
25. We found mCPP to induce a global decrease in regional cerebral
blood ﬂow (rCBF) compared to placebo in OCD patients, but not in controls. mCPP,
however, did not induce obsessive-compulsive symptoms or anxiety symptoms.
In the present study, we sought to investigate the behavioral and rCBF effects of
mCPP in patients with OCD, using 
99mTc-HMPAO SPECT with magnetic resonance
imaging (MRI) co-registration to improve the anatomical localization of the regions of
interest (ROIs). The mCPP challenge was performed using a double-blind placebo-
controlled cross-over design.
69 Chapter 3
2Hfdst2-6 XP  18-01-2005  14:03  Pagina 69Patients and Methods
Patients
Patients suffering from OCD according to the Diagnostic and Statistical Manual of
Mental Disorders (DSM-IV)
26 were recruited from the psychiatric outpatient clinic of
the University Medical Center Utrecht. Patients with concomitant other anxiety
disorders, major depressive disorder, a score higher than 15 on the Hamilton Depression
Rating Scale (HDRS)
27 and alcohol or drug abuse were excluded. All patients were drug-
free for at least two weeks before the challenge procedure. Those taking ﬂuoxetine
had to be drug-free for 8 weeks. Patients were in good physical health as determined
by physical examination, routine laboratory tests and an electrocardiogram. All subjects
were aged between 18 - 60 years. Female subjects who were pregnant, lactating women
and women not using reliable methods for contraception were excluded.
Ten patients were included in the study. One patient dropped out after the first
challenge procedure. Another patient refused to perform the MRI scan. One of the
SPECT-scans of a third patient was not obtained on the PRISM 3000 SPECT camera
used in this study, because of a malfunction. Therefore the data of this patient were
discarded. The results of this study are based on the remaining seven (3 men, 4 women)
patients. Clinical characteristics of patients are summarized in Table 1. Mean length
70
Table 1. Patient Characteristics.
Patient Sex Age (yrs) Symptom  YBOCS
duration (yrs) total score obsessions compulsions
1F 2 6 7 1 8 1 1 7
2F 3 7 22 26 12 14
3F 4 0 10 24 12 12
4M 4 8 36 32 16 16
5M 2 9 19 20 8 12
6M 2 7 11 33 15 18
7F 4 8 28 27 13 14
mean±SEM 36.4 ± 3.6 19.0 ± 4.0 25.7 ± 2.1 12.4 ± 1.0 13.3 ± 1.3
F = female; M = male; YBOCS = Yale-Brown Obsessive-Compulsive Scale
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handed, none of the patients was drug-naive. All patients had obsessive-compulsive
symptoms of at least moderate severity as determined by the mean Yale-Brown
Obsessive-Compulsive Scale (YBOCS) score of 25.7 ± 2.1
28, 29. Patients suffered from
cleaning compulsions, repeating rituals, ordering, counting, hoarding and collecting
and listmaking. The mean score on the Hamilton Anxiety Rating Scale (HAS)
30 and
HDRS was 10.8 ± 1.0 and 6.0 ± 1.0, respectively. The study was approved by the Ethics
Review Committee of the University Medical Centre Utrecht. Written informed consent
was obtained from all patients.
Challenge Procedure
Patients were tested using a double-blind, placebo-controlled, cross-over design with
mCPP (0.5 mg/kg p.o.). Patients were randomly allocated to the order of the tests,
which were performed one week apart. mCPP was obtained from Aldrich Chemical
Company, Milwaukee, WI. Patients were asked to refrain from alcohol or coffee 
12 hours before the challenge procedure. They remained in a semi-recumbent position
for the duration of the challenge procedure and were not allowed to eat or sleep.
Patients arrived in the morning for the challenge procedure. An indwelling
intravenous catheter was inserted in an antecubital vein and kept patent with 1 ml
heparine 100 units, following each blood-sample drawing. Blood pressure, pulse rate
and oral temperature were measured at t = -60 minutes and repeated every half hour
for the remainder of the procedure, with the last measurement at t = 180 minutes.
Behavioral effects were measured with the Yale-Brown Obsessive-compulsive Challenge
Scale (YBOCCS) (derived from the YBOCS
31, a 10-item scale validated for 60 minute
interval ratings and the Dutch translation of the Proﬁle of Mood Scale (POMS)
32, a 21-
item self-rating scale for mood and anxiety changes. From the POMS, six subscales
(anxiety, depression, vigor, somatic symptoms, hostility and fatigue) were derived.
The YBOCCS and the POMS were obtained every hour, starting at t = -60 minutes.
Baseline measurements were taken at t = 0. Blood samples were drawn at t = -30
minutes, and this was repeated every 30 minutes with the last measurement at t = 210
minutes. Blood samples for mCPP plasma level determination were analyzed using a
high performance liquid chromatographic method
33. At 10.30 AM patients received
capsules with mCPP or placebo (t = 0 minutes). 
99mTc-HMPAO was administered
intravenously 180 minutes after administration of mCPP/placebo. From 15 minutes
before up to 10 minutes after administration of 
99mTc-HMPAO patients were instructed
to remain silent. SPECT acquisition started 60 minutes after administration of HMPAO,
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on a separate occasion.
SPECT and MRI methods
99mTc-HMPAO dose was 800 MBq (± 5%) for all subjects. Administration was in a low
ambient noise environment and patients had their eyes and ears open. SPECT
acquisition was performed with subjects head immobilized with velcro bands. Imaging
data were acquired using a triple-headed, rotating gamma camera system (PRISM 3000,
Picker, Ohio, USA) with UHRFAN beam collimators. A routine protocol of step and
shoot mode (6 degree angles with a total of 60 projections), duration of 60 seconds
per projection and 140 KeV photon peak with a 10% window was followed. Images
were reconstructed in a 64×64 pixel matrix, with a reconstruction diameter of 25 cm.
The acquired data were pre-filtered using Metz filters (over a distance of 10 cm),
followed by ramp-filtered back projection and reconstructed as transaxial slices of 
7.1 mm.
For segmentation of the SPECT data, a MRI scan was acquired from each patient, with
the following parameters; scanner Philips ACS NT 1.5 Tesla, scan 3D_FFE, TE = 4.6 ms,
TR = 30 ms, matrix 128 by 128, FOV 256 by 256 mm, ﬂip angle 30, slice thickness 1,2 mm,
150 slices. This volume was re-sliced to isotropic voxels of 1 mm, and was brought into
spatial correspondence with the MNI standard brain
34 using a rigid body transformation
(i.e. translations and rotations only), that was computed with the MNI AutoReg
software
35.
Images were re-sliced to isotropic voxels of 2 mm
3, and were further treated as 3D
volumes. Next, the two rigid body transformations that co-register the two SPECT
volumes to the MRI volume were computed using the linear version of the ANIMAL
registration software
36. Mutual information was selected as objective function because
it yields good results for cross_modality registration
37.
Regions of interest (ROIs) were manually created for each individual subject on the
MRI volume, using Analyze software
38. The ROIs were the caudate nucleus, putamen,
thalamus, OFC and cerebellum bilaterally, and were identiﬁed and outlined on the
basis of a standard MRI-based neuroanatomical atlas
39. The ROI masks were then
overlaid on the co-registered SPECT volumes, and ROI mean HMPAO uptake (total
counts/number of voxels) was calculated automatically for each ROI and for each
SPECT volume. Finally, mean HMPAO uptake values for the ROIs were normalized to
the mean uptake value of the cerebellum.
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Statistical analyses were performed by means of the Statistical Package for the Social
Sciences (SPSS for WINDOWS software), version 11.5 (SPSS inc., Chicago, 2002).
Baseline differences between mCPP and placebo for behavioral and physiological
measurements were analyzed with paired Student t-tests.
YBOCCS scores were analyzed using multivariate analysis of variance (MANOVA)
with ‘treatment’ (mCPP or placebo) and ‘time’ as within factors. Patients were post
hoc divided into responders and non-responders to the challenge procedure. Patients
were considered responders when their YBOCCS increased by 20%, irrespective of
challenge condition
8, 40. A Fisher’s exact test was used for determination of a difference
in number of YBOCCS responders and non-responders.
Physiological measurements and the subscales of the POMS were analyzed using
multivariate analysis of variance (MANOVA) with ‘treatment’ (mCPP and placebo) and
‘time’ as within factors.
rCBF data were deﬁned as the absolute HMPAO uptake normalized to the reference
region cerebellum. rCBF data were analyzed with paired Student t-tests. rCBF data of
responders and non-responders were compared with t-tests for independent groups.
Relationship between the behavioral ratings (YBOCCS maximal score and anxiety
maximal score) and rCBF data were analyzed with a Spearman’s rank correlation test. All
results were presented as mean ± SEM and were reported as signiﬁcant when p < 0.05.
Results
During the mCPP challenge patients suffered from nausea, dizziness, headache and
cold chills, but tolerated these symptoms well. One patient developed a panic attack
following mCPP and another patient complained of headache and lightheadedness
following placebo.
Behavioral effects
YBOCCS. The baseline YBOCCS scores (mean ± SEM) on the mCPP (4.4 ± 1.7) and
placebo (3.4 ± 1.1) test day were not signiﬁcantly different. Mean maximal YBOCCS
scores following mCPP and placebo were 11.8 ± 2.2 and 7.4 ± 2.3, respectively. Statistical
analysis revealed no signiﬁcant ‘treatment by time’ interaction.
Response on the YBOCCS (≥ 20% increase on score) was seen in 5 out 7 patients
during mCPP and in 3 out 7 during placebo . Two patients responded on both placebo
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signiﬁcant difference between the number of responders and non-responders during
mCPP and placebo.
POMS. Baseline scores for the 6 subscales of the POMS on the two test days were not
signiﬁcantly different. Multivariate analyses for the interaction ‘treatment by time’
for the anxiety subscale of the POMS showed a significant difference (F = 15.978, 
df = 4.3, p = 0.011). Baseline anxiety score (mean ± SEM) for placebo and mCPP were
2.4 ± 0.6 and 2.9 ± 0.7 respectively, and increased to a maximal score of 3.0 ± 0.7 and
6.7 ± 2.3, respectively. No signiﬁcant effects were seen on any of the other subscales
when comparing mCPP to placebo.
Regional cerebral blood ﬂow effects
HMPAO uptake in the reference region cerebellum was not signiﬁcantly affected by
mCPP as compared to placebo. mCPP did not signiﬁcantly affect rCBF in any of the
ROIs as compared to placebo (Table 2).
A signiﬁcant positive correlation was found for rCBF of the left putamen (during
mCPP session) and maximal YBOCCS ratings (ρ = 0.625, n = 14, p = 0.017). When
patients were stratiﬁed post hoc into responders and non-responders on the YBOCCS
score, a significantly higher rCBF was found in left OFC of responders (t = -2.181, 
df = 12, p = 0.050, see Figure 1). Statistical analysis showed no signiﬁcant correlations
between maximal anxiety ratings on the POMS and the rCBF.
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Table 2. rCBF for ROI/cerebellum (mean ± SD) during mCPP and placebo.
ROI placebo mCPP P
L caudate ncl 0.803 ± 0.128 0.782 ± 0.143 NS
R caudate ncl 0.746 ± 0.106 0.770 ± 0.096 NS
L putamen 1.107 ± 0.069 1.111 ± 0.040 NS
R putamen 1.100 ± 0.067 1.111 ± 0.057 NS
L thalamus 0.941 ± 0.057 0.963 ± 0.032 NS
R thalamus 0.938 ± 0.082 0.917 ± 0.039 NS
L OFC 0.903 ± 0.128 0.885 ± 0.107 NS
R OFC 0.950 ± 0.091 0.957 ± 0.042 NS
rCBF = regional cerebral blood ﬂow; ROI = region of interest; OFC = orbitofrontal cortex
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There were no signiﬁcant differences for mean baseline measurements of pulse rate,
systolic and diastolic blood pressure and body temperature on both test days. Statistical
analyses showed no signiﬁcant interaction for any of these parameters.
mCPP plasma levels
Plasma mCPP levels reached mean plateau levels of 35.7±9.1ng/ml at t = 120 minutes,
and remained at this level for the remainder of the challenge procedure.
Figure 1. rCBF of left orbitofrontal cortex/cerebellum in YBOCCS responders and non-
responders
Discussion
In this placebo-controlled mCPP challenge paradigm in OCD patients a signiﬁcant
increase in anxiety, but no effect on obsessive-compulsive symptoms was found after
mCPP challenge. mCPP did not significantly affect rCBF in any of the regions of
interest. However, a signiﬁcant positive correlation was found between YBOCCS score
and rCBF of the left putamen during the mCPP session. In addition, post hoc analyses
showed that patients who responded to the challenge procedure with an increase in
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signiﬁcantly higher rCBF in the left orbitofrontal cortex as compared to non-responders.
mCPP has previously been found to induce obsessive-compulsive symptoms
3-7. These
ﬁndings has led to the hypothesis of a hypersensitivity of the 5-HT system in OCD
patients. The data are, however, not unequivocal in that other investigations on mCPP
were not able to replicate these ﬁndings
7-10. It has been suggested that a high dose of
mCPP induces considerable anxiety symptoms that may impair assessment of
obsessive-compulsive symptoms. In a dose-response relationship with two mCPP
dosages (0.25 and 0.5 mg/kg p.o.) and placebo in OCD patients, obsessive-compulsive
symptoms were induced in 6/12 patients with the lower dosage of mCPP, whereas only
1 patient responded to the high mCPP dose. Also, a non-signiﬁcant increase in anxiety
ratings was seen only during the high dose of mCPP
41. The discrepant ﬁndings in the
literature with regard to obsessive-compulsive provoking properties of mCPP in OCD
patients may therefore in part be attributed to dosing effects.
In the present study, mCPP was found to induce anxiety symptoms in OCD patients,
but this was not reﬂected by signiﬁcant changes in rCBF. A study investigating patients
with simple phobia has revealed rCBF to decrease in various brain regions including
the orbitofrontal cortex and hippocampus following in vivo exposure
42. Zohar et al.
43
also found decreased cortical rCBF measured with 
133Xe-SPECT in OCD patients
experiencing anxiety during in vivo exposure. In the present study however, no
changes in rCBF were measured despite a signiﬁcant increase in anxiety symptoms. The
lack of statistical power might be one reason for the negative rCBF ﬁndings in this
investigation. On the other hand, it is possible that anxiety symptoms may be reﬂected
in brain areas which were not under investigation in this study.
The post-hoc stratiﬁcation of OCD patients into responders and non-responders to
the test procedure, irrespective of challenge condition, revealed a higher rCBF in the
left OFC. Since this ﬁnding was observed across challenge groups, the increase in rCBF
probably results from the increase in obsessive-compulsive symptoms resulting from
the challenge procedure perse, which may include patient factors and environmental
factors, rather than from mCPP administration only. The present ﬁndings of increased
rCBF in the OFC and putamen is in accordance with previous ﬁndings during in vivo
exposure challenge tests in OCD patients
20-23.
In keeping with the present study, no exacerbation of obsessive-compulsive
symptoms was found in a previous study of our group
25. In this study mCPP caused a
global decrease in rCBF in OCD patients, but not in controls. In controls a slight but
non-signiﬁcant increase in HMPAO uptake was seen during mCPP. Two functional
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in controls and reported increased glucose metabolism
44 and increase blood oxygen
level dependant signal
45 during mCPP in various ROIs including the caudate nucleus,
pallidum, frontal cortex, thalamus and cerebellum. The different routes of mCPP
administration and different imaging modalities cannot directly be compared, but
mCPP seems to induce a general increase in cerebral blood ﬂow and metabolism in
controls. Although our previous and present study showed different results in the rCBF
of OCD patients, a similar increase in rCBF as seen in controls following mCPP was not
found in OCD patients.
A major limitation of the study presented is the small sample size, leading to the
risk of Type II error. Also heterogeneity in the clinical and neurobiological
characteristics of OCD patients can cause differences in response to mCPP.
Furthermore, environmental factors during the challenge procedure can inﬂuence the
symptoms experienced by patients, e.g. aspects like blood drawings can provoke
symptoms. On the other hand, the presence of the investigator can be reassuring so
that patients experience less severe symptoms.
In conclusion, mCPP has anxiogenic properties in OCD patients. The YBOCCS score
correlated positively with left putamen rCBF. Irrespective of mCPP or placebo
administration, in patients who showed an increase in YBOCCS score, a signiﬁcantly
higher rCBF in OFC was found as compared to the YBOCCS non-responders. Findings
on obsessive-compulsive symptom inducing effects of mCPP in OCD patients remain
controversial and are for the main part probably due to differences in design.
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The non-selective serotonin (5-HT) receptor agonist meta-chlorophenylpiperazine
(mCPP) has been reported to elicit symptoms in patients with obsessive-compulsive
disorder (OCD). MK-212, another non-selective 5-HT receptor agonist, does not seem to
induce obsessive-compulsive symptoms in OCD patients. The major pharmacological
difference between mCPP and MK-212 is their afﬁnity for the 5- HT1D receptor. The aim
of this study was to explore the role of the 5-HT1D receptor in the pathophysiology of
OCD, by using a challenge paradigm with the selective 5-HT1D receptor agonist
sumatriptan (Imigran
®). A randomized, double-blind, placebo-controlled cross-over
challenge with sumatriptan (100 mg p.o.) was performed in 15 OCD patients. Neither
the obsessive-compulsive symptoms nor mood or anxiety symptoms changed
significantly following sumatriptan administration as compared to placebo.
Sumatriptan did induce a signiﬁcant increase in plasma growth hormone (GH) levels.
In the present study, no indication was found for the role of the 5-HT1D receptor in
the pathophysiology of OCD. It should be noted, however, that sumatriptan does not
readily pass the blood-brain barrier. Selective 5-HT1D receptors with better brain
penetrating properties may shed more light on the role of this 5-HT receptor subtype
in OCD.
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Symptom provocation through a pharmacological challenge with serotonin (5-HT)
receptor agents is a commonly used means to characterize serotonergic function in
obsessive-compulsive disorder (OCD). The 5-HT receptor agonist meta-chlorophenyl-
piperazine (mCPP) has been extensively used for this purpose. Some investigators have
found mCPP to induce obsessive-compulsive symptoms
1-4, hinting at a possible role for
5-HT in OCD, but others could not replicate these ﬁndings
3, 5-7.
mCPP is a non-selective 5-HT receptor agonist with high affinity for the 5-HT2C
receptor, but it also binds to 5-HT1A, 5-HT1D, 5-HT2, 5-HT3 and α2-adrenergic receptors.
To dissect the mechanism of action underlying the OCD symptoms inducing properties
of mCPP, studies with more selective agents are warranted. Several agents have already
been tested, including ipsapirone and buspirone (5-HT1A receptor agonists)
8-10,
ondansetron (5-HT3 antagonist)
11 and MK-212 (5-HT1A, 5-HT1B and 5-HT2C receptor
agonist)
12. All were found to be ineffective in inducing obsessive-compulsive symptoms.
The major difference between MK-212 and mCPP is the afﬁnity for the 5-HT1D receptor
of the latter compound. The data may suggest, therefore, that the effects of mCPP on
obsessive-compulsive symptoms could be due to its afﬁnity for the 5-HT1D receptor
subtype, although other mechanisms cannot be excluded as yet.
A high density of the 5-HT1D receptor is found in the basal ganglia and frontal cortex
13.
These brain areas have also been reported to be involved in the pathophysiology of
OCD
14. It is therefore of interest to investigate the role of the 5-HT1D receptor in OCD.
Sumatriptan (Imigran
®) is a selective 5-HT1D receptor agonist, clinically used for the
treatment of migraine. Preliminary results of a challenge study with sumatriptan in
OCD have revealed an exacerbation of obsessive-compulsive symptoms
15. In order to
assess the role of the 5-HT1D receptor in OCD, behavioral effects were investigated
during a placebo-controlled challenge with sumatriptan. Neuroendocrine effects were
determined as a measure of central cerebral activity of sumatriptan.
Patients and Methods
Patients
Patients aged 18-60 years, referred to the outpatient clinic of the University Hospital
Utrecht and suffering from OCD according to the Diagnostic and Statistical Manual of
Mental Disorders (DSM- IV)
16 were recruited for this study. Patients with concomitant
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Hamilton depression scale
17 and alcohol or drug abuse were excluded. Patients suffering
from migraine or those who had previously used sumatriptan were also excluded.
Subjects were in good physical health as determined by physical examination, routine
laboratory tests and an electrocardiogram. Female patients who were pregnant,
lactating women and women not using reliable methods of contraception were
excluded.
The clinical characteristics of patients are summarized in Table 1. Fifteen patients 
(12 women, three men) were included in this study. Four patients were drug-naive.
The washout period for patients using antidepressants other than ﬂuoxetine was at
84
Table 1. Patient Characteristics.
Patient Sex Age (yrs) Duration YBOCS  YBOCS  YBOCS 
symptoms total  score obsessions compulsions
(yrs)
1F 4 2 17 34 18 16
2F 2 0 2.5 29 13 16
3M 2 5 6 1 871 1
4F 4 6 37 23 12 11
5M 4 5 16 27 15 12
6F 4 2 13 32 16 16
7F 3 8 29 26 13 13
8M 37 5 26.5 12.5 14
9F 39 27 29 14.5 14.5
10 F 49 19 32 15 17
11 F 23 10 20 10 10
12 F 43 27 29 12 17
13 F 56 20 32 16 16
14 F 28 20 31 17 14
15 F 24 15 21 11 10
mean ± SD 39.4 ± 11.4 17.6 ± 9.7 27.3 ± 4.9 13.5 ± 2.9 13.8 ± 2.5
F = female, M = male, YBOCS = Yale-Brown Obsessive-compulsive Scale
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fluoxetine. Mean ± SD length and weight were 170.9 ± 8.2 cm and 68.2 ± 11.5 kg,
respectively. All patients had OCD symptoms of at least moderate severity as
determined by the Yale-Brown Obsessive-Compulsive scale (YBOCS) score at entry
(mean ± SD score 27 ± 5; maximal score 40)
18, 19. Patients suffered most from checking
and washing compulsions accompanied by counting, but also ordering compulsions
and rituals were present. Less often, excessive listmaking, need to touch and tell and
hoarding compulsions were reported. The mean ± SD score on the Hamilton Anxiety
Rating Scale
20 was 9.8 ± 5.0 and the score on the Hamilton Depression Rating Scale
was 7.5 ± 4.0. The study was approved by the Ethics Committee of the University
Hospital Utrecht. Written informed consent was obtained from all patients.
Methods
Patients were subjected to a challenge procedure with sumatriptan 100 mg p.o. or
placebo on two separate occasions, 1 week apart. The study was conducted according
to a randomized, placebo-controlled, double-blind and cross-over design. Patients
fasted for 12 hours before the procedure. They were asked to refrain from extensive
use of alcohol, coffee and chocolate during the study period. Patients remained in a
semi-recumbent position for the duration of the challenge and were not allowed to
sleep or eat.
On arrival at 8.45 AM an indwelling IV catheter was inserted in an antecubital vein
and kept patent with 1 ml heparin 100 units, following each blood-sample drawing.
After 30 min. of adaptation, subjects received a capsule with sumatriptan or placebo
(t = 0 min). Blood pressure and pulse rate were measured at baseline (t = 0) and at 
30 min intervals for the remainder of the test, with the last measurement at 240 min.
Blood samples for sumatriptan and growth hormone (GH) plasma level determination
were drawn at the same time points. Sumatriptan was analyzed using high performance
liquid chromatography
21. GH was assayed using a commercially available radio-
immunoassay (RIA) kit (Oris Industry Company Gif-sur Yvette, France), which had a
lower limit of detection of 0.5 mU/L. The intra- and inter-assay coefﬁcients of variation
for the GH determination were 8 and 11 %, respectively.
Behavioral measurements were completed every 60 min from baseline by means of
two psychometric scales; the Dutch translation of the Proﬁle of Mood Scale (POMS)
22,
a 21-item self-rating scale from which six subscales (anxiety, depression, vigor, somatic
symptoms, hostility and fatigue) can be derived and the Yale-Brown Obsessive-
compulsive challenge scale (YBOCCS)
23, an abbreviated and modiﬁed version of the
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rating scale with a maximal score of 100. The YBOCCS was administered twice at each
time point. Firstly, the YBOCCS was administered to assess the “actual” obsessive-
compulsive symptoms experienced during the test. This is the primary measure for
this study. Because OCD patients are frequently bothered by their symptoms in speciﬁc
situations only (e.g. performing household tasks, driving the car, working at the ofﬁce),
it was also attempted to mimic these situations by asking patients to picture themselves
in these situations. The speciﬁc aversive situation was “talked through” for 5 minutes
with the patients, until they could clearly imagine themselves in that situation.
Subsequently, the YBOCCS was administered again, asking the patients to take the
imaginary situations into account while rating their symptoms. At all time points, the
“actual” and “imagining” YBOCCS scores were assessed in this ﬁxed order.
Statistical analysis
Statistical analyses were performed by means of the Statistical Package for the Social
Sciences (SPSS for WINDOWS software, Chicago, 1999). Baseline differences for
behavioral, physiological and GH measurements were analyzed with paired Student’s
t-tests. The YBOCCS was analyzed in three statistical ways. The “actual” and
“imagining” YBOCCS scores were analyzed using multivariate analysis of variance
with repeated measures. Secondly, change scores during sumatriptan and placebo were
calculated by subtracting the baseline score from the maximal score reached during the
challenge. Differences in change scores for “actual” and “imagining” YBOCCS scores
were analyzed using paired Student’s t-tests. And ﬁnally, a 2 × 2 χ
2 analysis was used for
determination of responders and non-responders in both groups. Patients were deﬁned
as responders when the YBOCCS showed an increase of ≥ 20% calculated from the
baseline measurement for each patient
6. Physiological measurements, GH measure-
ments and the subscales of the POMS were analyzed using multivariate analysis of
variance with repeated measures.
All results were reported as signiﬁcant when p < 0.05 with two-tailed test. Huyn-Feldt
adjustment for data that depart from the sphericity assumption was used for the
analysis of variance.
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2Hfdst2-6 XP  18-01-2005  14:03  Pagina 86Figure 1. Sumatriptan succinate. Mean ± SEM sumatriptan plasma levels (ng/ml) after an
acute oral dose of sumatriptan 100 mg for the duration of the challenge procedure in 
15 OCD patients.
Results
Biochemical and neuroendocrine effects of sumatriptan
The mean peak sumatriptan plasma level was 69.9 ng/ml (range 31-123 ng/ml). The
peak level was reached at 60 minutes after administration of sumatriptan. From 
60 minutes sumatriptan plasma levels gradually declined (Figure 1).
For the statistical analysis of the GH data, two patients with high baseline GH levels
(more than 2 SD deviating from baseline) were excluded. Thus, GH data were evaluated
for the remaining 13 patients. The baseline GH levels were not different on both test
days; the mean ± SD baseline levels on the sumatriptan and placebo test day were 
5.7 ± 6.8 mU/l and 4.3 ± 4.6 mU/l, respectively. Administration of sumatriptan caused
a signiﬁcant rise in plasma GH levels as compared to placebo (Figure 2). Multivariate
analysis of variance with repeated measures on time revealed a significant drug by
time interaction (F = 4.35, df = 2.31, p = 0.019).
87 Chapter 4
0
20
40
60
80
0 30 60 90 120
Time (in minutes)
P
l
a
s
m
a
 
s
u
m
a
t
r
i
p
t
a
n
 
(
n
g
/
m
l
)
150 180 210 240
2Hfdst2-6 XP  18-01-2005  14:03  Pagina 87Figure 2. Growth hormone. Mean ± SEM plasma growth hormone levels (mU/l) after an
acute oral dose of sumatriptan 100 mg and placebo, for the duration of the challenge
procedure in 13 OCD patients.
Behavioral effects
The challenge procedure was well tolerated by all patients. Sumatriptan did not cause
a signiﬁcant change in obsessive-compulsive symptoms, mood or anxiety, as measured
by the YBOCCS and POMS. Sumatriptan did cause a signiﬁcant increase in somatic
symptoms and fatigue, as measured by the POMS.
The obsessive-compulsive symptoms at baseline as assessed with the YBOCCS,
referred to as the “actual YBOCCS”, were (mean ± SD) 8.3 ± 7.9 for sumatriptan and 
9.7 ± 8.2 for placebo. The baseline values on the two tests were not statistically different.
Multivariate analysis of variance with repeated measures on time did not show
signiﬁcant effects for the actual YBOCCS. The mean YBOCCS change from baseline
(Table 2) after sumatriptan and placebo was not signiﬁcantly different. Twelve patients
on sumatriptan and nine patients on placebo could be classiﬁed as responders to the
test as assessed with the YBOCCS. The response rate among the treatment conditions
was not signiﬁcantly different.
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situation, referred to as the “imagining YBOCCS”, substantial higher baseline values
were obtained as compared to “actual YBOCCS”. The mean ± SD baseline values for the
two conditions were not statistically different (sumatriptan 23.6±6.1; placebo 23.1±7.4).
Multivariate analysis of variance with repeated measures on time did not show any
signiﬁcant effect. Using this procedure, one patient responded on sumatriptan and
three on placebo challenge. The response rate between the challenge conditions was
not signiﬁcantly different.
Mean baseline scores for the six subscales of the POMS (Table 2) revealed no
significant differences between sumatriptan and placebo. Multivariate analysis of
variance with repeated measures on time revealed signiﬁcant drug by time interactions
for the subscales “somatic symptoms” (F = 3.57, df = 2.82, p = 0.024) and “fatigue” 
(F = 3.28, df = 2.24, p = 0.046). All other subscales were not different for the two
conditions.
Physiological effects
There were no signiﬁcant differences at baseline for pulse rate, systolic and diastolic
blood pressure during the sumatriptan and placebo challenge. Multivariate analysis of
variance with repeated measures on time showed no signiﬁcant effect for any of these
physiological parameters.
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Table 2. Mean (± SD) maximum change in symptoms from baseline.
Sumatriptan Placebo p-value
YBOCCS
actual 4.0 ± 4.2 3.3 ± 4.1 NS
imagining 1.4 ± 1.9 1.6 ± 1.8 NS
POMS
anxiety 1.3 ± 2.3 0.5 ± 1.1 NS
depression 0.7 ± 1.1 0.3 ± 0.8 NS
hostility 0.4 ± 1.1 0.3 ± 0.6 NS
vigour 0.5 ± 1.1 0.3 ± 0.6 NS
fatigue 1.1 ± 1.3 0.6 ± 0.9 0.046
somatic symptoms 1.2 ± 1.9 0.7 ± 1.2 0.024
YBOCS = Yale Brown Obsessive-compulsive Scale, POMS = Proﬁle of Mood Scale, NS = not signiﬁcant
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The major ﬁnding of this challenge study is that administration of the 5-HT1D receptor
agonist sumatriptan did not induce an exacerbation of obsessive-compulsive symptoms
in OCD patients. Moreover, sumatriptan did not alter mood or anxiety symptoms in
these patients. Thus, the present data do not hint at a role for 5-HT1D receptor in the
pathophysiology of OCD. The data of the present study are at variance with a
preliminary report of Zohar
15, who described an exacerbation of obsessive-compulsive
symptoms in OCD patients challenged with sumatriptan.
In the present study, oral administration of sumatriptan caused a marked rise in the
plasma drug levels, reaching a peak value at 60 minutes after administration. This
ﬁnding is in keeping with data reported previously
24 and concurs with the observed side
effects as assessed with the POMS. Similar side effects have been reported by others
25.
The signiﬁcant rise in plasma GH levels reported in this study is also in accordance
with early reports
26, 27. Although the GH data do suggest a central effect, the extent to
which sumatriptan reaches brain regions thought to be implicated in the
pathophysiology of OCD remains questionable, as sumatriptan does not seem readily
to cross the blood-brain barrier
28. There is anecdotal evidence for sumatriptan inducing
psychiatric symptoms. In a small trial (n = 8), patients treated with sumatriptan for
migraine attacks reported symptoms resembling those of panic disorder patients
29. In
another report, an acute onset of depressive symptoms was described after treatment
with sumatriptan for migraine, in a patient with a history of recurrent depression
30. It
has been postulated that, despite its poor penetration of the blood-brain barrier,
sumatriptan might exert central cerebral effects in areas not shielded by the blood-
brain barrier, such as the area postrema, choroid plexus, dorsal root ganglia or
hypophyseal circulation
31 or in subjects in whom the blood-brain barrier is less efﬁcient
due to the disease process. Selective 5- HT1D receptor agonists or antagonists with better
penetrating properties for the blood-brain barrier are warranted, to further explore the
role of the 5-HT1D receptors in the pathophysiology of OCD.
The rationale for the present study was primarily based on data reporting that mCPP
exacerbated obsessive-compulsive symptoms, however, the literature is not
unequivocal in this respect. Not all investigators reported mCPP to induce obsessive-
compulsive symptoms in OCD patients
3, 5-7. One explanation for these discrepant
ﬁndings is that mCPP induces obsessive-compulsive symptoms in a subgroup of OCD
patients only. The data published thus far do not allow ﬁrm conclusions to be drawn
in this respect. Another possibility is that the effect of mCPP depends on the procedure
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procedures in OCD patients may be context-dependent; unforeseen symptom
provoking triggers during the test, persistent effects of provocative events preceding
the challenge, or the “reassuring” presence of the investigator or the environment (a
hospital room) might influence the outcome. Patients frequently experience their
symptoms when performing certain tasks or in certain situations. To mimic these
situations experimentally, patients were asked to imagine a situation in which they
usually suffer most from obsessive-compulsive symptoms. The YBOCCS administered
during this imagination period, referred to as “imagining” YBOCCS, was an attempt
to take these speciﬁc conditions into account. It should be emphasized, however, that
the rating scale employed has not been validated using this procedure. The results
show substantially higher baseline scores with this procedure, supporting the notion
that the outcome may be context-dependent, but there was no effect of the outcome
of the challenge. On the contrary, the change from baseline and the number of
responders on placebo and sumatriptan were smaller as compared to the “actual” test,
suggesting that test effects, if any, might have been overruled by symptoms elicited by
the imagination procedure.
Patients included in this study represented a heterogenous sample with regard to
the symptomatology, medication history and response to treatment. Therefore, it
cannot be ruled out that sumatriptan may induce obsessive-compulsive symptoms in
a subgroup of patients. Although it must be said that the present study is subject to the
risk of type II error from the aforementioned sources, the behavioral effects of
sumatriptan were too low and inconsistent to be useful as a challenge agent in studies
with a sample size which is feasible in most centers.
In conclusion, the 5-HT1D receptor agonist sumatriptan did not induce obsessive-
compulsive symptoms during a placebo-controlled cross-over challenge paradigm in
OCD patients. Sumatriptan did cause a signiﬁcant rise in plasma GH levels, indicating
that the dose was high enough to induce hypothalamic-pituitary effects. In view of
the poor blood-brain barrier penetrating properties of sumatriptan, it cannot be ruled
out that sumatriptan levels in brain regions thought to be implicated in the
pathophysiology of OCD, have been too low to be effective. Selective 5-HT1D receptor
agonists with better penetrating properties for the blood-brain barrier are warranted
to further our understanding with respect to the role of this receptor subtype in OCD.
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Functional imaging studies have pointed to a role of the orbitofrontal cortex (OFC),
striatum and thalamus in the pathophysiology of obsessive-compulsive disorder
(OCD). Effective treatment has been found to change brain activity within this
circuitry. The aim of the present study was to explore possible differential effects of
OCD responders and non-responders to drug treatment on the regional cerebral blood
ﬂow (rCBF). rCBF was measured in 15 out of 22 patients with OCD who completed an
open-label trial with fluvoxamine. Patients were studied with 
99mTc-HMPAO single
photon emission computed tomography (SPECT) before and after 12 weeks of
treatment. In addition, a structural MRI was obtained on all patients. Regions of interest
were OFC, caudate nucleus, putamen and thalamus. Seven patients responded to
treatment. rCBF was signiﬁcantly decreased in the left caudate nucleus and left and
right putamen in both responders and non-responders to treatment. In responders,
but not in non-responders, a significant decrease in rCBF was found in the right
thalamus. Pre-treatment cerebellar- and whole brain HMPAO uptake was signiﬁcantly
higher in responders to treatment compared to non-responders. We suggest that the
thalamus plays a central role in the response to drug treatment.
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Obsessive-compulsive disorder (OCD) is a severe, chronically disabling illness
characterized by intrusive ritualistic thoughts and behaviors, over which patients have
often little control. Treatment with serotonin reuptake inhibitors (SRIs) is currently the
mainstay for drug treatment of patients with OCD. Although a substantial number of
OCD patients beneﬁt from this treatment, a sizable minority is refractory and in those
who do respond residual symptoms usually persist, despite a meaningful clinical
response. Generally, improvement is attained in about 40-60% of the patients on
monotherapy with SRIs
1. These findings underline the necessity of getting a better
understanding of the mechanisms underlying the effects of SRIs in this disorder.
Brain imaging research in OCD has indicated involvement of specific brain
structures, which led to an assumed dysfunction in the fronto-striatal-thalamic-frontal
circuit. Structural imaging studies have found alterations in frontal grey and white
matter, caudate nucleus and ventrical volumes in OCD patients
2-6. Functional imaging
studies have shown metabolic changes in frontal cortex, anterior cingulate, caudate
nucleus and thalamus
7-12, which were increased during symptom provocation
13-15. These
ﬁndings seem state-dependent as successful treatment with SRIs or behavioral therapy
decreased metabolism in aforementioned regions
16-23. Various neuroimaging studies
found predictors for treatment response. A beneﬁcial treatment response to SRIs was
predicted by higher pre-treatment metabolism in the prefrontal cortex
24, lower
metabolism in the caudate nucleus
16 and lower metabolism in the orbitofrontal cortex
(OFC)
17, 22, 25, 26. Higher values in the OFC were associated with good response following
behavioral therapy
25. In the posterior cingulate cortex, pre-treatment values were higher
following response to SRIs
26 and cingulotomy
27.
The thalamus is of particular interest in OCD, because it is thought to play a pivotal
role in integrating intero- and exteroceptive information relayed to cortical areas
28. In
pediatric OCD patients, pre-treatment increased thalamic volumes were decreased
following paroxetine treatment
29, but not after cognitive behavioral therapy
30. Using
proton magnetic resonance spectroscopy, decreased thalamic N-acetyl aspartate (NAA)
levels, a marker for neuronal number and activity, were found in drug-naive OCD
patients when compared with controls
31.
The aim of this study was to get more insight in the effects of SRI treatment on brain
metabolism by measuring the effect of ﬂuvoxamine on the regional cerebral blood
ﬂow (rCBF) in the fronto-striatal-thalamic-frontal circuit of patients responding and
non-responding to this treatment. We used single photon emission computed
97 Chapter 5
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(MRI) to ensure a more accurate assessment of the brain regions of interest.
Patients and Methods
Patients
Patients aged 18-55 years, referred to the outpatient clinic of the University Medical
Center Utrecht and suffering from OCD according to the Diagnostic and Statistical
Manual of Mental Disorders (DSM-IV)
32 were recruited for this study. Patients with
concomitant anxiety disorders, major depressive disorder, a score of more than 15 on
the 17-item Hamilton Depression Rating Scale (HDRS)
33 and alcohol or drug abuse
were excluded. Subjects were in good physical health as determined by physical
examination and routine laboratory tests. Female patients who were pregnant, lactating
women and women not using reliable methods for contraception were excluded.
Twenty-two patients were included in the study. Two patients dropped out during
week 8 and 12, because of lack of response to treatment. Four patients refused to
perform the MRI scan and due to technical problems the SPECT data of one patient was
lost. The results of this study are based on the data set of the remaining ﬁfteen patients
(4 men, 11 women). Six patients were drug-naive. The washout period for patients
using antidepressants was 2 weeks (8 weeks for ﬂuoxetine). The mean ± SD age was 
34.5 ± 11.8 years. The mean duration of symptoms was 13.6 ± 10.2 (range 3-30) years.
Mean length and weight were 172.6 ± 8.3 cm and 69.4 ± 12.6 kg, respectively. All patients
suffered from obsessive-compulsive symptoms of at least moderate severity as
determined by the Yale-Brown Obsessive-compulsive Scale (YBOCS) score of 
28.2 ± 5.2
34, 35. The subscores “obsessions” and “compulsions” derived from the YBOCS
were 14.0 ± 2.9 and 14.2 ± 2.7, respectively. Patients suffered from checking and cleaning
compulsions, but also from ordering- and repeating rituals, list making and obsessions
only. Two patients suffered from motor tics. The mean score on the Hamilton Anxiety
Rating Scale (HAS)
36 was 10.4 ± 5.3 and the score on the HDRS was 7.1 ± 3.5. Seven out
of 15 patients were responders to treatment by a pre-established criterion (see statistical
analysis). The patient characteristics stratiﬁed into responders and non-responders are
summarized in Table 1. There were no signiﬁcant differences between the responder
groups on any of the demographic variables. The study was approved by the Ethics
Committee of the University Medical Center Utrecht. Written informed consent was
obtained from all patients.
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Fluvoxamine treatment started with 50 mg/day, immediately after performance of
the pre-treatment 
99m-Tc-hexametyl-propyleneamineoxime (HMPAO) SPECT scan. The
ﬂuvoxamine dosage was increased to a maximum of 300 mg/day, if tolerated. Neither
use of other psychotropic drugs, nor behavioral and/or cognitive therapy was allowed
during the study. Assessments of blood pressure, pulse rate, weight, YBOCS, Clinical
Global Impression Scale (CGI) and HAS were performed at week 0, 2, 4, 8 and 12. The
HDRS was assessed at week 0 and 12. After 12 weeks of ﬂuvoxamine treatment the post-
treatment 
99mTc-HMPAO SPECT scan was performed. On a separate occasion after
treatment a MRI scan was performed.
SPECT and MRI methods
From 15 minutes before up to 10 minutes after intravenous administration of 
99mTc-
HMPAO, subjects were instructed to remain silent. 
99mTc-HMPAO dose was 800 MBq 
(± 5%) for all subjects. They were lying supine in a low ambient noise environment with
their eyes and ears open. SPECT acquisition was performed with subjects head
immobilized with velcro bands. Imaging data were acquired using a triple-headed,
rotating gamma camera system (PRISM 3000, Picker, Ohio, USA) with UHRFAN beam
collimators. A routine protocol of step and shoot mode (6 degree angles with a total
of 60 projections), duration of 60 seconds per projection and 140 KeV photon peak
with a 10% window was followed. Images were reconstructed in a 64 × 64 pixel matrix,
with a reconstruction diameter of 25 cm. The acquired data were pre-filtered using
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Table 1. Clinical characteristics of OCD patients stratified into responders and non-
responders to ﬂuvoxamine treatment (mean ± SD).
Responders (n = 7) Non-responders (n = 8) P
Age (years) 30.6 (± 11.0) 37.9 (± 12.0) n.s.
Duration of symptoms (years) 11.1 (± 7.6) 15.8 (± 12.1) n.s.
Height (cm) 170.6 (± 8.4) 174.4 (± 8.3) n.s.
Weight (kg) 68.1 (± 5.6) 70.5 (± 16.9) n.s.
Gender (M/F) 2/5  2/6  -
Drug-naive (number) 3  3  -
OCD = obssessive-compulsive disorder; M = male; F = female; n.s. = non-signiﬁcant (P > 0.05)
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reconstructed as transaxial slices of 7.1 mm.
For segmentation of the SPECT data, a MRI scan was acquired from each patient,
with the following parameters; scanner Philips ACS NT 1.5 Tesla, scan 3D-FFE, TE = 4.6
ms, TR = 30 ms, matrix 128 by 128, FOV 256 by 256 mm, ﬂip angle 30, slice thickness
1,2 mm, 150 slices. This volume was re-sliced to isotropic voxels of 1 mm, and was
brought into spatial correspondence with the MNI standard brain
37 using a rigid body
transformation (i.e. translations and rotations only), that was computed with the MNI
AutoReg software
38.
Images were re-sliced to isotropic voxels of 2 mm
3, and were further treated as 3D
volumes. Next, the two rigid body transformations that co-register the two SPECT
volumes to the MRI volume were computed using the linear version of the ANIMAL
registration software
39. Mutual information was selected as objective function because
it yields good results for cross-modality registration
40.
Regions of interests (ROIs) were manually created for each individual subject on the
MRI volume, using Analyze software
41. The ROIs were the caudate nucleus, putamen,
thalamus, OFC and cerebellum bilaterally, and were identiﬁed and outlined on the
basis of a standard MRI-based neuroanatomical atlas
42. The ROI masks were then
overlaid on the co-registered SPECT volumes, and ROI mean HMPAO uptake (total
counts/number of voxels) was calculated automatically for each ROI and for each
SPECT volume. Finally, mean HMPAO uptake values for the ROIs were normalized to
the mean uptake value of the cerebellum and to the mean uptake value of the whole
brain, yielding a double set of rCBF data for each patients (see section on statistical
analysis).
Statistical Analysis
Statistical analyses were performed by means of the Statistical Package for the Social
Sciences (SPSS for WINDOWS software), version 11.5(SPSS inc., Chicago, 2002). Patients
were defined as responders to fluvoxamine treatment when the YBOCS total score
showed a decrease of 25%, after 12 weeks of treatment. Patient characteristics, baseline
behavioral- and physical measurements and fluvoxamine dosage were compared
between response-groups using t-tests for independent groups.
Behavioral (YBOCS, HAS, HDRS and CGI) and physiological measurements were
analyzed using multivariate analysis of variance (MANOVA) with ‘time’ as within factor
and baseline measurement as a covariate. Pre-treatment (normalized) rCBF data of
both response groups were compared using Student’s t-tests for independent groups.
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and whole brain were also analyzed with Student’s t-tests.
The effect of treatment on the rCBF values for the ROIs was analyzed using MANOVA
with treatment and ROI as within factors and response as between factor. Student’s 
t-test was used post hoc to evaluate response and treatment effects. All results are
presented as mean ± SD and are reported as signiﬁcant when p < 0.05.
Results
Clinical variables
Obsessive-compulsive symptoms were significantly reduced in 7 out of 15 OCD
patients after ﬂuvoxamine treatment, as measured by the total score of the YBOCS (see
Table 2).
There was a statistically signiﬁcant interaction between response to treatment and
behavioral assessments. Responders showed a statistically signiﬁcant greater decrease
on the YBOCS subscales obsessions and compulsions, HAS and CGI, as compared to
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Table 2. Clinical assessments in OCD responders and non-responders before and after
treatment with ﬂuvoxamine (mean ± SD).
Responders (n = 7) Non-responders (n = 8)
Pre- Post- Pre- Post- F p
treatment treatment treatment treatment
YBOCS 27.9 ± 7.2 17.4 ± 4.4 28.5 ± 3.0 25.5 ± 3.7 4.264 0.029 
a
total score
YBOCS 13.7 ± 4.1 8.7 ± 2.8 14.3 ± 1.5 11.8 ± 1.8 3.600 0.012 
b
obsessions
YBOCS 14.1 ± 3.2 8.7 ± 2.1 14.3 ± 2.3 13.6 ± 2.9 8.139 0.003 
a
compulsions
HAS 11.4 ± 5.8 5.1 ± 2.6 9.5 ± 5.0 9.3 ± 6.1 3.348 0.024 
b
CGI 5.6 ± 1.0 4.3 ± 0.5 5.4 ± 0.7 5.3 ± 0.7 7.149 0.005 
a
HDRS 8.0 ± 3.8 4.1 ± 1.8 6.4 ± 3.3 5.9 ± 5.5 2.746 0.099
OCD = obsessive-compulsive disorder;YBOCS = Yale-Brown Obsessive-compulsive Scale; HAS =
Hamilton Anxiety Rating Scale; CGI = Clinical Global Impression Scale; HDRS = Hamilton
Depression Rating Scale, 
a multivariate tests, 
b Huynh-Feldt correction
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both groups for any of the ratings scales. Of the seven (3 men, 4 women) patients
excluded from the study, 4 were non-responders (including the 2 drop-outs) and 
3 responders to treatment.
Brain SPECT imaging results
In the reference regions cerebellum and whole brain pre-treatment HMPAO uptake
was signiﬁcantly different between responders and non-responders to treatment with
responders showing a higher uptake in both regions as compared to non-responders
(cerebellum t = -2.557, df = 13, p = 0.024; whole brain t = -2.555, df = 13, p = 0.024). After
ﬂuvoxamine treatment, HMPAO uptake was signiﬁcantly decreased in both reference
regions in responders (cerebellum t = 3.362, df = 6, p = 0.015; whole brain = 3.327, 
df = 6, p = 0.016), but not in non-responders (Figure 1). Post-treatment HMPAO uptake
was no longer statistically different between responders and non-responders for both
reference regions.
Fluvoxamine treatment was associated with a statistically significant decrease in
rCBF in a number of ROIs. Multivariate analysis showed a statistically signiﬁcant mean
treatment effect for both normalization methods (cerebellum F = 15.888, df = 5.9, 
p = 0.004; whole brain F = 10.436, df = 4.1, p = 0.019). In addition, a statistically
signiﬁcant ROI × treatment × response interaction was found for normalization to the
cerebellum (F = 7.558, df = 5.9, p = 0.019) and a statistical trend was seen for
normalization to whole brain (F = 5.591, df = 4.1, p = 0.056). Post hoc analysis on the
difference scores in rCBF (before and after treatment) in both responder groups
separately, found a signiﬁcantly decreased rCBF for the right thalamus in responders
to treatment (cerebellum = 2.987, df = 6, p = 0.024; whole brain t = 2.427, df = 6, 
p = 0.051) (Figure 1). In non-responders, a non-signiﬁcant increase in right thalamic
rCBF was seen. In the right caudate nucleus, a non-signiﬁcant trend for a differential
effect between responders and non-responders was found.
With all patients entered in the analysis, ﬂuvoxamine treatment was associated with
a significant decrease in rCBF in the left caudate nucleus for both normalization
methods (whole brain t = 3.341, df = 14, p = 0.005; cerebellum t = 3.296, df = 14, 
p=   0.005) and bilaterally in the putamen (left putamen: whole brain t = 4.527, df = 14,
p < 0.001 and cerebellum t = 3.900, df = 14, p = 0.002; right putamen: whole brain 
t = 4.022, df = 14, p = 0.001 and cerebellum t = 4.766, df = 14, p < 0.001). The OFC was
not signiﬁcantly affected by ﬂuvoxamine treatment (Table 3). Pre-treatment rCBF data
of the ROIs in responders versus non-responders were not statistically different.
102
2Hfdst2-6 XP  18-01-2005  14:03  Pagina 102103 Chapter 5
T
a
b
l
e
 
3
.
 
R
O
I
/
w
h
o
l
e
 
b
r
a
i
n
 
r
C
B
F
 
r
a
t
i
o
s
 
(
m
e
a
n
 
±
S
D
)
 
f
o
r
 
v
a
r
i
o
u
s
 
R
O
I
s
 
i
n
 
O
C
D
 
p
a
t
i
e
n
t
s
 
r
e
s
p
o
n
d
i
n
g
 
a
n
d
 
n
o
n
-
r
e
s
p
o
n
d
i
n
g
 
t
o
 
ﬂ
u
v
o
x
a
m
i
n
e
t
r
e
a
t
m
e
n
t
.
R
e
s
p
o
n
d
e
r
s
 
(
n
 
=
 
7
)
N
o
n
-
r
e
s
p
o
n
d
e
r
s
 
(
n
 
=
 
8
)
R
O
I
/
c
e
r
e
b
e
l
l
u
m
a
R
O
I
/
w
h
o
l
e
 
b
r
a
i
n
a
P
r
e
-
t
r
e
a
t
m
e
n
t
P
o
s
t
-
t
r
e
a
t
m
e
n
t
P
r
e
-
t
r
e
a
t
m
e
n
t
P
o
s
t
-
t
r
e
a
t
m
e
n
t
F
P
F
P
l
e
f
t
 
c
a
u
d
a
t
e
 
n
u
c
l
e
u
s
0
.
8
0
6
 
±
0
.
0
8
0
0
.
7
6
8
 
±
0
.
0
7
8
0
.
8
2
6
 
±
0
.
1
1
4
0
.
7
7
7
 
±
0
.
1
0
4
9
.
9
9
4
0
.
0
0
8
1
0
.
2
8
5
0
.
0
0
7
r
i
g
h
t
 
c
a
u
d
a
t
e
 
n
u
c
l
e
u
s
0
.
8
0
3
 
±
0
.
0
9
7
0
.
7
7
3
 
±
0
.
1
2
1
0
.
8
2
6
 
±
0
.
1
2
3
0
.
8
2
8
 
±
0
.
1
0
8
0
.
5
0
0
0
.
4
9
2
0
.
5
7
2
0
.
4
6
3
l
e
f
t
 
p
u
t
a
m
e
n
1
.
0
8
2
 
±
0
.
0
7
4
1
.
0
4
1
 
±
0
.
0
5
0
1
.
1
4
6
 
±
0
.
0
5
2
1
.
0
8
6
 
±
0
.
0
7
2
1
4
.
1
3
1
0
.
0
0
2
1
9
.
4
2
3
0
.
0
0
1
r
i
g
h
t
 
p
u
t
a
m
e
n
1
.
1
0
4
 
±
0
.
0
7
2
1
.
0
6
9
 
±
0
.
0
5
0
1
.
1
5
7
 
±
0
.
0
6
6
1
.
1
0
8
 
±
0
.
0
5
6
2
1
.
4
3
7
0
.
0
0
1
1
5
.
1
2
1
0
.
0
0
2
l
e
f
t
 
t
h
a
l
a
m
u
s
0
.
9
5
6
 
±
0
.
0
5
3
0
.
9
4
7
 
±
0
.
0
7
4
1
.
0
4
1
 
±
0
.
0
7
7
1
.
0
2
8
 
±
0
.
0
7
7
1
.
0
1
2
0
.
3
3
3
1
.
3
4
5
0
.
2
6
7
r
i
g
h
t
 
t
h
a
l
a
m
u
s
 
b
0
.
9
9
6
 
±
0
.
0
6
6
0
.
9
6
3
 
±
0
.
0
6
9
1
.
0
2
5
 
±
0
.
0
7
7
1
.
0
3
4
 
±
0
.
0
8
2
0
.
9
7
5
0
.
3
4
1
1
.
0
0
3
0
.
3
3
5
l
e
f
t
 
O
F
C
1
.
6
5
3
 
±
0
.
0
3
6
1
.
6
6
9
 
±
0
.
0
4
6
1
.
6
4
4
 
±
0
.
0
5
4
1
.
6
4
3
 
±
0
.
0
4
5
0
.
2
2
3
0
.
6
4
5
0
.
7
0
9
0
.
4
1
5
r
i
g
h
t
 
O
F
C
1
.
6
6
3
 
±
0
.
0
4
9
1
.
6
7
5
 
±
0
.
0
5
0
1
.
6
6
0
 
±
0
.
1
1
1
1
.
6
7
1
 
±
0
.
0
9
3
0
.
5
9
8
0
.
4
5
3
1
.
4
7
7
0
.
2
4
6
R
O
I
 
=
 
r
e
g
i
o
n
 
o
f
 
i
n
t
e
r
e
s
t
;
 
r
C
B
F
 
=
 
r
e
g
i
o
n
a
l
 
c
e
r
e
b
r
a
l
 
b
l
o
o
d
 
ﬂ
o
w
;
 
O
F
C
 
=
 
o
r
b
i
t
o
f
r
o
n
t
a
l
 
c
o
r
t
e
x
 
a
M
A
N
O
V
A
 
R
O
I
 
b
y
 
t
r
e
a
t
m
e
n
t
 
b
s
i
g
n
i
ﬁ
c
a
n
t
 
d
e
c
r
e
a
s
e
 
i
n
 
r
e
s
p
o
n
d
e
r
s
 
(
n
o
r
m
a
l
i
z
e
d
 
t
o
 
w
h
o
l
e
 
b
r
a
i
n
:
  P  
=
 
0
.
0
5
1
;
 
n
o
r
m
a
l
i
z
e
d
 
t
o
 
c
e
r
e
b
e
l
l
u
m
:
  P  
=
 
0
.
0
2
4
)
2Hfdst2-6 XP  18-01-2005  14:03  Pagina 103Figure 1. Difference scores ± SEM (before and after treatment) for ROI/whole brain rCBF
ratios in OCD-responders and non-responders to ﬂuvoxamine treatment.
Fluvoxamine dosage and physical measurements
The mean ﬂuvoxamine dosage at 12 weeks of treatment was 268.3 ± 46.7 mg/day; the
dosage for responders and non-responders were not signiﬁcantly different.
Systolic blood pressure decreased signiﬁcantly in all patients during treatment, but
this effect was not clinically relevant (week 0: 128 mm Hg, week 12: 120 mm Hg).
Diastolic blood pressure, pulse rate and weight did not change during treatment.
104
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** *
OCD = obsessive-compulsive disorder; L = left; R = right; caud = caudate nucleus; OFC =
orbitofrontal cortex; put = putamen; thal = thalamus; cerebel = cerebellum
* statistically signiﬁcant change from baseline (p < 0.05)
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In this SPECT study, using co-registered MRI scans to ensure exact neuroanatomical
localization of the ROIs, a treatment-response related change in rCBF was found in
the right thalamus of OCD patients after fluvoxamine therapy. Twelve weeks of
treatment caused a signiﬁcant decrease in rCBF in the right thalamus of patients who
responded to treatment, but not in treatment-non-responders. In addition, a treatment-
related, but not response-related, decrease in rCBF was found in the caudate nucleus
and putamen. The data suggest that the “pharmacological” effect of ﬂuvoxamine is
reflected in both the caudate nucleus and putamen, but that the “anti-obsessive-
compulsive” effect is revealed predominantly in the thalamus, suggesting that this
region might play a central role in the generation of obsessive-compulsive symptoms.
The thalamus is thought to play a key role in the fronto-striatal-thalamic-frontal
circuit, which is composed of a direct and indirect system. These two pathways are
purported to operate in parallel, with opposing effects at the level of the thalamus.
Earlier investigations have already pointed to the role of the thalamus in OCD.
Differences in brain activity between patients and controls were seen in the thalamus
under baseline conditions
12, 19. In a challenge paradigm a positive association between
symptom intensity and rCBF in the thalamus was found
14. Saxena and co-workers
22
have reported a decrease in metabolic activity in the thalamus of both OCD responders
and non-responders to paroxetine treatment. In another study by the same
investigators paroxetine treatment effects were compared between OCD and major
depression patients. In OCD responders decreased metabolic activity in the thalamus
was found
23. Baxter et al.
18 have reported decreased thalamic metabolism in responders
to fluoxetine treatment, but information on non-responders was not presented.
Recently, Lacerda et al.
43 found an inverse correlation between the right thalamic rCBF
and compulsive behavior.
Additional evidence for involvement of the thalamus in OCD comes from a structural
MRI study in children with OCD, showing increased pre-treatment thalamic volumes
which decreased following paroxetine treatment
29. On the other hand, in a cognitive
behavioral treatment study no changes were found in thalamic volume
30. It is difﬁcult,
however, to compare ﬁndings of the various imaging techniques, as volumetric data,
rCBF and metabolic ﬁndings are different modalities.
Findings from neuroimaging data in OCD suggest that the fronto-striatal-thalamic-
frontal circuit is involved in the pathogenesis of OCD. Moreover, symptoms such as
difﬁculty in planning, learning new information, perseveration, or shifting behavioral
105 Chapter 5
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28, 44. The fronto-striatal-
thalamic-frontal circuit is a functional pathway in which input from multiple cortical
areas are funnelled through subcortical nuclei to the thalamus and subsequently
projected back to speciﬁc cortical areas. Five known fronto-subcortical circuits (motor,
oculomotor, dorsolateral prefrontal, lateral orbitofrontal, and anterior cingulate circuit)
have been deﬁned, each with its speciﬁc functions, e.g. motor functions, executive
functions, social behavior and motivational states. Each circuit has both a direct and
an indirect pathway with opposing effects on the thalamus. The direct loop connects
the striatum, via the globus pallidus interna - substantia nigra complex directly with
the thalamus. The indirect loop runs from the striatum via the globus pallidus externa
and the subthalamic nucleus to the globus pallidus interna - substantia nigra complex
and then to the thalamus. Functionally, the direct pathway has a net excitatory effect
on the thalamus, whereas the indirect pathway has a net inhibitory inﬂuence on the
thalamus.
Drawing on the fronto-striatal-thalamic-frontal model of OCD, Baxter et al.
18 have
hypothesized an augmented resting neuronal activity in this circuit of OCD patients,
which normalizes after successful treatment. This notion suggests state-dependent,
“anti-obsessional” mechanisms within this circuit. The response-related changes in
thalamic rCBF observed in this treatment study, point towards a central role for the
thalamus in the anti-obsessional effects of SRIs. It may be hypothesized that the
thalamus represents the final common pathway in the mechanism underlying
symptom reduction following SRI treatment in OCD and that perhaps an imbalance
between the direct and indirect pathway to the thalamus is crucial in this respect.
A confounding factor in this study was the higher HMPAO uptake in the reference
regions cerebellum and whole brain in responders compared to non-responders at
baseline. Moreover, cerebellar and whole brain HMPAO uptake decreased following
treatment in responders, but not in non-responders, yielding no post-treatment
signiﬁcant differences between both groups. This posed a methodological problem in
the normalization procedure. Statistical analyses were therefore performed using both
normalization methods and effects were considered statistically significant only if
both methods yielded signiﬁcant results.
The increased HMPAO uptake in the cerebellum and whole brain at baseline and
the subsequent decrease in activity after successful treatment is an interesting ﬁnding
in itself. It may suggest a role for the cerebellum in the pathophysiology of OCD. Some
data on the cerebellum in OCD have been presented. In a PET study
8 an increased
absolute cerebral glucose metabolic rate (CMRglc) was found in the cerebellar region
106
2Hfdst2-6 XP  18-01-2005  14:03  Pagina 106in OCD patients and a MRI study showed a decrease in cerebellar white matter volume
5.
There is also circumstantial evidence for the cerebellum to be involved in other
psychiatric disorders such as schizophrenia, autism and dementia, suggesting a role
beyond its motor effects
45. It may be hypothesized that higher pre-treatment HMPAO
uptake in the cerebellum and whole brain is a predictor for response to SRI treatment.
Other confounding factors are the small sample size, which increases risk for a type
II error and the heterogeneous symptom proﬁle of the patients included in this study.
In conclusion, ﬂuvoxamine treatment in OCD patients signiﬁcantly decreased rCBF
in the left caudate nucleus, putamen and right thalamus. The rCBF decrease in the
right thalamus was associated with a decrease in obsessive-compulsive symptoms.
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Discussion
2Hfdst2-6 XP  18-01-2005  14:04  Pagina 113This thesis sought to investigate the effects of the serotonin (5-HT) system on
behavioral aspects and on cerebral blood ﬂow in patients suffering from obsessive-
compulsive disorder (OCD). OCD is a highly common psychiatric disorder, in which
patients suffer from recurrent intrusive and inappropriate ideas. It causes marked
distress in patients and they respond to these ideas by performing repetitive behavior
in an excessive way and according to certain rules, for instance washing or checking
compulsions.
The role of the 5-HT system and the involvement of brain regions in OCD are
described in the introduction of this thesis (Chapter 1). Pharmacological treatment
with serotonin reuptake inhibitors (SRIs) were found effective in OCD patients,
although a substantial number of OCD patients responds only partially or not at all.
In general, treatment response is seen in about 40-60% of the patients on monotherapy
with SRIs
1-3. Recent investigations show a beniﬁcial effect of antipsychotic medication
in addition to SRI’s in treatment-resistant OCD patients
4, 5.
The role of 5-HT in OCD is further investigated in challenge studies, using several
5-HT probes. Most extensively investigated is meta-chlorophenylpiperazine (mCPP),
a non-selective 5-HT agonist with high afﬁnity for the 5-HT2C receptor. The ﬁndings of
mCPP on behavioral aspects in OCD patients are heterogenous; several studies found
an exacerbation of obsessive-compulsive symptoms
6-14, while a substantial number of
investigations did not report an increase of symptoms
13, 15-18. Confounding factors as
behavioral ratings, environmental factors during challenge procedure and patients
characteristics are an important factor in these divergent ﬁndings. Nevertheless, 5-HT
seems to play an important role in the pathophysiology of OCD.
In OCD patients both structural and functional imaging studies have been
performed. The structural imaging data do not show a clear consensus. In several
studies volumetric changes (both increase and decrease) of the caudate nucleus, frontal
cortex, thalamus and white matter were seen
19-24, but in other studies this was not
replicated
21, 25-32. Functional imaging studies showed more consistent ﬁndings during
symptoms exacerbation, in which activity in aformentioned brain regions was
increased
12, 33-37. These findings seemed state-dependant as activity was normalized
during treatment
38-46. The imaging ﬁndings in OCD pointed to the involvement of the
fronto-striatal-thalamic-frontal circuit in this disorder. When results are studied in
detail however, striking differences are seen in activity of the various components of
the fronto-striatal-thalamic-frontal circuit in each investigation.
114
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proposed
3. They all describe the fronto-striatal-thalamic-frontal circuit, and a
dysfunction in this brain circuit is generally associated with symptoms such as difﬁculty
in planning, learning of new information, perseveration, or shifting of behavioral
sets
47, 48. Each hypothesis considers a distinguished primary site of action, that is the
striatum, thalamus or caudate nucleus, which than results in a secondary cortical
hyperactivity. One of the hypothesis describes the subcortical nuclei and their sensory
gating function. It is speculated that in patients suffering from OCD, an inefﬁcient
sensory gating proces may bring continous irrelevant information to consiousness,
which are percieved by patients as obsessions. As a consequence, patients respond with
an exaggerated or inappropriate behavior by performing compulsions
47, 48.
The effects of the 5-HT system on behavior in OCD patients was investigated in this
thesis with the 5-HT2C receptor agonist meta-chlorophenylpiperazine (mCPP, 
0.5 mg/kg) (Chapter 2 and 3) and the 5-HT1D receptor agonist sumatriptan (Chapter 4).
The main finding was that neither mCPP nor sumatriptan were able to induce
obsessive-compulsive symptoms.
As decribed in the literature, the ﬁndings on the symptom exacerbating properties
of mCPP are heterogeneous; both positive
6, 8-10, 13 and negative findings have been
reported
13, 15, 16, 18. Several factors should be considered for these divergent results. There
are reports that in patients with high mCPP plasma levels no exacerbation of 
obsessive-compulsive symptoms occur
13. A “high” dose of mCPP induces marked
anxiety symptoms, so that obsessive-compulsive symptoms may become masked. A
placebo-controlled dose-response study with mCPP, using a high (0.5 mg/kg) and low 
(0.25 mg/kg) dose, found a signiﬁcant increase in obsessive-compulsive symptoms in
the low dose as compared to the high mCPP dose
49. Up till now, all the challenge tests
using mCPP orally have used the high mCPP dose. A dose-reponse effect may therefore
contribute to the different behavioral ﬁndings following mCPP challenges.
In Chapter 4, sumatriptan did not induce obsessive-compulsive symptoms.
Sumatriptan was thought to have poor penetrating abilities for the blood-brain
barrier
50, but later reports showed otherwise
51, 52. An acute dose of the 5-HT1B/1D receptor
agonist zolmitriptan in OCD patients was also unable to induce obsessive-compulsive
symptoms
53, even while zolmitriptan is thought to have good penetrating abilities of
the blood-brain barrier. In contrast to these negative findings, a single-dose of
sumatriptan (100 mg) was found to increase obsessive-compulsive symptoms in 4 out
of 5 patients
54 and 3 out of 8 patients
55. The latter group of investigators also performed
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patients. They reported a decrease in obsessive-compulsive symptoms after 4 weeks of
treatment. At the start of the treatment they did not report an acute increase of
obsessive-compulsive symptoms
56. A sumatriptan-SPECT study mentioned 4 of the 
14 patients to experience an increase in symptoms
57.
The ﬁndings on the 5-HT1D receptor in OCD are therefore not conclusive, but they
can not rule out involvement of the 5-HT1D receptor in OCD. This is also strengthened
by genetic ﬁndings that reported a linkage disequilibrium between the 5-HT1Db receptor
gene and OCD
58. Further research on the 5-HT1D receptor is warranted to understand
its role in OCD.
In this thesis it is concluded that the behavioral effects of mCPP and sumatriptan in
OCD patients are varying because of methodological differences. Besides the
proposed dose-related effects of mCPP, several other aspects should be considered.
Various studies reported a number of patients responding to the challenge, but ﬁndings
were not always signiﬁcant due to lack of statistical power, as the investigations were
usually performed with small sample sizes.
Another factor is that standardization of a challenge procedure is a challenge in
itself. Unforseen factors and patient-related aspects during symptom provocation are
able to inﬂuence behavioral outcome during the challenge procedure. Patients may
experience anxiety and obsessive-compulsive symptoms for instance due to the
blooddrawings during the challenge. Also, the presence of the investigator during the
challenge procedure may have a reassuring effect on patients so that they do not report
behavioral symptoms. Therefore, methodological aspects may signiﬁcantly inﬂuence
the data on behavioral ﬁndings in OCD.
Regional cerebral blood ﬂow (rCBF) in OCD patients was investigated in this thesis
during challenge studies with mCPP (Chapter 2 and 3) and during treatment with
ﬂuvoxamine (Chapter 5).
In Chapter 2, mCPP did not affect obsessive-compulsive symptoms whereas a general
decrease in rCBF in OCD patients, but not in controls, was seen
59. The decrease in rCBF
was seen in all brain regions under investigation. In Chapter 3, imaging techniques
were improved by using multimodality imaging. SPECT together with MRI imaging
were performed in each patient to ensure more exact anatomical delineation of the
brain regions investigated. mCPP again did not exacerbate obsessive-compulsive
symptoms, but in contrast to Chapter 2, mCPP did not affect rCBF. YBOCCS ratings
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analyses showed that patients who responded to the challenge procedure with an
increase in obsessive-compulsive symptoms, irrespective of the challenge condition,
revealed a signiﬁcantly higher rCBF in the left orbitofrontal cortex (OFC) as compared
to non-responders. These ﬁndings on the OFC and putamen are in concordance with
the literature, as several imaging studies have reported increased activity in these brain
regions in OCD patients
34-37. In Chapter 3 patients experienced a signiﬁcant increase in
anxiety symptoms, but no signiﬁcant correlation was found with rCBF.
The increase in obsessive-compulsive symptoms in Chapter 3 was not related to
mCPP, but to other undeﬁned factors during the challenge procedure. The patients
studied in this thesis were a heterogeous group considering their symptom proﬁle. It
is conceivable that within symptom subgroups different responses to challenge
procedures may occur. In a few fMRI studies more speciﬁc symptom dimensions were
studied. Patients with washing compulsions and checking compulsions were studied
during a washing related exposure trial; patients with washing compulsions showed
increased activity in visual area and the insula, whereas in patients with checking
compulsions increased fronto-striatal activity was seen
60. Another study also found
increased activity in the insula during washing-related task and also in the prefrontal
cortex and parahippocampal gyrus
61. These ﬁndings suggest that different symptom
dimensions may be mediated by distinct neuronal circuits. An important study by
Mataix Cols et al.
62 considering this aspect was recently performed. The authors
discussed that the artificial division between symptom dimensions (investigating
different patients with varying symptom proﬁles) can be improved by categorically
dividing symptoms within each patient. They therefore tested each patient with various
stimuli, in a provocation paradigm. They found that each symptom dimension was
mediated by a distinct, but partially overlapping neuronal system. Washing
compulsion were mediated by the prefrontal cortex and caudate nucleus, checking
compulsions by the putamen/globus pallidus, thalamus and dorsal cortical areas and
hoarding symptoms by the OFC.
In this thesis it is concluded that the function of the fronto-striatal-thalamic-
frontal circuit will be better understood by studying subgroups of obsessive-
compulsive symptoms. It would have been interesting to study the symptom
dimensions in Capter 3, but unfortunally sample size was too small for to post-hoc
investigation. The correlation of obsessive-compulsive symptoms and the putamen
and OFC are interesting ﬁndings though when seen in the light of the fronto-striatal-
thalamic-frontal circuit.
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Fluvoxamine caused a decrease of rCBF in the caudate nucleus and putamen, but only
in patients in which ﬂuvoxamine was effective, a decrease in thalamic rCBF was seen.
These ﬁndings may suggest that the pharmacological effect of ﬂuvoxamine is reﬂected
in the caudate nucleus and putamen, but the anti-obsessive-compulsive effect is
predominantly revealed in the thalamus. Earlier investigations have already pointed
to the role of the thalamus in OCD. Differences in brain activity between patients and
controls were seen in the thalamus under baseline conditions
46, 63. In a challenge
paradigm a positive association between symptom intensity and rCBF in the thalamus
was found
35. Treatment studies with paroxetine have reported a decrease in metabolic
activity in the thalamus of OCD patients
35, 43. Baxter et al.
44 have reported decreased
thalamic metabolism in responders to ﬂuoxetine treatment, but information on non-
responders was not presented. Recently, Lacerda et al.
64 found an inverse correlation
between the right thalamic rCBF and compulsive behavior. A structural MRI study in
children with OCD showed increased pre-treatment thalamic volumes which decreased
following paroxetine treatment
24. On the other hand, in a cognitive behavioral
treatment study no changes were found in thalamic volume
65.
The thalamus has a crucial localisation in the fronto-striatal-thalamic-frontal circuit.
It stands at the crossroad between the direct and indirect loop, which have opposing
effects on the thalamus
47, 48. The treatment response-dependent changes in thalamic
rCBF found in Chapter 5 may point towards a central role for the thalamus in the anti-
obsessional effects of SRIs. It is intriguing to speculate about the possible role of the
thalamus in OCD but anything said about a clinical symptom and a putative
anatomical site will be highly speculative. Nevertheless, the thalamus seems to
withhold crucial information on future treatment options in OCD and should be
investigated at its subthalamic nuclei level, next to studies on receptor level.
In both Chapter 2 and 5 the reference region cerebellum was under inﬂuence of mCPP
and ﬂuvoxamine. This ﬁnding caused a major methodological problem for the SPECT
normalization method, but it was also an intriguing finding. The cerebellum is
regularly chosen as a reference region in OCD research as it is thought not to be
involved in its pathogenesis. The cerebellum has widespread connections with the
basal ganglia and different cortical areas
66. Several reports have pointed to a role of
the cerebellum in visuospatial functions, memory, linguistic and cognitive functions
67-
73 and may even be involved in other psychiatric disorders like schizophrenia and
autism
74, 75. The cerebellum has been found to play a role in cognitive function like
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motor development seem closely related and motor problems coincide in cognitive
function disorders as ADHD, dyslexia and autism
76, 77. Perhaps in the future this brain
area may rise above its known function in coordinating motor behavior.
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7Samenv XP  18-01-2005  14:07  Pagina 125Psychiatrische stoornissen zijn zeer regelmatig voorkomende ziektebeelden die vaak
grote gevolgen hebben voor het leven van patiënten. De ziekte heeft niet alleen invloed
op de patiënt zelf, maar is tevens belastend voor andere gezinsleden, vrienden en
kennissen. De klachten kunnen ook interfereren met prestaties op het werk.
De obsessive-compulsieve stoornis (OCS) is in het dagelijks leven beter bekend als
een ziekte die gepaard gaat met dwangklachten, waaronder bijvoorbeeld smetvrees of
controledwang. Vaak vertellen mensen niet dat ze last hebben van deze klachten omdat
ze zich ervoor schamen of niet weten dat het een ziekte is waarvoor behandel-
mogelijkheden bestaan.
OCS komt in ongeveer 1,5% van de populatie voor en komt daarmee ongeveer even
vaak voor als schizofrenie. OCS wordt gekenmerkt door dwanggedachten, zoals
bijvoorbeeld de angst voor besmetting, ernstige twijfel of een handeling wel goed is
gedaan of het volgen van vaste rigide regels voor bepaalde activiteiten (rituelen).
Daarnaast komen dwanghandelingen voor, zoals heel frequent handen wassen, vele
malen controleren of sloten van deuren of gaskranen wel dicht zijn. De dwangklachten
brengen ernstige onrust en angst met zich mee, waar patiënten zeer onder lijden.
Daarnaast kunnen de klachten uren per dag in beslag nemen. De gevolgen zijn niet
onaanzienlijk; patiënten komen niet meer toe aan verplichtingen zoals bijvoorbeeld
op tijd op het werk verschijnen of aan zorgtaken voor het gezin. Op de naasten heeft
de ziekte een grote impact; zij moeten regelmatig naar de regels van de patiënt leven
om deze zomin mogelijk te belasten en de minste angst te bezorgen. Dit brengt vaak
conﬂicten in relaties teweeg en kan soms zelfs leiden tot het verbreken hiervan.
Momenteel bestaat de behandeling van OCS uit medicatie en psychotherapie. De
gouden standaard voor de behandeling met psychofarmaca is behandeling met
antidepressiva die de serotonine huishouding in de hersenen beïnvloeden. Serotonine
is één van de stoffen in de hersenen die informatie van de ene zenuwcel doorgeeft aan
de volgende (neurotransmitter). De medicamenteuze behandeling heeft bij ongeveer
60% van de patiënten effect; een deel van deze patiënten wordt hiermee klachtenvrij,
maar het overige deel van de mensen blijft met restklachten zitten. De medicatie
langdurig moet worden gebruikt (jarenlang) om een opnieuw opvlammen van de
ziekte te voorkomen. Veertig procent van de patiënten kunnen met medicatie echter
niet worden geholpen. Naast medicijnen is cognitieve gedragstherapie een effectieve
vorm van behandeling, waarbij patiënten leren om hun dwangklachten onder controle
te krijgen.
De huidige wetenschappelijke inzichten laten zien dat een aantal gebieden in de
hersenen een belangrijke rol spelen in OCS. Uit het beeldvormend onderzoek is de
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(kernen in het midden van de hersenen) bij OCS gebleken. Deze gebieden maken deel
uit van hersencircuits, waarin speciﬁeke informatie wordt voortgeleid.
Eén van de hypothesen van het onderliggend probleem bij OCS is dat een bepaald
deel van de hersenen overactief is. Hierdoor zijn de gedachten over bijvoorbeeld ‘besmet
zijn’ niet vluchtig maar persisteren, waardoor deze gedachten steeds opnieuw worden
ervaren. Als reactie op deze dwanggedachte zet een patiënt er een handeling tegenover
(handen wassen) om de gedachte te verdrijven. Echter, mogelijk omdat het bepaalde
hersengebied overactief is, blijft de gedachte steeds terugkeren en blijft betrokkene
steeds maar weer de handen wassen.
Onder normale omstandigheden komt er een zeer grote hoeveelheid aan informatie
de hersenen binnen. Voordat deze tot ons bewustzijn doordringen worden deze echter
al geﬁlterd door ons brein en wordt alleen de belangrijke informatie doorgelaten. Dit
wordt de filterfunctie genoemd en het striatum heeft hierin waarschijnlijk een
belangrijke rol. Bij OCS patiënten zou deze functie verstoord zijn.
In verschillende onderzoeken waarbij klachten worden uitgelokt zie je een verhoogde
activiteit in bovengenoemde hersengebieden. Wanneer patiënten worden behandeld
en hun klachten verminderen, wordt er ook een daling in activiteit van betreffende
hersengebieden gezien.
Verschillende vragen over het ziektebeeld OCS blijven echter nog onbeantwoord; is
het te voorspellen welke patiënten op welke medicijnen het beste zullen reageren?
Behoren de verschillende dwangklachten tot hetzelfde ziektebeeld of bestaan er
subtypen van de ziekte? Reageren de eventuele subtypen van de ziekten anders op
verschillende behandelingen? Zijn er andere medicijnen die patiënten effectiever
kunnen behandelen?
Om OCS klachten te kunnen onderzoeken zijn er testsituaties ontwikkeld om dwang-
klachten bij patiënten voor een korte periode (ongeveer 2 uren) uit te lokken. Tijdens
het ervaren van symptomen kunnen vervolgens vragenlijsten en metingen van
verschillende aard worden verricht om meer inzicht in dit ziektebeeld te verkrijgen.
Nadat de symptomen zijn weggeëbd wordt de testsituatie beëindigd. Deze tests,
zogeheten symptoom-provocatie-tests (challenge-tests), kunnen worden uitgevoerd
met farmacologische stoffen of door middel van voorwerpen waarvan bekend is dat ze
bij betreffende patiënt klachten uitlokken.
Uit de effectiviteit van antidepressiva die het serotonine systeem beïnvloeden bij
OCS, blijkt de betrokkenheid van serotonine in dit ziektebeeld. De informatie-
overdracht tussen zenuwcellen gebeurt door binding van de neurotransmitter aan een
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geïdentificeerd. Er zijn aanwijzingen dat een aantal subtypen een specifieke rol bij
OCS zouden spelen. Eén van de meest onderzochte farmacologische stoffen bij OCS is
mCPP (meta-chlorophenylpiperazine), dat afﬁniteit heeft voor de serotonine-2C-receptor.
In dit proefschrift is onderzocht of bepaalde subtypen van de serotonine receptor een
speciﬁeke rol spelen bij OCS. Zowel de farmacologische stof mCPP werd onderzocht
als ook sumatriptan, dat juist meer afﬁniteit heeft voor de serotonine-1D-receptor. In
hoofdstuk  2 worden de resultaten beschreven van een dubbelblind, placebo-
gecontroleerd experiment waarbij 7 OCS-patiënten en 8 gezonde vrijwilligers een
challenge test met mCPP (0.5 mg/kg p.o.) hebben ondergaan, en waarbij tevens een
99mTc-HMPAO-SPECT scan werd gemaakt. Hoofdstuk 3 beschrijft de resultaten van de
studie waarbij 7 OCS-patiënten een placebo-gecontroleerde, dubbelblinde challenge
test met mCPP (0.5 mg/kg p.o.) ondergingen, en waarbij eveneens een 
99mTc-HMPAO-
SPECT scan en een MRI scan werden vervaardigd. De effecten van de serotonine-1D-
receptor agonist sumatriptan werden onderzocht in hoofdstuk 4, waarbij 15 OCS-
patiënten een dubbelblinde, placebo-gecontroleerde symptoom-provocatie-test met
sumatriptan 100 mg p.o. ondergingen. Zowel mCPP als sumatriptan bleek niet in staat
om een signiﬁcante (aanzienlijke) toename van dwangklachten te induceren.
In de literatuur wordt in verschillende onderzoeken gevonden dat mCPP goed in
staat is om een tijdelijke toename van dwangklachten te bewerkstelligen. Echter, er zijn
ook verschillende onderzoeken beschreven waarin juist geen effect van mCPP op
dwangklachten werd gezien. Deze verschillende resultaten kunnen worden verklaard
door verschillen die er waren in het uitvoeren van de symptoom-provocatie-tests en
de verschillende karakteristieken van patiënten (bijvoorbeeld geslacht, eerder
medicatiegebruik, duur van de klachten, type klachten). Deze aspecten zouden ook
een verklaring kunnen zijn voor de resultaten in dit proefschrift.
Een andere verklaring voor de negatieve bevindingen in dit proefschrift ten aanzien
van mCPP is de hoeveelheid mCPP in het bloed (mCPP-concentratie). In een aantal
eerdere onderzoeken is gemeld dat bij patiënten die een hoge mCPP-concentratie
hadden, weinig dwangklachten werden gerapporteerd. Maar bij lagere mCPP-spiegels
werden juist meer dwangklachten gezien. Eén studie heeft dit onderzocht waarbij
patiënten zowel een hoge als lage dosering mCPP kregen. Er werden respectievelijk
weinig en veel dwangklachten gemeld
1. Een verschil in mCPP concentratie is daarom
nog een mogelijke verklaring voor de wisselende resultaten in de literatuur en dit
fenomeen zou nader moeten worden onderzocht.
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een aantal kleinere onderzoeken die wel een toename van klachten beschrijven na
toediening van sumatriptan. Daarnaast wordt er bij genetisch onderzoek gevonden
dat de serotonine-1D-receptor een rol speelt bij OCS. Omdat er tot nu toe relatief weinig
onderzoek naar de rol van de serotonine-1D-receptor bij OCS is gedaan, zal
vervolgonderzoek hier meer helderheid over moeten verschaffen. Op grond van de
huidige gegevens zou de rol van de serotonine-1D-receptor bij OCS niet direct kunnen
worden uitgesloten.
Tijdens de symptoom-provocatie-test zijn er meerdere factoren (voorzien en
onvoorzien) welke de resultaten aanzienlijk kunnen beïnvloeden. Als er bijvoorbeeld
metingen van het angstniveau plaatsvinden kan het ook zijn dat er angst werd gemeten
welke samenhing met het afnemen van bloed. Andersom kan de aanwezigheid van
een arts juist geruststellend zijn waardoor er juist geen angst wordt gerapporteerd. 
In dit proefschrift wordt geconcludeerd dat standaardisering van symptoom-
provocatie-tests een belangrijke factor is in de reproduceerbaarheid van dit soort
onderzoek.
In dit proefschrift is voorts met behulp van beeldvormend onderzoek onderzocht
welke hersengebieden zijn betrokken bij OCS, nadat de symptomen met behulp van
medicatie zijn verminderd. Tevens werd onderzocht welke hersengebieden betrokken
zijn ten tijde van het manifest worden van OCS klachten.
Het beeldvormend onderzoek werd verricht door middel van een SPECT scan (Single
Photon Emmision Computed Tomography) waarmee de bloeddoorstroming in de
hersenen kan worden gemeten. Hiermee wordt informatie verkregen over de activiteit
van verschillende hersengebieden en ook verandering in activiteit kan worden
gemeten. Er werd tevens een MRI scan vervaardigd om de precieze localisatie van de
hersengebieden nauwkeurig te kunnen vastleggen.
In hoofdstuk 2 werd het effect van mCPP op de bloeddoorstroming in de hersenen
gemeten met een 
99mTc-HMPAO-SPECT scan. Om een meer nauwkeurige localisatie
van de verschillende hersengebieden te waarborgen werd in hoofdstuk 3 naast de 
99mTc-HMPAO-SPECT scan een MRI scan gemaakt. Ondanks het feit dat in hoofdstuk
2 en 3 de toediening van mCPP geen signiﬁcante toename van dwangklachten voor de
hele groep liet zien, werd er wel een milde verergering van klachten gezien. De
resultaten van de SPECT scans waren dat er ten tijde van deze milde verergering van
klachten een toename in de hersenactiviteit in met name de frontale cortex en het
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een toename van klachten laat zien, bijvoorbeeld mensen die lijden aan smetvrees,
maar niet bij diegenen die last hebben van controledwang. Een aantal recente studies
wijzen in deze richting
2. Bij een groep patiënten met OCS werden verschillende stimuli
aangeboden die specifieke dwangklachten kunnen uitlokken: smetvrees, controle-
dwang en verzameldwang. In deze studie werd gevonden dat de verschillende type
symptomen verschillende hersengebieden activeerden. Dit zou een goede verklaring
kunnen zijn waarom de eerdere onderzoeken steeds een iets ander resultaat laten zien.
In die eerdere resultaten waren de patiënten die deelnamen aan het onderzoek namelijk
niet geselecteerd op één type symptoom.
In dit proefschrift wordt daarom geconcludeerd dat de rol van de hersengebieden
bij patiënten met OCS duidelijker zullen worden wanneer verschillende symptoom-
groepen van dit ziektebeeld apart zullen worden onderzocht.
In hoofdstuk 5 werden  15 OCS-patiënten behandeld met het antidepressivum
ﬂuvoxamine gedurende 12 weken. Voorafgaande aan de behandeling en na 12 weken
werd een 
99mTc-HMPAO-SPECT scan vervaardigd en tevens een MRI scan gemaakt.
Zeven van de 15 patiënten reageerden met een vermindering van klachten op de
behandeling. Dit aantal was zoals verwacht op basis van eerdere bevindingen in de
literatuur. Bij de patiënten die een vermindering van klachten rapporteerden, bleek de
activiteit in de thalamus was verminderd. Dit werd echter niet gezien bij de patiënten
waarbij ﬂuvoxamine geen verbetering van klachten gaf.
Eerder literatuuronderzoek geeft duidelijk de betrokkenheid aan van de thalamus
in OCS en bevestigd dus de resultaten uit dit proefschrift. De thalamus lijkt een centrale
rol te spelen in de bij OCS betrokken hersencircuits. De thalamus is een groot
kerngebied in de hersenen en bestaat uit verschillende onderdelen. Het lijkt belangrijk
om in de toekomst het OCS onderzoek ook te richten op de thalamus maar met
name ook op de betrokkenheid van de subthalame kernen.
Referenties
1. Erzegovesi S, Martucci L, Henin M, Bellodi L. Low versus standard dose mCPP challenge in
obsessive-compulsive patients. Neuropsychopharmacology. 2001;24:31-36.
2. Mataix Cols D. Distinct neural correlates of washing, checking, and hoarding symptom.
Archives of General Psychiatry. 2004;61:564.
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(tijdens een intake-gesprek voor een behandeltrial)
dokter:  ‘Hoe verliepen uw klachten het afgelopen jaar?’
patiënt:  ‘Als een bergparabool’
(tijdens een behandelconsult)
dokter:  ‘Hoe gaat het nu met u?’
patiënte:  ‘Ik weet nu honderd procent zeker dat de stekker van het
strijkijzer uit het stopcontact is’
dokter (opgewekt):  ‘Dus het gaat beter met u!’
handeling patiënte:  Patiënte buigt naar voren en haalt een strijkijzer uit haar tas...
(tijdens een placebo-gecontroleerde behandelstudie)
patiënt:  ‘Dokter, ik weet zeker dat deze tabletjes geen placebo zijn, want
iedere keer als ik ze inneem voel ik het ﬂadderen achter mijn
ogen.
dokter (vage blik): ‘??????’
patiënt:  ‘Echt waar, ik heb die pilletjes aan mijn collega’s uitgedeeld en 
zij voelden ook geﬂadder achter hun ogen’
dokter (niet-vage blik): ‘KTq!!bRZ#pXt^rH%!!!’
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nu de vrije hand om het volgende te zeggen.
Verankerd aan de basis:
Lieve Pa, mijn beste paranimf, ‘je staat vlak naast me’. Jouw liefde voor boeken en studeren
is ook de mijne geworden. We zijn trots op elkaar.
Lieve Ma, je hebt me geleerd om doelen in mijn leven te stellen en ze vervolgens ook na
te streven. Daarom sta ik waar ik nu ben.
De daadwerkelijke verwezenlijking van dit boekje:
Aan alle moedige patiënten die deel hebben genomen tijdens dit, soms belastend,
onderzoek ben ik veel dank verschuldigd. Jullie hebben dit vrijwillig gedaan in de hoop
dat er in de toekomst betere behandelmogelijkheden zullen worden ontwikkeld.
Hooggeleerde promotor, beste Hans, je hebt mogelijkheden geschapen waardoor ik me
gesteund voelde om lastige beslissingen te nemen. Je inspirerende en enthousiaste kijk op
de wetenschap en op de psychiatrie is aanstekelijk en roept op tot meer.
Hooggeleerde professor Westenberg, beste Herman, je kritische en wetenschappelijke
manier van denken ademt door dit boekje en heeft mij laten zien in welke vorm
wetenschap zou moeten worden bedreven.
Beste Nick Ramsey en René Mandl, jullie hebben de gehele imaging techniek op jullie
genomen en mij prachtige plaatjes aangeleverd. Het is voor mij onbegonnen werk om te
analyseren welke en hoeveel bewerkingen jullie moeten hebben uitvoeren, maar het
resultaat was dat ik ze vervolgens kon ANALYZEN en de gegevens interpreteren.
André Klompmakers en Sytske de Graaf werkten in het Laboratorium Psychiatrie met grote
precisie aan alle bepalingen van dit onderzoek. Dank jullie wel voor de prettige
samenwerking.
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blinde testmedicatie. En het was iedere keer weer een plechtig moment als de code, lege
artis, werd verbroken.
Beste Harold van Megen en Irene van Vliet, destijds liep ik totaal ongehinderd door enige
ervaring in de psychiatrie rond op de angstpoli. Bedankt voor de ‘introductie’ en het
inspirerende en enthousiaste overleg over kliniek en wetenschap.
Professor R.S. Kahn ben ik zeer erkentelijk voor de ﬁnanciële ondersteuning ten tijde van
nood in de angst-vakgroep.
Beste Lucres en paranimf, eindeloos lang geleden begonnen we als twee aparte ‘eentjes’ in
de voornamelijk schizofrene kantoortuin. Destijds waren er never-ending stories en
urenlange lunches. Deze ‘levensgesprekken’ zijn inmiddels omgevormd tot huwelijken,
banen en (aanstaand) off-spring. Nu dan dit laatste puzzelstukje en ik ben benieuwd welke
spannende avonturen we in de toekomst gaan beleven.
Hallo! aan ALLE kantoortuinleden, tot de dag van vandaag vraag ik me af wie toch bedacht
heeft dat ons kantoor kenmerken van een tuin zou hebben. Een broeikas zou in meerdere
opzichten een betere benaming zijn. Werken op deze locatie was in ieder geval gezellig,
luidruchtig, emotioneel, discutabel, een frustratie, inspirerend en behulpzaam. En daarom
was het zo’n leuke sfeer. Allen veel succes en plezier toegewenst.
Beste Jeanette Sopocua; jij hebt op Schiphol toegang gehad tot waar ik alleen maar van
kan dromen. Ooit heb ik willen reageren op een vacature voor air-trafﬁc-controllers, maar
ik studeerde (helaas) al geneeskunde. Let’s keep on dreaming…
Beste Margo Jongsma, jij bent zo vriendelijk en behulpzaam geweest om met me mee te
denken over alles wat ik moest doen rondom het boekje. Je hebt me erover gemaild,
gebeld, spullen op de post gedaan, deadlines voor me in de gaten gehouden, gezorgd dat de
juiste ofﬁciële papieren bij de juiste personen kwamen voor de juiste handtekening. Je
bent een gouden hulp geweest in de afronding van dit boekje, dank je wel.
Er zijn nog veel meer mensen die mij direct en indirect wegwijs hebben gemaakt in de
wetenschap, computers, literatuur, patiëntenzorg en uitvoering van onderzoek. Mijn grote
dank hiervoor.
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De afgelopen jaren was er maar beperkt tijd voor mijmeringen. Ik stond daarom graag in
de rij bij de kassa, het benzinestation of in de ﬁle.
En ik moet conluderen dat ik:
... blij ben met datgene wat ik heb gekozen,
... gelukkig ben met degenen die ik heb ontmoet.
Lieve André, tussen promoties en specialisaties door zijn we samen een gezin geworden. 
Je huwelijksaanzoek tijdens mijn eerste buitenlandse congres in Venetië was uniek. We
hebben elkaar enthousiast gemaakt voor ons beider vakgebied. En telkens overtreffen we
elkaar met grandiose toekomstplannen. 
Dromerig staan we in de werkelijkheid.
‘...You can always be my Wingman...’
... en uit onze Liefde werd prachtig Leven,
Lieve Micha en Anna, hoeveel uren heb ik niet gefascineerd naar jullie zitten kijken. Jullie
eigen persoonlijkheden en voorkeuren zijn volop in ontwikkeling. Ik wens jullie een leven
vol mogelijkheden en uitdagingen toe. Kies maar wat je wilt, het is het allemaal waard.
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De auteur van dit proefschrift is geboren op 24 februari 1965 te Utrecht. Na 7 jaar in
Amsterdam gewoond te hebben, verhuisde ze naar Bilthoven, alwaar ze de lagere en
middelbare school volgde. In 1984 behaalde ze het vwo-diploma aan Het Nieuwe
Lyceum te Bilthoven. Vervolgens startte ze met de studie Geneeskunde aan de
Rijksuniversiteit Utrecht en rondde deze in 1992 af.
Gedurende één jaar was ze werkzaam als arts-assistent Inwendige Geneeskunde,
Cardiologie en Pulmonologie in het Elkerliek Ziekenhuis te Helmond.
In 1994 startte ze haar werkzaamheden als arts-onderzoeker bij de vakgroep
Pyschiatrie van het Academisch Ziekenhuis Utrecht, onder leiding van 
dr. J.A. den Boer en dr. H.G.M. Westenberg.
In 1996 trad zij in het huwelijk met André P. van Beek, thans internist-endocrino-
loog. Twee jaar later werd hun zoon Micha geboren en 4 jaar later hun dochter
Anna. In 1999 begon zij haar specialisatie Psychiatrie in het Academisch Medisch
Centrum te Amsterdam (opleider prof. dr. B.P.R. Gersons en prof. dr. D. Schreuder)
en in dat jaar overleed haar vader. Sinds 2004 is zij werkzaam bij de GGZ-Drenthe in
de Ouderenpsychiatrie.
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Dan ga je op reis
Gekleed in een stalen harnas of een verenpracht
Verwachtingsvol
Als je kan vliegen
Dan zijn er geen hindernissen
De route bekend
Instinctmatig
Als je kan vliegen
Dan zijn er geen grenzen
Grenzeloos begrensd
Onbegrensd
Als je kan vliegen
Dan lonkt een onbekende wereld
Zorgeloos Licht
Onweerstaanbaar
Voor mijn vader
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behorende bij het proefschrift
The Effects of Serotonergic Intervention 
on Behavior and Cerebral Blood Flow 
in Obsessive-compulsive Disorder
Kamini Lucil Ho Pian
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aan de farmacologische stof zelf, maar aan de onderzoekers en patiënten
(Hoofdstuk 2 en 3).
2. Het meten van de cerebrale bloeddoorstroming is slechts een indirecte
maat van de resultante van een zeer uitgebreid proces in de hersenen
(Hoofdstuk 2, 3 en 5).
3. Het ontrafelen van de obsessief-compulsieve stoornis gaat stap voor stap,
symptoom voor symptoom (Hoofdstuk 5).
4. Het is een utopie dat één serotonine receptor een bepalend aandeel in een
ziektebeeld heeft (Hoofdstuk 4).
5. Alle kleine beetjes wetenschappelijk bewijs helpen (dit proefschrift).
6. Patiënten met de obsessief-compulsieve stoornis zijn moedige maar
wanhopige mensen (dit proefschrift).
7. Het wordt tijd om je collegæ te overtuigen van het belang van vrije tijd,
wanneer je ze in het weekend tegenkomt op je werkplek.
8. Kinderen zijn als een computer; bij de laatste gaat het ﬂopje in de 
aahh-drive, bij een kind moet het fopje in de èèhh-drive.
9. Het aanschaffen van een airconditioning op de werkplek wordt bespoedigd
als er technische apparatuur is bezweken.
10. De verspreiding van een kleverige substantie neemt exponentieel toe
nadien ze in aanraking is geweest met kindervingertjes.
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– Als je begint te typen met twee vingers, en er na verloop van tijd achter
komt dat je het blind kunt.
– Op het moment dat je het als sociaal onwenselijk begint te ervaren
wanneer wordt gevraagd hoe het met je promotie gaat.
– Wanneer je data-ordners zijn aangevreten door een muis.
12. Beknopte samenvatting van zoon (5 jaar) na uitleg over de herkomst van
kindertjes: “...dus Anna en ik zijn Made In Mama?”
13. The organ of the mind is the brain.
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